



(86) Date de dépôt PCT/PCT Filing Date: 2006/06/07
(87) Date publication PCT/PCT Publication Date: 2007/06/21
(85) Entrée phase nationale/National Entry: 2007/12/06
(86) N° demande PCT/PCT Application No.: IB 2006/003977
(87) N° publication PCT/PCT Publication No.: 2007/069078
(30) Priorités/Priorities: 2005/06/07 (US60/688,207);
2005/12/16 (US60/751,401)

(51) Cl.Int./Int.Cl. *C12N 1/14* (2006.01),
A23K 1/00 (2006.01), *A23K 1/16* (2006.01),
A23L 1/03 (2006.01), *A23L 1/30* (2006.01)

(71) Demandeur/Applicant:
OCEAN NUTRITION CANADA LTD., CA

(72) Inventeurs/Inventors:
BURJA, ADAM M., CA;
RADIANGTYAS, HELIA, CA;
BARROW, COLIN JAMES, CA;
WINDUST, ANTHONY JAMES, CA

(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : MICRO-ORGANISMES EUCARYOTES POUR PRODUIRE DES LIPIDES ET DES ANTIOXYDANTS
(54) Title: EUKARYOTIC MICROORGANISMS FOR PRODUCING LIPIDS AND ANTIOXYDANTS

(57) Abrégé/Abstract:

Disclosed are compositions and methods related to eukaryotic microorganisms that can produce unsaturated fatty acids which can be purified and used.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2007 (21.06.2007)

PCT

(10) International Publication Number
WO 2007/069078 A2

- (51) International Patent Classification: **Not classified**
- (21) International Application Number: PCT/IB2006/003977
- (22) International Filing Date: 7 June 2006 (07.06.2006)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/688,207 7 June 2005 (07.06.2005) US
60/751,401 16 December 2005 (16.12.2005) US
- (71) Applicant (for all designated States except US): **OCEAN NUTRITION CANADA LTD.** [CA/CA]; 101 Research Drive, Dartmouth, Nova Scotia B2Y 4T6 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BURJA, Adam, M.** [AU/CA]; 5881 Spring Garden Road, Halifax, Nova Scotia B3H 1Y2 (CA). **RADIANINGTYAS, Helia** [ID/CA]; 5881 Spring Garden Road, Halifax, Nova Scotia B3H 1Y2 (CA). **BARROW, Colin, James** [NZ/CA]; 404 Francklyn Street, Halifax, Nova Scotia B3H 1A8 (CA). **WINDUST, Anthony, James** [CA/CA]; P.O. Box 51, 6740 Rideau Valley Drive South, Kars, Ontario K0A 2E0 (CA).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2007/069078 A2

(54) Title: EUKARYOTIC MICROORGANISMS FOR PRODUCING LIPIDS AND ANTIOXIDANTS

(57) Abstract: Disclosed are compositions and methods related to eukaryotic microorganisms that can produce unsaturated fatty acids which can be purified and used.

EUKARYOTIC MICROORGANISMS FOR PRODUCING LIPIDS AND ANTIOXIDANTS

1. This application claims the benefit of and priority to U.S. Provisional Application No. 60/688,207, filed June 7, 2005, and U.S. Provisional Application No. 60/751,401, filed
5 December 16, 2005 which are both incorporated by reference herein their entirety.

I. BACKGROUND

2. There is overwhelming scientific evidence that (n-3) highly unsaturated fatty acids such as docosahexaenoic acid (DHA) have a positive effect on cardio-circulatory diseases, chronic inflammations and brain disorders. The (n-6) fatty acids on the other hand have been
10 noted as intermediate metabolites within the eicosanoid steroids, such as prostaglandins, leucotrienes or the like.

3. Currently, the main source of these highly unsaturated fatty acids is fish, with DHA and eicosapentaenoic acid (EPA) noted within various blue fish (such as sardines and tuna) at amounts around 20% and 10%, respectively. Yet, if one intends to use fish oil as the sole source
15 of these lipids, several disadvantages exist, such as problems with flavor taint, uncontrollable fluctuations in availability, natural fish oil content variability, as well as the potential to accumulate harmful environmental pollutants. In addition, if one intends to obtain a highly purified (n-3) or (n-6) oil from these sources, it is very difficult to preferentially separate and purify.

II. SUMMARY

4. Disclosed are compositions and methods related to a eukaryote of the order Thraustochytriales and family Thraustochytriaceae which when cultured produce quantities of unsaturated fatty acids, such as omega 3 (n-3) and/or omega 6 (n-6) oils, such as DHA, EPA and DPA, capable of being purified and used as all such compositions are used and more, because of
25 their means of production.

III. BRIEF DESCRIPTION OF THE DRAWINGS

5. The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments and together with the description illustrate the disclosed compositions and methods.

6. Figure 1 shows a chart showing the results obtained from fatty acid methylation of the lipids derived from ONC-T18.

7. Figure 2 graphically depicts a fatty acid methyl ester comparison between the original ONC-T18 isolate collected at Advocate Harbor and that of the ONC-T18

Thraustochytrium sp. deposited with ATCC as PTA-6245. All peaks were identified by Gas Chromatography and Mass Spectrometry.

8. ~~Figure 3 shows a scatter plot graph of results from ONC-T18 biomass optimization experiments performed. These experiments used a technique known as the Taguchi method in order to determine the optimal conditions for growth of ONC-T18 under various media conditions.~~
9. Figure 4 shows a bar graph of the fatty acid profile of ONC-T18, grown under optimal conditions (example 4) over a nine day period.
10. Figure 5 shows a chart of oil producing organisms isolated as described elsewhere herein.
11. Figure 6 shows a branched phylogenetic tree of the relationship between the 18S rRNA gene of ONC-T18 and other Thraustochytriales.
12. Figure 7 shows lipid and DHA production of ONC-T18 under different conditions.
13. Figure 8 shows a modified graph with information about growth conditions on it for the eukaryotes disclosed herein. (Modified from Ratledge, C. (2004), Lipid Technol. 16:34-39).
14. Figure 9 shows a proposed metabolic pathway for the production of PUFAs for the disclosed eukaryotes.
15. Figure 10 shows a comparison of fatty acid production maxima and compositions under various alternative, low-cost carbon sources.
16. Figure 11 shows a grouping of isolates collected based on their C20 and C22 PUFA profiles. Results were compared to two reference strains: ATCC 20891 and MYA-1381.
17. Figure 12 shows a 18S rRNA Neighbour-joining tree of strain ONC-T18. The bar represents genetic distance, while square brackets depict GenBank derived sequences used within this phylogenetic tree.
18. Figure 13 shows the fatty acid profile of ONC-T18 grown in medium containing 2 g L⁻¹ yeast extract, 8 g L⁻¹ L-glutamate, 6 g L⁻¹ sea salt and 60 g L⁻¹ glucose in 3 different types of fermentation: agar plate (1.5% agar, 25°C, 27 days), flasks (50 ml in 250 ml flask, 120 RPM, 25°C, 3 days) and 5 L bioreactor (4 lpm air, pO₂ 90%, 25°C, 3 days).
19. Figure 14 shows the HPLC chromatogram of carotenoid compounds isolated from *Thraustochytrium* sp. ONC-T18. For example, Astaxanthin, Zeaxanthin, Canthaxanthin, Echinenone, and β-Carotene were isolated from *Thraustochytrium* sp. ONC-T18.
20. Figure 15 shows typical biomass, total fatty acid (TFA), DHA production and glucose utilization of *Thraustochytrium* sp. ONC-T18 maintained in a 5 L bioreactor for 168 h

with medium composed of 60 g L⁻¹ glucose, 2 g L⁻¹ yeast extract, 8 g L⁻¹ glutamic acid and 6 g L⁻¹ salt (4 lpm air, pO₂ 90%, 25°C, pH 7-9).

21. Figure 16 shows postulated pathways involved in the formation of astaxanthin in *Thraustochytrium* sp. ONC-T18.

5

IV. DETAILED DESCRIPTION

22. Before the present compounds, compositions, articles, devices, and/or methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods or specific recombinant biotechnology methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular
10 embodiments only and is not intended to be limiting.

23. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the method and compositions described herein. Such equivalents are intended to be encompassed by the claims
15 below.

A. Definitions

24. As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a pharmaceutical carrier” includes mixtures of two or more such carriers,
20 and the like.

25. Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the
25 particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also
30 understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “10” is disclosed then “less than or equal to 10” as well as “greater than or equal to 10” is also disclosed. It is also understood that throughout the application, data is provided in a number of different formats, and that this data,

represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point "10" and a particular data point "15" are disclosed, it is understood that greater than, greater than or equal to, less than, ~~less than or equal to~~, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each
5 unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

26. By "reduce" or other forms of reduce means lowering of an event or characteristic. It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be
10 referred to. For example, "reduces phosphorylation" means lowering the amount of phosphorylation that takes place relative to a standard or a control. It is understood that unless specifically indicated otherwise, a compound or composition or condition can be reduced relative to another compound or composition or condition.

27. By "inhibit" or other forms of inhibit means to hinder or restrain a particular
15 characteristic. It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, "inhibits phosphorylation" means hindering or restraining the amount of phosphorylation that takes place relative to a standard or a control. It is understood that unless specifically indicated otherwise, a compound or composition or condition
20 can be inhibited relative to another compound or composition or condition.

28. By "prevent" or other forms of prevent means to stop a particular characteristic or condition. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce or inhibit. As used herein, something could be reduced but not inhibited or prevented, but something that is reduced could also be inhibited or prevented. It is understood
25 that where reduce, inhibit or prevent are used, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed. Thus, if inhibits phosphorylation is disclosed, then reduces and prevents phosphorylation are also disclosed.

29. The term "therapeutically effective" means that the amount of the composition used is of sufficient quantity to ameliorate one or more causes or symptoms of a disease or disorder.
30 Such amelioration only requires a reduction or alteration, not necessarily elimination.

30. The term "carrier" means a compound, composition, substance, or structure that, when in combination with a compound or composition, aids or facilitates preparation, storage, administration, delivery, effectiveness, selectivity, or any other feature of the compound or

composition for its intended use or purpose. For example, a carrier can be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject.

31. Throughout the description and claims of this specification, the word “comprise” and variations of the word, such as “comprising” and “comprises,” means “including but not limited to,” and is not intended to exclude, for example, other additives, components, integers or steps.

32. The term “cell” as used herein also refers to individual microbial cells, or cultures derived from such cells. A “culture” refers to a composition comprising isolated cells of the same or a different type.

33. The term “metabolite” refers to active derivatives produced upon introduction of a compound into a biological milieu, such as a patient.

34. When used with respect to pharmaceutical and nutraceutical compositions, the term “stable” is generally understood in the art as meaning less than a certain amount, usually 10%, loss of the active ingredient under specified storage conditions for a stated period of time. The time required for a composition to be considered stable is relative to the use of each product and is dictated by the commercial practicalities of producing the product, holding it for quality control and inspection, shipping it to a wholesaler or direct to a customer where it is held again in storage before its eventual use. Including a safety factor of a few months time, the minimum product life for pharmaceuticals is usually one year, and preferably more than 18 months. As used herein, the term “stable” references these market realities and the ability to store and transport the product at readily attainable environmental conditions such as refrigerated conditions, 2°C to 8°C.

35. References in the specification and concluding claims to parts by weight, of a particular element or component in a composition or article, denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed. Thus, in a compound containing 2 parts by weight of component X and 5 parts by weight component Y, X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.

36. A weight percent of a component, unless specifically stated to the contrary, is based on the total weight of the formulation or composition in which the component is included.

37. “Isolating” and any form such as “isolate” refer to a situation where something is in a form wherein it can be manipulated or further purified. Isolated and its forms indicates that something is in a current state which is different than a previous state. For example, a ribosomal

RNA molecule can be "isolated" if it is, for example removed from an organism, synthesized or recombinantly produced. Often, the "isolation" of one thing is in relation to something else. For example, a eukaryote as discussed herein can be isolated as discussed herein, by, for example, culturing the eukaryote, such that the eukaryote survives in the absence of appreciable amounts (detectable) of other organisms. It is understood that unless specifically indicated otherwise, any of the disclosed compositions can be isolated as disclosed herein.

38. "Purify" and any form such as "purifying" refers to the state in which a substance or compound or composition is in a state of greater homogeneity than it was before. It is understood that as disclosed herein, something can be, unless otherwise indicated, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% pure. For example, if a given composition A was 90% pure, this would mean that 90% of the composition was A, and that 10% of the composition was one or more things, such as molecules, compounds, or other substances. For example, if a disclosed eukaryotic microorganism, for example, produces 35% DHA, this could be further "purified" such that the final lipid composition was greater than 90% DHA. Unless otherwise indicated, purity will be determined by the relative "weights" of the components within the composition. It is understood that unless specifically indicated otherwise, any of the disclosed compositions can be purified as disclosed herein.

39. "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

40. "Primers" are a subset of probes which are capable of supporting some type of enzymatic manipulation and which can hybridize with a target nucleic acid such that the enzymatic manipulation can occur. A primer can be made from any combination of nucleotides or nucleotide derivatives or analogs available in the art which do not interfere with the enzymatic manipulation.

41. Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.

42. Disclosed are the components to be used to prepare the disclosed compositions as well as the compositions themselves to be used within the methods disclosed herein. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular species of the family Thraustochytriaceae is disclosed and discussed and a number of modifications that can be made to a number of organisms including species of the family Thraustochytriaceae are discussed, specifically contemplated is each and every combination and permutation of these species from the family Thraustochytriaceae and the modifications that are possible unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited each is individually and collectively contemplated meaning combinations, A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered disclosed. Likewise, any subset or combination of these is also disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E would be considered disclosed. This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the disclosed methods.

B. Compositions

43. Disclosed are eukaryotic microorganisms of the order Thraustochytriales, preferably *Thraustochytrium* or *Schizochytrium* species, having the ability to produce lipids, such as fatty acids, such as unsaturated fatty acids, such as omega-3 fatty acids, such as omega-6 fatty acids, and omega-9 fatty acids, such as the (n-3) series of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), (n-6) series of docosapentaenoic acid (DPA) and the (n-9) series of palmitic and stearic acids. The disclosed eukaryotic microorganisms can also produce antioxidants, such as but not limited to the carotenoid compound carotene, (for example β -carotene) and the xanthophylls compounds astaxanthin, zeaxanthin, canthaxanthin, and echinenone.

44. Also disclosed are conditions for the isolation and growth of the eukaryotic microorganisms. For example, herewith are heterotrophic growth conditions for production of the disclosed lipids and antioxidants, for example, both individually and cumulatively. Accordingly, it is possible through the use of this unique eukaryote, to effectively produce the

(n-3) series of DHA and/or the (n-6) series of DPA and/or the carotenoid series of antioxidant compounds and/or the xanthophylls series of antioxidant compounds, which are useful as or within nutraceuticals, food additives, pharmaceuticals or industry.

45. Disclosed are compositions comprising a eukaryotic microorganism comprising or
5 consisting of a *Thraustochytrium* species, an example as disclosed herein being the ONC-T18 strain which has a deposit number of ATCC accession number PTA-6245.

46. It is understood that the eukaryotic microorganism and any clones, modified organisms or genes isolated from said organism as set forth in ONC-T18 are also disclosed. The disclosed organisms have the ability to produce unsaturated fatty acids, such as lipids containing
10 the omega-3 series of DHA and EPA, and the omega-6 series of DPA and various antioxidant such as carotenoids, xanthophylls and phenolics.

47. Also disclosed are processes for the production of biomass containing said compounds. Further disclosed are processes for preparing omega-3, omega-6 and carotenoid compounds utilizing the eukaryotic microorganism. Also disclosed are processes for the
15 production of microbial derived (or single celled) oils.

48. In addition, disclosed are the fatty acids and carotenoids produced by the disclosed eukaryotic microorganism and any progeny (genetically modified or otherwise), various feedstuffs, nutraceuticals, pharmaceutical and food supplemented with the lipids and antioxidants, as well as a process for utilizing these compounds as an additive for various
20 feedstuffs and foods.

49. U.S. Patent No. 5,130,242 to Barclay disclosed a collection and screening process to isolate strains of microorganisms with the following characteristics for the production of omega-3 fatty acids: 1) capable of heterotrophic growth; 2) produce a high content of omega-3 fatty acids; 3) unicellular; 4) produce a low content of standard and omega-6 fatty acids; 5) non-
25 pigmented, white or colorless cells; 6) thermotolerant (e.g., ability to grow above 30°C); and 7) eurhaline (e.g., ability to grow at a wide range of salinities, but preferably at low salinity).

50. The '242 disclosure also describes a process for the heterotrophic production of whole-celled or extracted microbial products with a high concentration of omega-3 fatty acids, which can later be used in animal or human food products. This process uses microorganisms
30 identified by the collection and screening process disclosed thereof. These microorganism, which are of the order Thraustochytriales, are cultured in ground grain. To enhance production of omega-3 fatty acids, low temperature stressing and high dissolved oxygen are used, as well as the addition of antioxidants, growth factors, vitamins, and phosphorous. The extracted products contain high concentrations of omega-3 fatty acids (e.g., C20:5w3, C22:5w3; and C22:6w3) and

low concentrations of omega-6 fatty acids (e.g., C20:4w6 and C22:5w6). Specifically, the ratios of the C20:5w3 to C22:6w3 fatty acids run from 1:1 to 1:30. Ratios of C22:5w3 to C22:6w3 fatty acids run from 1:12 to only trace amounts of C22:5w3. Also, the microorganisms produce from 0.6 to 0.72 % DHA, 0 to 5 % DPA, and 0 to 18.9 % EPA, by weight of total fatty acid.

5 51. U.S. Patent No. 6,451,567 to Barclay disclosed a process for growing *Thraustochytrium* and *Schizochytrium* in a non-chloride medium (<3g/L) containing sodium salts (e.g., sodium sulfate). The non-chloride medium results in cell aggregate sizes of less than 150 μ m. The disclosed process produces microorganisms and extracts that are useful in food products for aquaculture. Further components of the food products include flaxseed, rapeseed,
10 soybean, and avocado meal. The microorganisms can produce 1.08 g/L of medium per day of omega-3 fatty acids. The '567 disclosure further describes various culture mediums, which include sea water, glucose (1, 3, 5, or 10 g/L), yeast extract (0.01, 0.2, 0.4 and 5 g/L), additional nitrogen sources such as protein hydrolysate (1 g/L), liver extract (1 g/L), glutamate (5 g/L), MSG (3 g/L), and additional salts, trace vitamins and minerals (e.g., KH_2PO_4 , MgSO_4 , and
15 gelatin extract).

52. U.S. Patent No. 6,582,941 to Yokochi et al. discloses a *Schizochytrium* species, strain SR21 and another *Schizochytrium* strain belonging to the same species that have the ability to produce fatty acid fractions having a high concentration of omega-3 DHA and/or omega-6 DPA and a low concentration of EPA. Also, disclosed are methods of culturing such microorganisms
20 and isolating such fatty acids. The medium used contains sea salt, yeast extract (0.2, 1.0, or 10 g/L), corn steep liquor (0.5, 1.0, or 10 g/L), glucose (10-120 g/L), plus additional salts (e.g., NH_4OAc , phosphates). The fatty acid compositions contain about 15 to 20% DHA by weight of biomass (about 28% by weight of total fatty acid). The compositions can be used in food products (e.g., baby milk).

25 53. U.S. Patent No. 6,607,900 to Bailey et al. disclosed a process for growing eukaryotic microorganisms (e.g., *Schizochytrium* sp. ATCC No. 20888) that are capable of producing at least 20% of their biomass as polyunsaturated lipids (particularly omega-3 and -6 fatty acids). The process involves culturing the microorganisms in a medium containing a carbon and nitrogen source. Also disclosed is the use of low dissolved oxygen levels (less than 3%) and low
30 chloride ion levels (less than 3 g/L) to enhance production. The microorganisms have a lipid production rate of at least 0.5 g/L/h. The lipid fraction is from 15 to 20 % DHA by weight of biomass (about 35% by weight of total fatty acid methyl ester).

54. U.S. Publication No. 2004/0161831 to Komazawa et al discloses a *Thraustochytrium* strain (LEF1; ATCC No. FERM BP-08568) that has the ability to produce DHA. By culturing in

conventional media, the microorganism can produce oil with at least 50% by weight DHA. The oil can be treated with a lipase prior to isolation of DHA. The oil can be used in food or drinks or the DHA can be hydrolyzed to produce behenic acid.

1. Fatty acids

5 55. Fatty acids are hydrocarbon chains that terminate in a carboxyl group, being termed unsaturated if they contain at least one carbon-carbon double bond, and polyunsaturated when they contain multiple such bonds. Long-chain polyunsaturated fatty acids (PUFA) or highly-unsaturated fatty acids (HUFA), may be divided into the (n-3) and (n-6) series as a result of the location of these double bonds. There is overwhelming scientific evidence that (n-3) highly
10 unsaturated fatty acids such as DHA have a positive effect on cardio-circulatory diseases, chronic inflammation and brain disorders. The (n-6) fatty acids on the other hand have been noted as intermediate metabolites within the eicosanoid steroids, such as prostaglandins, leucotrienes or the like.

15 56. Polyunsaturated fatty acids can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 double and/or triple carbon-carbon bonds. For example, polyunsaturated fatty acids can comprise 3-8, 4-7, or 5-6 double and/or triple carbon-carbon bonds.

20 57. Currently, the main source of these highly unsaturated fatty acids is fish, with DHA and EPA noted within various blue fish (such as sardines and tuna) at amounts around 20% and 10%, respectively. Yet, if one intends to use fish oil as the sole source of these lipids, several disadvantages exist, such as problems with flavor taint, uncontrollable fluctuations in availability, natural fish oil content variability, as well as the potential to accumulate harmful environmental pollutants. In addition, if one intends to obtain a highly purified (n-3) or (n-6) oil from said sources, it is very difficult to preferentially separate and purify. Specifically, a large
25 market is available within the neonatal supplement market for a highly concentrated form of DHA. If fish oil were to be the source of said products, then DHA would have to be preferentially isolated in large quantities from EPA. Clearly an alternative source of highly purified and production tailored source of these highly unsaturated fatty acids is needed.

30 58. In addition to fish oils, various microorganisms (mainly marine) are able to produce and/or accumulate the (n-3) series of docosahexaenoic acid. Of particular interest is the fact that microbial production is not subject to fluctuations caused by external variables such as seasonality, weather and food supply. For example, the following microorganisms are known as having the ability to produce DHA: the deep-sea derived bacterium *Vibrio marinus* (ATCC 15381), *Vibrio* sp. T3615, *Photobacterium profundum* SS9, *Mortierella marina* MP-1 and *Psychromonas kaikoeae* (ATCC BAA-363T); microalgal species such as *Cryptothecodinium*

cohnii, *Cyclotella cryptica*, and *Mortierella alpina* (1S-4); and the protists *Thraustochytrium* sp. (ATCC 20892), *Thraustochytrium aureum* (ATCC 34304) and *Thraustochytrium roseum*.

According to a process utilizing these purified organisms, however, the amount of docosahexaenoic acid produced per gram of biomass per liter is low, being within the range of 10 to 500 mg. Some examples and representative microbial oil producing organisms are shown in Figure 5.

59. Omega 3s have been shown to have beneficial effects and the oils and compositions disclosed herein can be used for anti-inflammatory effect on cystic fibrosis (Cochrane Database Syst Rev. 3), rheumatoid arthritis (Drugs 63: 845-53), asthma (Ann Allergy Asthma Immunol 90: 371-7) and thrombotic stroke (Prev Cardiol 6: 38-1), cardio-protective, as well as a direct effect on arteriosclerosis and arrhythmia (Prostaglandins Leukot Essent Fatty Acids. 63:351-62), inhibition of cancer proliferation in breast and prostate cancer cell lines and reduction in animal experiments (Am J Clin Nutr 77: 532-43), anti-psychotic effect on schizophrenia (J Neural Transm Suppl 64:105-17) and other psychiatric diseases (Can J Psychiatry 48: 195-203), immunonutrient supplement used for normal neonatal development and in the treatment of neonatal infections (Eur J Pediatr 162: 122-8), and pathological pain treatment by directly attenuate the neuronal and ganglial processes that underlie neuropathic and inflammatory pain (Prostaglandins Leukot Essent Fatty Acids 68: 219-24).

2. Thraustochytriaceae

a) ONC-T18

60. The marine organism ONC-T18, as disclosed herein, was collected as part of a PUFA producing microbial isolation trip, with over 60 pure cultures isolated (see table 7 for details). Further, ONC-T18 was isolated from the leaves of salt marsh grasses in the Advocate Harbor, Bay of Fundy, Nova Scotia, Canada. Through microscopic examinations and serial culture purification techniques, the strain was believed to be a single microorganism belonging to the genus *Thraustochytrium*. All strains and two ATCC comparison cultures (ATCC 20891 & MYA-1381) were grown on 0.5% glucose, 0.2% peptone, 0.2% yeast extract in sea-water (SW) and underwent GC (fatty acid methyl ester, FAME) analysis.

61. Figure 6 shows a proposed phylogenetic tree of the relationship between ONC-T18, and other closely related organisms.

62. ONC-T18 was originally isolated as a single microbe using classic pine pollen baiting techniques, followed by culturing on selective medium. Specifically, a nutrient medium containing 5 g L⁻¹ glucose, 2 g L⁻¹ peptone, 2 g L⁻¹ yeast extract to 1 L of 0.2 μm filtered sea water was prepared. The fatty acid profile of ONC-T18 was then determined using the Bligh

and Dyer extraction method and PUFA gas chromatographic techniques. Chromatographic results demonstrated the ability of this strain to produce increased amounts of TFA, DHA, as well as marked quantities of EPA and DPA.

5 63. The disclosed eukaryotic microorganism can be used in a process for preparing a lipid or fat containing DHA, EPA and DPA, but is not limited to the above-mentioned ONC-T18 or PTA-6245 strain, but any derivation of said strain whether it be via genetic modification, chemical mutagenesis, fermentative adaptation or any other means of producing mutants of the strain, whereby the product of these modifications have genetic or morphological and functional features such as the eukaryotic microorganism, as disclosed herein.

10 64. Disclosed are eukaryotic microorganism capable of producing a lipid composition having distinctive lipid class properties, and the solution to the problem of maintaining a stable, reliable and economical source for such a lipid having high functionality and additional value according to the same. Therefore, wild-type strains producing the (n-3) series of DHA and the (n-6) series of DPA to a greater degree as well as variant and recombinant strains designed to
15 produce these polyunsaturated fatty acids to a greater degree are disclosed herein. Such variant or recombinant microorganisms include those designed to have a higher content of said lipids than those produced by the original wild-type strain, when cultured using the same conditions and media. In addition, microorganisms designed to produce a lipid containing similar amounts of the (n-3) series of DHA, EPA and the (n-6) series of DPA can be selected, as compared with
20 the corresponding wild-type strains, effectively using substrates having a superior cost performance, are also included.

25 65. Disclosed are compositions comprising a eukaryotic microorganism of the order Thraustochytriales wherein the eukaryotic microorganism produces unsaturated fatty acids. The polyunsaturated fatty acids can be, for example, omega 3 or omega 6 fatty acids, such as DHA and DPA.

66. Disclosed are compositions comprising a eukaryote, wherein the composition produces a lipid.

67. Also disclosed are compositions wherein the lipid comprises a lipid as disclosed herein.

30 68. Also disclosed are compositions, wherein the eukaryote comprises a member of the order Thraustochytriales.

69. Also disclosed are compositions, wherein the eukaryote has a 18S ribosome RNA gene sequence having at least 80% identity to SEQ ID NO:1.

70. It is understood that any form of characterization described herein, such as by genetics or by the lipid signatures or by the classifications, for the eukaryotic microorganisms can be used to characterize the microorganisms as disclosed herein. The eukaryotic microorganism can comprise one or more microorganisms from the family Thraustochytriaceae; and examples are ATCC accession number 20888, 20889, 20890, 20891, and 20892. There are a variety of characteristics that can be used related to the organisms and the unsaturated fatty acids they produce. It is understood that these can be used in any combination or permutation to define a set or sets of organisms or oils or antioxidants, for example. One characteristic is the classification of the organisms themselves, the genetic identification of the organisms, the lipid and antioxidant profiles of the organisms, and the growth conditions of the organisms, for example.

b) Classification

71. The eukaryotic microorganism can be from the phylum Labyrinthulomycota. The eukaryotic microorganism can be from the class Labyrinthulomycetes. The eukaryotic microorganism can be from the subclass Thraustochytridae. The eukaryotic microorganism can be from the order Thraustochytriales. The eukaryotic microorganism can be from the family Thraustochytriaceae. The eukaryotic microorganism can be from the genus *Thraustochytrium*. The eukaryotic microorganism can be a *Thraustochytrium* sp. The eukaryotic microorganism can be *Thraustochytrium aureum*. The eukaryotic microorganism can be *Thraustochytrium roseum*. The eukaryotic microorganism can be *Thraustochytrium striatum*. The eukaryotic microorganism can be from the genus *Schizochytrium*. The eukaryotic microorganism can be *Schizochytrium* sp. The eukaryotic microorganism can be a modified version of any of the listed eukaryotic microorganisms. The eukaryotic microorganism can also comprise any currently unknown or isolated members of said prokaryotes class, subclass, order, family or genus. A combination of eukaryotic microorganisms can be any combination of any organisms disclosed herein, including, one or more of the *Thraustochytrium* sp., *Schizochytrium* sp., *Thraustochytrium aureum*, *Thraustochytrium striatum* and *Thraustochytrium roseum*.

72. The eukaryotic microorganisms from the family Thraustochytriaceae can be any of those disclosed above. The eukaryotic microorganism can comprise the organism having ATCC accession number PTA-6245.

c) Genetics

73. The eukaryotic microorganism can have 18S rRNA sequence SEQ ID NO:1. The eukaryotic microorganism can have an 18S rRNA sequence that, for example, has about 90% homology, or any other identity disclosed herein, to SEQ ID NO:1. The eukaryotic

microorganism can have an 18S rRNA sequence that hybridizes under stringent conditions, or any other conditions as disclosed herein, to SEQ ID NO:1, or a portion of SEQ ID NO:1.

74. The sequence similarity/identity and nucleic acid hybridization of the nucleic acids of the organisms can be as described herein. Specifically, comparison of SEQ ID NO:1 with
5 nucleic acid sequences found in the genomic database, GenBank (National Centre for Biotechnology Information, National Institute of Health, Bethesda, MD, USA) using the BLAST (Basic local alignment search tool) algorithm identified SEQ ID NO:1 as being related (91% similarity) to several eukaryotic Thraustochytrid species, closely related to *Thraustochytrium* sp. CHN-1 [AB126669] (94.5% similarity) and *Thraustochytriidae* sp. N1-27 [AB073308] (95.5%
10 similarity), and most closely related to *Thraustochytrium striatum* [AF265338] (97.5% similarity).

3. (1) Sequence similarities

75. It is understood that as discussed herein the use of the terms homology and identity mean the same thing as similarity. Thus, for example, if the use of the word homology is used
15 between two non-natural sequences it is understood that this is not necessarily indicating an evolutionary relationship between these two sequences, but rather is looking at the similarity or relatedness between their nucleic acid sequences. Many of the methods for determining homology between two evolutionarily related molecules are routinely applied to any two or more nucleic acids or proteins for the purpose of measuring sequence similarity regardless of whether
20 they are evolutionarily related or not.

76. In general, it is understood that one way to define any known variants and derivatives or those that might arise, of the disclosed genes and proteins herein, is through defining the variants and derivatives in terms of homology to specific known sequences. This identity of particular sequences disclosed herein is also discussed elsewhere herein. In general,
25 variants of nucleic acids and proteins herein disclosed typically have at least, about 50, 55, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent homology to the stated sequence or the native sequence. Those of skill in the art readily understand how to determine the homology of two proteins or nucleic acids, such as genes. For example, the homology can be calculated after aligning the two
30 sequences so that the homology is at its highest level.

77. Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman *Adv. Appl. Math.* 2:482, 1981, by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48:443, 1970, by the search for similarity

method of Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection.

5 78. The same types of homology can be obtained for nucleic acids by for example the algorithms disclosed in Zuker, M. *Science* 244:48-52, 1989, Jaeger et al. *Proc. Natl. Acad. Sci. USA* 86:7706-7710, 1989, Jaeger et al. *Methods Enzymol.* 183:281-306, 1989 which are herein incorporated by reference for at least material related to nucleic acid alignment. It is understood that any of the methods typically can be used and that in certain instances the results of these
10 various methods may differ, but the skilled artisan understands if identity is found with at least one of these methods, the sequences would be said to have the stated identity, and be disclosed herein.

 79. For example, as used herein, a sequence recited as having a particular percent homology to another sequence refers to sequences that have the recited homology as calculated
15 by any one or more of the calculation methods described above. For example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using the Zuker calculation method even if the first sequence does not have 80 percent homology to the second sequence as
20 calculated by any of the other calculation methods. As another example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using both the Zuker calculation method and the Pearson and Lipman calculation method even if the first sequence does not have 80 percent
25 homology to the second sequence as calculated by the Smith and Waterman calculation method, the Needleman and Wunsch calculation method, the Jaeger calculation methods, or any of the other calculation methods. As yet another example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using each of calculation methods (although, in practice, the different calculation methods will often result in different calculated homology percentages).

(2) Hybridization/selective hybridization

30 80. The term hybridization typically means a sequence driven interaction between at least two nucleic acid molecules, such as a primer or a probe and a gene. Sequence driven interaction means an interaction that occurs between two nucleotides or nucleotide analogs or nucleotide derivatives in a nucleotide specific manner. For example, G interacting with C or A interacting with T are sequence driven interactions. Typically sequence driven interactions occur

on the Watson-Crick face or Hoogsteen face of the nucleotide. The hybridization of two nucleic acids is affected by a number of conditions and parameters known to those of skill in the art. For example, the salt concentrations, pH, and temperature of the reaction all affect whether two nucleic acid molecules will hybridize.

5 81. Parameters for selective hybridization between two nucleic acid molecules are well known to those of skill in the art. For example, in some embodiments selective hybridization conditions can be defined as stringent hybridization conditions. For example, stringency of hybridization is controlled by both temperature and salt concentration of either or both of the hybridization and washing steps. For example, the conditions of hybridization to achieve
10 selective hybridization may involve hybridization in high ionic strength solution (6x SSC or 6x SSPE) at a temperature that is about 12-25°C below the T_m (the melting temperature at which half of the molecules dissociate from their hybridization partners) followed by washing at a combination of temperature and salt concentration chosen so that the washing temperature is about 5-20°C below the T_m . The temperature and salt conditions are readily determined
15 empirically in preliminary experiments in which samples of reference DNA immobilized on filters are hybridized to a labeled nucleic acid of interest and then washed under conditions of different stringencies. Hybridization temperatures are typically higher for DNA-RNA and RNA-RNA hybridizations. The conditions can be used as described above to achieve stringency, or as is known in the art. (Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold
20 Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989; Kunkel et al. *Methods Enzymol.* 154:367, 1987 which is herein incorporated by reference for material at least related to hybridization of nucleic acids). A preferable stringent hybridization condition for a DNA:DNA hybridization can be at about 68°C (in aqueous solution) in 6x SSC or 6x SSPE followed by washing at 68°C. Stringency of hybridization and washing, if desired, can be reduced
25 accordingly as the degree of complementarity desired is decreased, and further, depending upon the G-C or A-T richness of any area wherein variability is searched for. Likewise, stringency of hybridization and washing, if desired, can be increased accordingly as homology desired is increased, and further, depending upon the G-C or A-T richness of any area wherein high homology is desired, all as known in the art.

30 82. Another way to define selective hybridization is by looking at the amount (percentage) of one of the nucleic acids bound to the other nucleic acid. For example, in some embodiments selective hybridization conditions would be when at least about, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the limiting nucleic acid is bound to the non-limiting nucleic acid. Typically,

the non-limiting primer is in for example, 10 or 100 or 1000 fold excess. This type of assay can be performed under conditions where both the limiting and non-limiting primer are for example, 10, 100 or 1000 fold below their k_d , or where only one of the nucleic acid molecules is 10, 100 or 1000 fold or where one or both nucleic acid molecules are above their k_d .

5 83. Another way to define selective hybridization is by looking at the percentage of primer that gets enzymatically manipulated under conditions where hybridization is required to promote the desired enzymatic manipulation. For example, in some embodiments selective hybridization conditions would be when at least about, 50, 55, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100
10 percent of the primer is enzymatically manipulated under conditions which promote the enzymatic manipulation, for example if the enzymatic manipulation is DNA extension, then selective hybridization conditions would be when at least about 50, 55, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the primer molecules are extended. Preferred conditions also include those
15 suggested by the manufacturer or indicated in the art as being appropriate for the enzyme performing the manipulation.

84. Just as with homology, it is understood that there are a variety of methods herein disclosed for determining the level of hybridization between two nucleic acid molecules. It is understood that these methods and conditions may provide different percentages of hybridization
20 between two nucleic acid molecules, but unless otherwise indicated meeting the parameters of any of the methods would be sufficient. For example, if 80% hybridization was required and as long as hybridization occurs within the required parameters in any one of these methods it is considered disclosed herein.

85. It is understood that those of skill in the art understand that if a composition or
25 method meets any one of these criteria for determining hybridization either collectively or singly it is a composition or method that is disclosed herein.

d) Composition of molecules produced

86. It is understood that the eukaryotes disclosed herein are capable of producing a number of compounds and compositions. The compounds and compositions can be used as a
30 signature, a way of identifying the organism. For example, one way of characterizing an organism is by the lipid profile that the organism produces. As disclosed herein these various lipid profiles can be used to characterize the organism as well as be purified, manipulated, and collected for a variety of reasons.

(1) Lipids

87. It is understood that each organism can produce some profile of unsaturated fatty acids, as disclosed herein. These profiles are characteristics of the organisms. Below are some examples, of unsaturated and other lipid profiles for the organisms.

5 88. The eukaryotic microorganism can produce, for example a lipid or fatty acid fraction of at least about 4 wt.% to 6 wt.% (e.g., about 5 wt.%), which comprises from about 0 wt. % to about 2 wt. % myristic acid (e.g., about 1 wt.%), from about 16 wt.% to about 20 wt.% (e.g., about 18 wt.%) palmitic acid, from about 0 wt. % to about 2 wt.% (e.g., about 1 wt.%) palmitoleic acid, from about 4 wt.% to about 8 wt.% (e.g., about 6 wt.%) stearic acid, from
10 about 30 wt.% to about 34 wt.% (e.g., about 32 wt.%) oleic acid, from about 40 wt.% to about 44 wt.% (e.g., about 42 wt.%) linoleic acid, and from about 0 wt.% to about 3 wt.% (e.g., about 2 wt.%) n-3 EPA per dried cellular biomass.

89. The eukaryotic microorganism can also produce, for example, a lipid or fatty acid fraction of at least about 1 wt.% to 3 wt.% (e.g., about 1.25 wt.%), which comprises from about
15 2 wt.% to about 4 wt.% (e.g., about 3 wt.%) myristic acid, from about 50 wt.% to about 60 wt.% (e.g., about 55 wt.%) palmitic acid, from about 2 wt.% to about 4 wt.% (e.g., about 3 wt.%) palmitoleic acid, from about 16 wt.% to about 20 wt.% (e.g., about 18 wt.%) stearic acid, from about 9 wt.% to about 13 wt.% (e.g., about 11 wt.%) oleic acid, from about 1 wt.% to about 3 wt.% (e.g., about 2 wt.%) eicosadienoic acid, and from about 6 wt.% to about 10 wt.% (e.g.,
20 about 8 wt.%) n-3 EPA per dried cellular biomass.

90. The eukaryotic microorganism, for example, such as ONC-T18, can produce at least about 30 wt.%, 40 wt.%, 50 wt.%, 60 wt.%, 70% wt.% or 80 wt.% (e.g., about 80 wt.%) of a lipid composition per dried cellular biomass. For example, the eukaryotic microorganism can produce a lipid composition comprising from about 25% to about 40% of an omega-3 fatty acid,
25 such as n-3 DHA, (for example, at least 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55% or 60% by weight), and from about 0% to about 3% of the omega-3 fatty acid, EPA, (for example, at least 1% or 2% by weight) and from about 4% to about 12% of an omega-6 fatty acid, such as n-6 DPA, (for example, at least 4%, 5%, 6%, 7%, 8%, 9%, or 10% by weight).

91. It is understood that the composition of the lipid produced by the eukaryotic
30 microorganism can be manipulated based on the growing conditions the eukaryotic microorganism exists in. By changing various parameters, as disclosed herein, the compositions can be manipulated to produce, for example a better yield of DHA or DPA. For example, the manipulation may not produce more actual grams, but the manipulation, may produce a better

ratio of DHA or DPA to EPA and other desired PUFAs, which may be desirable from a purification standpoint. Varying conditions are discussed herein.

92. Figure 10 shows a possible metabolic pathway for the various PUFAs produced by the disclosed eukaryotic microorganism, consistent with fatty acid methyl ester metabolite tracking. Proteins which can be identified within the pathways which as disclosed herein are polyketide synthase, using for example a degenerative primer study, (Metz et al. (2001) Science 293:290-3 and Kaulmann & Hertweck (2002) Angew. Chem. Int. Ed. 41:1866-9). Also elongases and desaturases, using for example a hybridization probe study can be identified. Also fatty acid synthases can be identified using, for example, a hybridization probe and/or a degenerative primer study.

4. Growing and culturing

93. A phenotypic microplate study including carbon; nitrogen (peptide nitrogen); phosphorus and sulfur; osmolytes, and pH was performed.]

94. An Orthogonal array (Taguchi) method was used to determine optimum media configurations and variations in nitrogen, carbon and salt concentration (Joseph J & Piganatiells JR (1998) IIE Trans, 20:247-254).

95. If you increase agitation or dO_2 you increase biomass production & TFA but decrease DHA. If you decrease agitation or dO_2 you decrease cellular biomass (g) & decrease TFA but increase DHA but also reduce C16:0, C16:1 & C18:1.

96. If you increase temperature you increase biomass production & TFA but decrease DHA. If you decrease temperature you decrease cellular biomass (g) & decrease TFA but increase DHA, but reduce C16:0, C16:1 & C18:1.

97. Cellular biomass derived from the disclosed eukaryotic microorganism can be obtained by inoculating a suitable natural or artificial seawater medium, containing from about 2% to about 100% of seawater. This eukaryotic microorganism is able to utilize various nutritional components within this medium. Examples of a carbon source used within the medium are carbohydrates such as glucose, fructose, dextrose, lactulose, galactose, maltotriose, maltose, lactose, glycogen, gelatin, starch (corn or wheat) as well as sugar derivatives such as acetate, m-inositol (derived from corn steep liquor), galacturonic acid (derived from pectin), L-fucose (derived from galactose), gentiobiose, glucosamine, α -D-glucose-1-phosphate (derived from glucose), cellobiose (derived from cellulose) dextrin (derived from corn) and α -cyclodextrin (derived from starch) and polyols such as maltitol, erythritol, adonitol and oleic acids such as glycerol and tween 80 and amino sugars such as N-acetyl-D-galactosamine, N-acetyl-D-glucosamine and N-acetyl- β -D-mannosamine. While, examples of a nitrogen source

are natural nitrogen sources such as peptone, yeast extract, malt extract and fish meal, or an organic nitrogen sources such as sodium glutamate, but not limited thereto. Furthermore, if necessary phosphates, such as potassium phosphate, and sodium phosphate, inorganic salts such as, ammonium sulfate, sodium bicarbonate, sodium orthovanadate, potassium chromate, sodium molybdate, selenous acid, nickel sulfate, copper sulfate, zinc sulfate, cobalt chloride, iron chloride, manganese chloride and calcium chloride may be used as trace nutrients, along with the chelating compound, ethylenediaminetetraacetic acid, alone or in conjunction with vitamins such as pyridoxine hydrochloride, thiamine hydrochloride, calcium pantothenate, p-aminobenzoic acid, riboflavin, nicotinic acid, biotin, folic acid and vitamin B₁₂. After preparing the medium, the pH is adjusted to between 3.0 and 10.0 using acid or base to adjust where appropriate, for example between pH 4.0 and 6.5, and the medium is sterilized by autoclaving, for example. Cultivation can be carried out for 1 to 30 days, 1 to 21 days, 1 to 15 days, 1 to 12 days, 1 to 9 days, or preferably 3 to 5 days at temperatures between 4 to 30°C, preferably 18 to 28°C, by aeration-shaking culture, shaking culture, stationary culture, batch culture, continuous culture, rolling batch culture, or wave culture, or the like.

98. The following conditions are an example of conditions that can allow for the production of a set of lipids in yields which allows for their use as a commodity. Investigation of culture conditions for ONC-T18 revealed that the eukaryotic microorganism disclosed herein grows well in natural or artificial sea water or in a medium containing down to 5% concentration of natural or artificial sea water. Carbon and nitrogen sources added to the medium may be those conventionally used as described above. The nitrogen source being either natural or organic in nature is relatively equal and total nitrogen concentration within the medium is kept constant. These sources are added to the medium at standard concentrations. If these conditions are met, little influence on the content of lipid, proportions or the amount of accumulated DHA, DPA and EPA is produced, as disclosed herein.

99. For high-concentration fermentation of ONC-T18, it is possible to use several methods to increase both cellular biomass and lipid production rates. These include, increasing both the carbon and nitrogen concentration in the medium (at a ratio of between 6:1 and 15:1, preferably between 6:1 and 13:1 and at temperatures between 4 to 30°C, preferably 18 to 28°C) from the range 5 g L⁻¹ to 60 g L⁻¹ to the range 100 g L⁻¹ and 160 g L⁻¹ and from the range 4 g L⁻¹ to 10 g L⁻¹ to the range 40 g L⁻¹ to 60 g L⁻¹, respectively. Using this method the proportion of biomass and lipid produced is also increased at comparable rates. Furthermore, it is possible to increase lipid production through the use of increased carbon sources from the range 5 g L⁻¹ to 60 g L⁻¹ to the range 100 g L⁻¹ and 160 g L⁻¹, while the nitrogen source remains constant.

Additionally, it is possible to increase biomass production while maintaining lipid content, through the use of increased amounts of nitrogen sources from the range 10 g L^{-1} to 60 g L^{-1} while the carbon source remains constant. Moreover, experimentation has determined that biomass and lipid production greatly increases with increased agitation from the range 100 and 5 1000 rpm, better at between 350 and 600 rpm and optimal at between 350 and 450 rpm, with only a marginal decrease in lipid content and no decrease in fatty acid profiles, with agitation particularly relevant at the early stages of heterotrophic fermentation. Experimentation has also determined that lipid production optima are achieved when the dissolved oxygen content of the culture medium is between 1 and 10%, optimally at 5%. Finally, the addition of acetate, trace 10 elements, metals and vitamins to the production medium (as mentioned above) increases the production of DHA, EPA and DPA with respect to other fatty acids without decreasing total lipid values.

100. By performing heterotrophic fermentation as described above, it is possible to consistently produce cellular biomass which produces a lipid containing the (n-3) series of DHA 15 in a culture of high concentration of not less than 5 g and more preferably not less than 20 g/L medium. Furthermore, experimentation has shown that most of these lipids accumulate during the later-exponential/transition stages of cultivation, after maximal biomass levels are reached. Yet, during the fermentation process, lipid content typically does not fall below 25% of the total biomass, typically maximizing at around 80%. The cultivation under the above conditions can 20 be carried out using a conventional agitation-fermenter. It is also possible to use a bubble column fermenter (batch or continuous cultures), or a wave fermentor.

101. Collection of cellular biomass prior to processing for lipid separation can be performed using various conventional methods such as centrifugation (such as solid-ejecting centrifuges) or filtration (such as cross-flow filtration) and may also include the use of a 25 precipitation agent for the accelerated collection of cellular biomass (such as sodium phosphate, calcium chloride or polyacridamide).

5. Isolation of Lipid

102. Figure 7 shows lipid and DHA profiles as functions of a variety of parameters. All of this data can be used to extract specific characteristics about the ONC-T18 eukaryotic 30 microorganism. Figure 13 shows a general fatty acid profile for the disclosed eukaryote.

103. The fat containing the (n-3) series of DHA and the (n-6) series of DPA can be obtained by breaking or disrupting the collected cell biomass, for example, via milling, ultrasonication, and then carrying out extraction with a solvent such as chloroform, hexane, methanol, ethanol or via supercritical fluid extraction means. The content of the resultant fat

containing the (n-3) series of DHA and the (n-6) series of DPA per gram of dried cellular biomass is preferably greater than 0.25 g and more preferably greater than 0.6 g.

104. The disclosed eukaryotic microorganisms, such as ~~ONC-T18~~, are able to produce lipid thus obtained, any of its variants and any associations between members of the same species of eukaryotic microorganisms whereby the lipid profile is as follows. The percentage of neutral lipids can be at least 95% by weight of total lipids. A typical composition of fatty acids for the eukaryotic microorganism, such as ONC-T18, in the neutral lipids is as follows: 15% of myristic acid, 8% of pentadecanoic acid, 35% of palmitic acid, 7% of palmitoleic acid, 1% of stearic acid, 2% of oleic acid, 1% of eicosapentaenoic acid, 6% of docosapentaenoic acid and 25% docosahexaenoic acid (GC spectra shown in Figure 1).

105. The disclosed eukaryotic microorganisms, such as ONC-T18, are able to produce lipid thus obtained, any of its variants and any associations between members of the same species of eukaryotic microorganisms whereby the lipid profile is as follows. The percentage of mono-, di- and tri-glycerides in the neutral lipid fraction of ONC-T18 is 0% to about 2%, 0 to about 2% and 96 to about 100%, respectively. While the polar lipid fraction with comprises between 5% and about 10% of the lipid fraction, comprises phosphotidylcholine, phosphotidylserine and phosphotidic acid both bound and unbound to neutral lipids.

106. It is understood that these lipids can be found in any combination or permutation within the organism. It is also understood that the concentrations of these lipids can be manipulated by changing the growing conditions and media conditions as discussed herein.

(1) Lipid as concentration

107. The eukaryotic microorganism can produce a lipid fraction comprising n-3 DHA, EPA and n-6 DPA at greater than or equal to about 4.0 g L⁻¹ of medium. The eukaryotic microorganism can produce a lipid composition comprising n-3 DHA, EPA and n-6 DPA at greater than or equal to about 20.0 g L⁻¹ of medium. The eukaryotic microorganism can produce a lipid composition comprising n-3 DHA, EPA and n-6 DPA at greater than or equal to about 14.0 g L⁻¹ of medium. The eukaryotic microorganism can produce from about 1.5 g L⁻¹ to about 5.0 g L⁻¹ (e.g., about 4.6 g L⁻¹) of the n-3 DHA, from about 0.5 g L⁻¹ to about 1.5 g L⁻¹ (e.g., about 0.22 g L⁻¹) of the n-3 EPA, and from about 0.5 g L⁻¹ to about 1.5 g L⁻¹ of the n-6 DPA. Furthermore, the eukaryotic microorganism can produce a lipid fraction comprising myristic, myristoleic, pentadecanoic, palmitic, palmitoleic, stearic oleic, linoleic, eicosadienoic, arachidonic, eicosapentaenoic, docosahexanoic and docosapentaenoic acids between 301.2 and 360.3 mg g⁻¹ or even up to 790 mg g⁻¹ of cellular biomass. The eukaryotic microorganism can also produce a fraction comprising between 44.3 and 57 mg g⁻¹ myristic acid (equal to 1134.5 to

1458.1 mg L⁻¹), 0.5 to 0.65 myristoleic acid (equal to 13.3 to 16.63 mg L⁻¹), 33.5 to 34.6 mg g⁻¹ pentadecanoic acid (equal to 856.9 to 885.1 mg L⁻¹), 121.9 and 165.1 mg g⁻¹ palmitic acid (equal to 3118.2 to 4223.3 mg L⁻¹), 7.9 to 28.5 mg g⁻¹ palmitoleic acid (equal to 202.1 to 729 mg L⁻¹), 4.38 to 5.9 mg g⁻¹ stearic acid (equal to 112 to 151 mg L⁻¹), 6.94 to 9.9 mg g⁻¹ oleic acid (equal to 177.5 to 253.2 mg L⁻¹), 0.4 to 1.3 mg g⁻¹ linoleic acid (equal to 11.26 to 33.3 mg L⁻¹), 0.5 to 1.0 mg g⁻¹ eicosadienoic acid (equal to 12.8 to 25.6 mg L⁻¹), 0.4 to 0.5 mg g⁻¹ arachidonic acid (equal to 10.2 to 13 mg L⁻¹), 75 to 100 mg g⁻¹ docosahexanoic acid (equal to 1918 to 2560 mg L⁻¹), 1.9 to 6 mg g⁻¹ eicosapentanoic acid (equal to 48.6 to 153.5 mg L⁻¹) and 17.1 to 33.7 mg g⁻¹ docosapentaenoic acid (equal to 437.4 to 862.1 mg L⁻¹), having a total fatty acid content within the cellular biomass of between 301 to 790 mg g⁻¹ (equal to 7700 to 20,209 mg L⁻¹).

(2) Other molecules

108. The eukaryotic microorganism can further produce carotenoids and xanthophylls. Examples of such carotenoids and xanthophylls include beta-carotene, lycopene, astaxanthin, canthaxanthin, phoenicoxanthin, zeaxanthin, echinenone, beta-cryptoxanthin, capsanthin, lutein, annatto, beta-apo-8-carotenal and beta-apo-8-carotenal-ester.

109. The xanthophylls produced by the disclosed eukaryotic microorganisms can be conjugated with the various PUFAs also produced by the disclosed eukaryotic microorganisms.

(a) Antioxidants

110. Generally, antioxidants are compounds that react with, and typically get consumed by oxygen. Since antioxidants typically react with oxygen, antioxidants also typically react with the free radical generators, and free radicals. ("The Antioxidants - The Nutrients that Guard Your Body" by Richard A. Passwater, Ph. D., 1985, Keats Publishing Inc., which is herein incorporated by reference at least for material related to antioxidants). The compositions can contain any antioxidants, and a non-limiting list would included but not be limited to, non-flavonoid antioxidants and nutrients that can directly scavenge free radicals including multi-carotenes, beta-carotenes, alpha-carotenes, gamma-carotenes, lycopene, lutein and zeaxanthins, selenium, Vitamin E, including alpha-, beta- and gamma- (tocopherol, particularly alpha-tocopherol, etc., vitamin E succinate, and trolox (a soluble Vitamin E analog) Vitamin C (ascorbic acid) and Niacin (Vitamin B₃, nicotinic acid and nicotinamide), Vitamin A, 13-cis retinoic acid, , N-acetyl-L-cysteine (NAC), sodium ascorbate, pyrrolidin-edithio-carbamate, and coenzyme Q₁₀; enzymes which catalyze the destruction of free radicals including peroxidases such as glutathione peroxidase (GSHPX) which acts on H₂O₂ and such as organic peroxidases, including catalase (CAT) which acts on H₂O₂, superoxide dismutase (SOD) which disproportionates O₂H₂O₂, glutathione transferase (GSHTx), glutathione reductase (GR), glucose

6-phosphate dehydrogenase (G6PD), and mimetics, analogs and polymers thereof (analogs and polymers of antioxidant enzymes, such as SOD, are described in, for example, U.S. Patent Ser. No. 5,171,680 which is incorporated herein by reference for material at least related to antioxidants and antioxidant enzymes); glutathione; ceruloplasmin; cysteine, and cysteamine (beta-mercaptoethylamine) and flavonoids and flavonoid like molecules like folic acid and folate. A review of antioxidant enzymes and mimetics thereof and antioxidant nutrients can be found in Kumar et al, *Pharmac. Ther.* 39: 301, 1988 and Machlin L. J. and Bendich, *FASEB Journal* 1:441-445, 1987 which are incorporated herein by reference for material related to antioxidants.

10 111. Flavonoids, also known as "phenylchromones," are naturally occurring, water-soluble compounds which have antioxidant characteristics. Flavonoids are widely distributed in vascular plants and are found in numerous vegetables, fruits and beverages such as tea and wine (particularly red wine). Flavonoids are conjugated aromatic compounds. The most widely occurring flavonoids are flavones and flavonols (for example, myricetin, (3,5,7,3',4',5',-
15 hexahydroxyflavone), quercetin (3,5,7,3',4'-pentahydroxyflavone), kaempferol (3,5,7,4'-tetrahydroxyflavone), and flavones apigenin (5,7,4'-trihydroxyflavone) and luteolin (5,7,3',4'-tetrahydroxyflavone) and glycosides thereof and quercetin).

112. Carotenoids are important natural pigments produced by many microorganisms and plants, usually red, orange or yellow in color. Traditionally, carotenoids have been used in the
20 feed, food and nutraceutical industries. They are known to be essential for plant growth and photosynthesis, and are a main dietary source of vitamin A in humans. Dietary antioxidants, such as carotenoids (beta-carotene, lycopene, astaxanthin, canthaxanthin, zeaxanthin, capsanthin, lutein, annatto, beta-apo-8-carotenal and beta-apo-8-carotenal-ester), exhibit significant anti-cancer activities and play an important role in the prevention of chronic diseases. Carotenoids
25 are potent biological antioxidants that can absorb the excited energy of singlet oxygen onto the carotenoid chain, leading to the degradation of the carotenoid molecule but preventing other molecules or tissues from being damaged.

113. Oxygen is required for metabolic functions, but it also presents challenges to cells. The human organism has a wide range of metabolic enzymes and antioxidants to rid its cells of
30 oxygen derived molecules. This oxidative stress is supposed to be a contributing factor in conditions such as rheumatoid arthritis, ischemic heart disease and stroke, Alzheimer's dementia, cancer and ageing. Therefore, antioxidants have the potential to protect against a wide spectrum of diseases. Several antioxidant compounds have been isolated from marine microbial sources; these include astaxanthin, beta-carotene and other carotenoids.

14. Carotenoids are a widely distributed group of naturally occurring pigments, with over 700 natural lipid-soluble pigments primarily produced by microalgal, macroalgal, bacterial and fungal species, with astaxanthin and its derivatives being of particular interest commercially. Astaxanthin is an extremely effective antioxidant protector. Yet, unlike beta-carotene, 5 astaxanthin readily crosses the blood-brain/retina barrier, and therefore also has potential to protect from diseases of the brain and the eyes. Preclinical studies suggest various beneficial effects of consuming astaxanthin such as: (i) inhibit cancer formation and growth in the bladder, colon, liver, mammary and the oral cavity; (ii) protect the retina of the eye from oxidative damage and thus has an effect against age related macular disease; (iii) promote increased 10 immune activity, (iv) provide protection from ultraviolet light damage, as well as (v) provide increased muscle endurance.

b) Isolation of microorganisms

115. Disclosed are microorganisms from the family Thraustochytriaceae obtained by a method comprising baiting a vegetative sample in salt water (natural sea or artificial) with pollen 15 grains and incubating; separating and transferring the grains to a heterotrophic medium and incubating; identifying an isolate that produces fatty acids, isolating from the identified isolate the microorganism from the family Thraustochytriaceae. Additional forms of isolation include media supplemented with appropriate antibiotics and identification via either by microscopic means as mentioned above or via the use of 18S rRNA gene primers or probes. The 20 heterotrophic medium can be as described below.

5. Lipids and other molecules produced by the eukaryotic microorganism

116. Disclosed are lipid compositions comprising from about 25 wt.% to about 40 wt.% of n-3 DHA, from about 6 wt.% to about 10 wt.% of n-6 DPA, and from about 0 wt.% to about 3 wt.% of n-3 EPA.

25 117. The lipid composition can further comprise from about 11 wt.% to about 15 wt.% (e.g., about 13 wt.%) myristic acid, from about 7 wt.% to about 11 wt. % (e.g., about 9 wt.%) pentadecanoic acid, from about 37 wt.% to about 41 wt.% (e.g., about 39 wt.%) palmitic acid, from about 3 wt.% to about 7 wt.% (e.g., about 5 wt.%) palmitoleic acid, from about 0 to about 3 wt.% (e.g., about 1 wt.%) stearic acid, or from about 1 wt.% to about 4 wt.% (e.g., about 2 wt.%) 30 oleic acid.

118. The lipid composition can comprise n-3 DHA in concentrations in excess of about 400 mg of biomass, n-6 DPA in concentrations in excess of 100 mg of biomass.

119. The lipid composition can further comprise carotenoids. Examples of such carotenoids include beta-carotene, lycopene, astaxanthin, zeaxanthin, canthaxanthin, echinenone,

phoenicoxanthin, capsanthin, lutein, annatto, beta-apo-8-carotenal, and beta-apo-8-carotenal-ester.

120. In one aspect, the composition can comprise at least about 24 wt.% n-3 DHA, about 1 wt. % n-3 DPA, about 6 wt.% n-6 DPA, and about 1 wt.% n-3 EPA.

5 **6. Compositions containing the molecules produced by the eukaryotic microorganism**

121. A foodstuff, supplement, pharmaceutical composition for both human and animal (including marine) can comprise the composition (lipid, lipid with antioxidant and antioxidant alone).

10 122. Also disclosed is an infant formula comprising the composition (lipid, lipid with antioxidant and antioxidant alone).

C. Methods

1. Methods of making lipids

123. Disclosed are methods of preparing a lipid composition, the method comprising:
15 culturing a eukaryotic microorganism comprising one or more microorganisms from the family Thraustochytriaceae, and isolating the lipid composition.

124. A variety of procedures can be employed in the recovery of the resultant cellular biomass from fermentation in various culture media, such as by filtration or centrifugation. The cells can then be washed, frozen, lyophilized, or spray dried, and stored under a non-oxidizing
20 atmosphere to eliminate the presence of oxygen, prior to incorporation into a processed food or feed product.

125. Cellular lipids containing the (n-3) DHA, EPA and (n-6) DPA PUFAs can also be extracted from the cellular biomass methods such as supercritical fluid extraction, or by extraction with solvents such as chloroform, hexane, methylene chloride, or methanol, and the
25 resulting extract evaporated under negative pressure to produce a sample of concentrated lipid material. The omega-3 and omega-6 PUFAs may be further concentrated by hydrolyzing the lipids and concentrating the highly unsaturated fraction by employing traditional methods such as urea adduction or fractional distillation, column chromatography, or by supercritical fluid fractionation. The cells can also be broken or lysed and the lipids extracted into vegetable or
30 animal (e.g. fish oils) oils. The extracted oils can be refined by well-known processes routinely employed to refine vegetable oils (e.g. by chemical or physical refining). These refining processes remove impurities from extracted oils before they are used or sold as edible oils. After refining, the oils can be used directly as a feed or food additive to produce omega-3 and/or

omega-6 enriched products. Alternatively, the oil can be further processed and purified as outlined below and then used in the above applications and also in pharmaceutical applications.

126. In another process for the production of enriched-(concentrated) omega-3 or omega-6 oils, the harvested cellular biomass (fresh or dried) can be ruptured or permeabilized by well-known techniques such as sonication, liquid-shear disruption methods, bead milling, pressing under high pressure, freeze-thawing, or enzymatic digestion of the cell wall. The lipids from the ruptured cells are extracted by use of a solvent or mixture of solvents such as hexane, chloroform, ether, or methanol. The solvent is removed and the lipids hydrolyzed by using any of the well-known methods for converting triglycerides to free fatty acids or esters of fatty acids including base, acid, or enzymatic hydrolysis. After hydrolysis is completed, the nonsaponifiable compounds are extracted into a solvent such as ether, hexane or chloroform and removed. The remaining solution is then acidified by addition of an acid, and the free fatty acid extracted into a solvent such as hexane, ether or chloroform. The solvent solution containing the free fatty acids can then be cooled to a temperature low enough for crystallization of the non-PUFA compounds, which can then be removed via filtration, centrifugation or settling. Resulting in the concentration of the remaining PUFA compounds and used as a nutritional supplements for humans, as a food additive, or as pharmaceutical applications.

127. Also, disclosed is a lipid composition prepared by the method disclosed above.

128. The microorganisms from the family Thraustochytriaceae can be any of the microorganisms disclosed above.

a) Medium

129. The heterotrophic medium can comprise sea salt (artificial or natural), one or more carbon sources, and one or more nitrogen sources. The sea salt can be present in an amount of from about 2.0 to about 40.0 g L⁻¹. The concentration of the carbon and nitrogen source used under standard cultivation conditions (not for high-concentration, but rather cost efficient fermentation) falls within the range of 5 g L⁻¹ to 60 g L⁻¹ and 4 g L⁻¹ to 10 g L⁻¹, respectively. For high-concentration fermentation, the concentration of the carbon and nitrogen source used under standard cultivation conditions falls within the range of 100 g L⁻¹ and 160 g L⁻¹ and 40 g L⁻¹ to 60 g L⁻¹, respectively. The trend being that for oil accumulation, the eukaryotic microorganism is grown in a culture medium (as those described above) in which the supply of nitrogen is limited after about 24 to about 48 hours, while the supply of carbon remains in abundance. This eukaryotic microorganism continues to assimilate the carbon (in the form of simple sugars) but can no longer undergo cell division due to a lack of nitrogen for the generation of relevant proteins and nucleic acids. The result being that these sugars are converted into storage oils,

much in the same way that Rattledge C. (*Lipid Tech.* 16:34-39, 2004) describes and figure 9 depicts this phenomenon specific for this organism.

130. The nitrogen source can be one or more of peptone, yeast extract, malt extract, and sodium glutamate. The nitrogen source can also be corn steep liquor or cotton seed extract. The nitrogen source can comprise yeast extract and/or peptone or monosodium glutamate. For example, the nitrogen source can include, but is not limited to EMD™ YE-MSG, EMD™ YE, EMD™ Peptone-MSG, Sigma™ YE-MSG, Sigma™ YE, Fermtech™ YE-MSG, Fermtech™ YE, or Fish meal (62% protein). The yeast extract can be present in an amount of about 2 g L⁻¹. The monosodium glutamate can be present in an amount of about 8 g L⁻¹.

131. The carbon source can be one or more of D-trehalose, glycerol, D-gluconic acid, L-lactic acid, D,L-malic acid, D-ribose, Tween 20, D-fructose, acetate, acetic acid, alpha-D-glucose, maltose, thymidine, L-asparagine, D-xylose, Tween 40, α-keto-glutaric acid, sucrose, L-glutamine, Tween 80, beta-methyl-D-glucoside, maltotriose, adenosinine, fumaric acid, bromo succinic acid, L-serine, D-cellobiose, L-alanyl-glycine, methyl pyruvate, L-malic acid, glycyl-L-proline, D-palcose, L-lyxose, pyruvic acid, alpha-D-lactose, dextrin, D-arabinose, 2-deoxy-D-ribose, gelatin, dextrose, starch, 3-0-beta-D-galactopyranosyl-D-arabinose, D-tagatose, 5-keto-D-gluconic acid, oxalomalic acid, sorbic acid, L-omithine, and dihydroxy acetate. In one aspect, the carbon source can be D,L-malic acid, D-fructose, D-xylose, fumaric acid, D-cellobiose, 5-keto-D-gluconic acid, pyruvic acid, alpha-D-lactose, corn dextrin, gelatin, corn starch or wheat starch.. The carbon source can be present in an amount of from about 1 g L⁻¹ to about 60 g L⁻¹ and up to about 200 g L⁻¹.

132. In one example, the medium can comprise about 5 g D-glucose, about 2 g peptone, and about 2 g yeast extract per liter of salt water (natural or artificial). In another, the medium can comprise about 60 g D-glucose, about 10 g yeast extract per liter of salt water (natural or artificial). In another, the medium can comprise about 8 g yeast extract, 32 g MSG, 24 g sea salt (natural and artificial) and 300 g D-glucose per liter.

133. The medium can further comprise phosphates (e.g., potassium phosphate and sodium phosphates). The medium can further comprise inorganic salts (e.g., ammonium sulfate, sodium bicarbonate, sodium orthovanadate, potassium chromate, sodium molybdate, selenous acid, nickel sulfate, copper sulfate, zinc sulfate, cobalt chloride, iron chloride, manganese chloride). The medium can further comprise a chelating compound (e.g., EDTA). The medium can further comprise vitamins (e.g., pyridoxine hydrochloride, thiamin hydrochloride, calcium pantothenate, p-aminobenzoic acid, riboflavin, nicotinic acid, biotin, folic acid, and vitamin B₁₂). The medium can be at a pH of from about 4.0 to about 6.5.

134. Incubation can be from about 1 to about 9 days (e.g., from about 3 to about 5 days).

Incubation can be at from about 18 to about 30°C (e.g., from about 18-25°C). Incubation can further comprise shaking or aeration.

135. Isolating the lipid can comprise contacting the microorganisms with an extraction solvent. The solvent can comprise one or more solvents chosen from chloroform, hexane, methanol, or ethanol, or supercritical CO₂.

136. The method can produce any of the compositions as disclosed above.

137. The eukaryotic microorganism can produce a lipid composition comprising n-3 DHA at greater than or equal to about 20 g L⁻¹ of medium. The eukaryotic microorganism can produce a lipid composition comprising n-3 DHA at greater than or equal to about 40 g L⁻¹ of medium. The eukaryotic microorganism can produce a lipid composition comprising n-3 DHA at greater than or equal to about 80 g L⁻¹ of medium.

2. Screening and identification methods

138. The eukaryotic microorganism as disclosed herein can produce a lipid containing the (n-3) series of docosahexaenoic acid and eicosapentaenoic acid and the (n-6) series of DPA. These eukaryotic microorganism can be selected, for example, with the following screening method. Vegetative samples can be (and were) placed in 20 mL vials containing 10 mL of sterile 0.2 µm filtered natural seawater containing penicillin and streptomycin at 300 and 500 mg L⁻¹, respectively. The vials were then baited with sterile pollen grains and incubated for 48 hours at 18 to 25°C. The pollen grains were then transferred onto agar plates containing antibiotics (as above) and incubated under the same conditions. Single, irregular, hyaline colonies made up of spherical or limaciform cells and atypical of either yeast or bacterial colonies were picked and sub-cultured on the same medium and under the same conditions as above. These isolates were then screened for growth and fatty acids using a nutrient liquid medium, prepared with 0.2 µm filtered natural seawater containing 5 g L⁻¹ glucose, 2 g L⁻¹ peptone and 2 g L⁻¹ yeast extract, with the resulting cellular biomass collected by centrifugation or sedimentation within a liquid medium. Fatty acids were directly transesterified using conventional methods, with the fatty acid methyl ester composition analyzed via gas chromatography, with strains that produce appropriate amounts of the n-3 series of DHA and the n-6 series of DPA selected for further work.

139. Disclosed are methods of identifying an eukaryotic microorganism, the method comprising: baiting a vegetative sample in salt water (natural sea or artificial) with pollen grains and incubating; transferring the grains to a heterotrophic medium and incubating; and identifying isolates that produce fatty acids.

140. Also disclosed are lipid compositions produced by the above identified eukaryotic microorganisms.

141. Also disclosed are lipid compositions produced by methods using the disclosed eukaryotic microorganisms and the methods disclosed herein.

142. Also disclosed are eukaryotic microorganisms (ONC-T18) having American Type Culture Collection accession number PTA-6245.

143. Also disclosed are eukaryotic microorganisms belonging to the order Thraustochytriales (ONC-T18) having 18S rRNA, such as SEQ ID 1, and identified as a *Thraustochytrium* sp.

144. Also disclosed is a eukaryotic microorganism, *Thraustochytrium* sp. capable of producing DHA and DPA in concentrations in excess of 400 mg L⁻¹ and 100 mg L⁻¹, respectively.

145. Also disclosed is a eukaryotic microorganism, *Thraustochytrium* sp. capable of producing carotenoids via heterotrophic fermentation as mentioned above in the range 50 to 1250 mg kg⁻¹ and astaxanthin, zeaxanthin, canthaxanthin, echinenine and beta-carotene in the range of 1 to 20 mg kg⁻¹, 0.25 to 10 mg kg⁻¹, 1 to 20 mg kg⁻¹, 1 to 20 mg kg⁻¹ and 1 to 200 mg kg⁻¹, respectively.

146. Also disclosed are processes for growing a eukaryotic microorganism comprising, culturing the eukaryotic microorganism under conditions, wherein the conditions comprise a medium comprising sodium chloride in the form of artificial sea salt (trophic marine) between 2.0 and 15.0 g L⁻¹; a nitrogen source in the form of yeast extract and monosodium glutamate at 2.0 and 8.0 g L⁻¹ respectively; and carbon in the form of glucose up to 130 g L⁻¹.

147. The disclosed processes can, for example, grow ONC-T18, whereby at least 24% weight is DHA, at least 6% by weight is DPA and at least 1 % is EPA of total fatty acid.

148. The disclosed processes for growth can also, for example, grow ONC-T18 such that at least 1% by weight is carotenoid material, with from 1 to 2% and at least 1.2% of that being astaxanthin, with from 0.25 and 1% and at least 0.45% being zeaxanthin, with from 5 to 16% and at least 9% being canthaxanthin, with from 1 to 2% and at least 1.2% of that being echinenone and from 12 to 16% and at least 14% by weight being beta-carotene.

3. Nucleic acids

149. There are a variety of molecules disclosed herein that are nucleic acid based, including for example the nucleic acids that encode, for example, rRNA, as well as any other proteins disclosed herein, as well as various functional nucleic acids. The disclosed nucleic acids are made up of for example, nucleotides, nucleotide analogs, or nucleotide substitutes.

Non-limiting examples of these and other molecules are discussed herein. It is understood that for example, when a vector is expressed in a cell, that the expressed mRNA will typically be made up of A, C, G, and U/T. Likewise, it is understood that if, for example, an antisense molecule is introduced into a cell or cell environment through for example exogenous delivery, it is advantageous that the antisense molecule be made up of nucleotide analogs that reduce the degradation of the antisense molecule in the cellular environment.

a) Nucleotides and related molecules

150. A nucleotide is a molecule that contains a base moiety, a sugar moiety and a phosphate moiety. Nucleotides can be linked together through their phosphate moieties and sugar moieties creating an internucleoside linkage. The base moiety of a nucleotide can be adenin-9-yl (A), cytosin-1-yl (C), guanin-9-yl (G), uracil-1-yl (U), and thymine-1-yl (T). The sugar moiety of a nucleotide is a ribose or a deoxyribose. The phosphate moiety of a nucleotide is pentavalent phosphate. An non-limiting example of a nucleotide would be 3'-AMP (3'-adenosine monophosphate) or 5'-GMP (5'-guanosine monophosphate).

151. A nucleotide analog is a nucleotide which contains some type of modification to either the base, sugar, or phosphate moieties. Modifications to nucleotides are well known in the art and would include for example, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, and 2-aminoadenine as well as modifications at the sugar or phosphate moieties.

152. Nucleotide substitutes are molecules having similar functional properties to nucleotides, but which do not contain a phosphate moiety, such as peptide nucleic acid (PNA). Nucleotide substitutes are molecules that will recognize nucleic acids in a Watson-Crick or Hoogsteen manner, but which are linked together through a moiety other than a phosphate moiety. Nucleotide substitutes are able to conform to a double helix type structure when interacting with the appropriate target nucleic acid.

153. It is also possible to link other types of molecules (conjugates) to nucleotides or nucleotide analogs to enhance for example, cellular uptake. Conjugates can be chemically linked to the nucleotide or nucleotide analogs. Such conjugates include but are not limited to lipid moieties such as a cholesterol moiety. (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 86:6553-6556, 1989),

154. A Watson-Crick interaction is at least one interaction with the Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute. The Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute includes the C2, N1, and C6 positions of a

purine based nucleotide, nucleotide analog, or nucleotide substitute and the C2, N3, C4 positions of a pyrimidine based nucleotide, nucleotide analog, or nucleotide substitute.

155. A Hoogsteen interaction is the interaction that takes place on the Hoogsteen face of a nucleotide or nucleotide analog, which is exposed in the major groove of duplex DNA. The Hoogsteen face includes the N7 position and reactive groups (NH₂ or O) at the C6 position of purine nucleotides.

b) Sequences

156. There are a variety of sequences related to, for example, SEQ ID NO:1, as well as any other nucleic acids and proteins disclosed herein that can be disclosed on Genbank, and these sequences and others are herein incorporated by reference in their entireties as well as for individual subsequences contained therein.

157. A variety of sequences are provided herein and these and others can be found in Genbank, at www.pubmed.gov. Those of skill in the art understand how to resolve sequence discrepancies and differences and to adjust the compositions and methods relating to a particular sequence to other related sequences. Primers and/or probes can be designed for any sequence given the information disclosed herein and known in the art.

c) Primers and probes

158. Disclosed are compositions including primers and probes, which are capable of interacting with the genes disclosed herein. In certain embodiments the primers are used to support DNA amplification reactions. Typically the primers will be capable of being extended in a sequence specific manner. Extension of a primer in a sequence specific manner includes any methods wherein the sequence and/or composition of the nucleic acid molecule to which the primer is hybridized or otherwise associated directs or influences the composition or sequence of the product produced by the extension of the primer. Extension of the primer in a sequence specific manner therefore includes, but is not limited to, PCR, DNA sequencing, DNA extension, DNA polymerization, RNA transcription, or reverse transcription. Techniques and conditions that amplify the primer in a sequence specific manner are preferred. In certain aspects the primers may be used as species or genus specific probes for the *Thraustochytrium* or *Bacillus* mentioned here. In this instance, primers would be designed to be specific to the eukaryotic microorganism, with PCR reactions subsequently carried out. Presence of target species would then be determined by successful PCR product formation. In certain aspects the primers can also be used for DNA amplification reactions, such as PCR or direct sequencing. It is understood that in certain aspects the primers can also be extended using non-enzymatic techniques, where for example, the nucleotides or oligonucleotides used to extend the primer are modified such that

they will chemically react to extend the primer in a sequence specific manner. Typically the disclosed primers hybridize with the nucleic acid or region of the nucleic acid or they hybridize with the complement of the nucleic acid or complement of a region of the nucleic acid.

d) Nucleic Acid Delivery

5 159. In the methods described above which include the administration and uptake of exogenous DNA into the cells of a subject (i.e., gene transduction or transfection), the disclosed nucleic acids can be in the form of naked DNA or RNA, or the nucleic acids can be in a vector for delivering the nucleic acids to the cells, whereby the antibody-encoding DNA fragment is under the transcriptional regulation of a promoter, as would be well understood by one of
10 ordinary skill in the art. The vector can be a commercially available preparation, such as an adenovirus vector (Quantum Biotechnologies, Inc. (Laval, Quebec, Canada). Delivery of the nucleic acid or vector to cells can be via a variety of mechanisms. As one example, delivery can be via a liposome, using commercially available liposome preparations such as LIPOFECTIN,
15 LIPOFECTAMINE (GIBCO-BRL, Inc., Gaithersburg, MD), SUPERFECT (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM (Promega Biotec, Inc., Madison, WI), as well as other liposomes developed according to procedures standard in the art. In addition, the disclosed nucleic acid or vector can be delivered *in vivo* by electroporation, the technology for which is available from Genetronics, Inc. (San Diego, CA) as well as by means of a SONOPORATION machine (ImaRx Pharmaceutical Corp., Tucson, AZ).

20 160. As one example, vector delivery can be via a viral system, such as a retroviral vector system which can package a recombinant retroviral genome (see e.g., Pastan et al., *Proc. Natl. Acad. Sci. U.S.A.* 85:4486, 1988; Miller et al., *Mol. Cell. Biol.* 6:2895, 1986). The recombinant retrovirus can then be used to infect and thereby deliver to the infected cells nucleic acid encoding a broadly neutralizing antibody (or active fragment thereof). The exact method of
25 introducing the altered nucleic acid into mammalian cells is, of course, not limited to the use of retroviral vectors. Other techniques are widely available for this procedure including the use of adenoviral vectors (Mitani et al., *Hum. Gene Ther.* 5:941-948, 1994), adeno-associated viral (AAV) vectors (Goodman et al., *Blood* 84:1492-1500, 1994), lentiviral vectors (Naidini et al., *Science* 272:263-267, 1996), pseudotyped retroviral vectors (Agrawal et al., *Exper. Hematol.*
30 24:738-747, 1996). Physical transduction techniques can also be used, such as liposome delivery and receptor-mediated and other endocytosis mechanisms (see, for example, Schwartzenberger et al., *Blood* 87:472-478, 1996). This disclosed compositions and methods can be used in conjunction with any of these or other commonly used gene transfer methods.

4. Expression systems

161. The nucleic acids that are delivered to cells typically contain expression controlling systems. For example, the inserted genes in viral and retroviral systems usually contain promoters, and/or enhancers to help control the expression of the desired gene product. A promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and may contain upstream elements and response elements.

162. It is understood that there are a variety of transcription control systems that can be used in the organisms disclosed herein, in addition to the general systems discussed below. It is understood that the organisms disclosed herein can be transfected and transformed with a variety of genes, such as marker genes, as discussed herein, or genes which have other desirable attributes, such as enhanced or unique growth characteristics.

a) Viral Promoters and Enhancers

163. Preferred promoters controlling transcription from vectors in mammalian host cells may be obtained from various sources, for example, the genomes of viruses such as: polyoma, Simian Virus 40 (SV40), adenovirus, retroviruses, hepatitis-B virus and most preferably cytomegalovirus, or from heterologous mammalian promoters, e.g. beta actin promoter. The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment which also contains the SV40 viral origin of replication (Fiers et al., *Nature*, 273:113, 1978). The immediate early promoter of the human cytomegalovirus is conveniently obtained as a *HindIII* E restriction fragment (Greenway, P.J. et al., *Gene* 18:355-360, 1982). Of course, promoters from the host cell or related species also are useful herein.

164. Enhancer generally refers to a sequence of DNA that functions at no fixed distance from the transcription start site and can be either 5' (Laimins, L. et al., *Proc. Natl. Acad. Sci.* 78:993, 1981) or 3' (Lusky, M.L., et al., *Mol. Cell Bio.* 3:1108, 1983) to the transcription unit. Furthermore, enhancers can be within an intron (Banerji, J.L. et al., *Cell* 33:729, 1983) as well as within the coding sequence itself (Osborne, T.F., et al., *Mol. Cell Bio.* 4:1293, 1984). They are usually between 10 and 300 bp in length, and they function in *cis*. Enhancers function to increase transcription from nearby promoters. Enhancers also often contain response elements that mediate the regulation of transcription. Promoters can also contain response elements that mediate the regulation of transcription. Enhancers often determine the regulation of expression of a gene. While many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, alpha-fetoprotein and insulin), typically one will use an enhancer from a

~~eukaryotic cell virus for general expression.~~ Preferred examples are the SV40 enhancer on the late side of the replication origin (100-270 bp), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

165. The promotor and/or enhancer may be specifically activated either by light or
5 specific chemical events which trigger their function. Systems can be regulated by reagents such as tetracycline and dexamethasone. There are also ways to enhance viral vector gene expression by exposure to irradiation, such as gamma irradiation, or alkylating chemotherapy drugs.

166. In certain embodiments the promoter and/or enhancer region can act as a
constitutive promoter and/or enhancer to maximize expression of the region of the transcription
10 unit to be transcribed. In certain constructs the promoter and/or enhancer region be active in all eukaryotic cell types, even if it is only expressed in a particular type of cell at a particular time. A preferred promoter of this type is the CMV promoter (650 bp). Other preferred promoters are SV40 promoters, cytomegalovirus (full length promoter), and retroviral vector LTR.

167. It has been shown that all specific regulatory elements can be cloned and used to
15 construct expression vectors that are selectively expressed in specific cell types such as melanoma cells. The glial fibrillary acetic protein (GFAP) promoter has been used to selectively express genes in cells of glial origin.

168. Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal,
human or nucleated cells) may also contain sequences necessary for the termination of
20 transcription which may affect mRNA expression. These regions are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding tissue factor protein. The 3' untranslated regions also include transcription termination sites. It is preferred that the transcription unit also contain a polyadenylation region. One benefit of this region is that it increases the likelihood that the transcribed unit will be processed and transported like mRNA.
25 The identification and use of polyadenylation signals in expression constructs is well established. It is preferred that homologous polyadenylation signals be used in the transgene constructs. In certain transcription units, the polyadenylation region is derived from the SV40 early polyadenylation signal and consists of about 400 bases. It is also preferred that the transcribed units contain other standard sequences alone or in combination with the above sequences
30 improve expression from, or stability of, the construct.

b) Markers

169. The viral vectors can include nucleic acid sequence encoding a marker product. This marker product is used to determine if the gene has been delivered to the cell and once

delivered is being expressed. Preferred marker genes are the *E. coli lacZ* gene, which encodes β -galactosidase, and green fluorescent protein.

170. In some embodiments the marker may be a selectable marker. Examples of suitable selectable markers for mammalian cells are dihydrofolate reductase (DHFR), thymidine kinase, neomycin, neomycin analog G418, hydromycin, and puromycin. When such selectable markers are successfully transferred into a mammalian host cell, the transformed mammalian host cell can survive if placed under selective pressure. There are two widely used distinct categories of selective regimes. The first category is based on a cell's metabolism and the use of a mutant cell line which lacks the ability to grow independent of a supplemented media. Two examples are: CHO DHFR-cells and mouse LTK-cells. These cells lack the ability to grow without the addition of such nutrients as thymidine or hypoxanthine. Because these cells lack certain genes necessary for a complete nucleotide synthesis pathway, they cannot survive unless the missing nucleotides are provided in a supplemented media. An alternative to supplementing the media is to introduce an intact DHFR or TK gene into cells lacking the respective genes, thus altering their growth requirements. Individual cells which were not transformed with the DHFR or TK gene will not be capable of survival in non-supplemented media.

171. The second category is dominant selection which refers to a selection scheme used in any cell type and does not require the use of a mutant cell line. These schemes typically use a drug to arrest growth of a host cell. Those cells which have a novel gene would express a protein conveying drug resistance and would survive the selection. Examples of such dominant selection use the drugs neomycin, (Southern P. and Berg, P., *J. Molec. Appl. Genet.* 1:327, 1982), mycophenolic acid, (Mulligan, R.C. and Berg, P. *Science* 209:1422, 1980) or hygromycin, (Sugden, B. et al., *Mol. Cell. Biol.* 5:410-413, 1985). The three examples employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid) or hygromycin, respectively. Others include the neomycin analog G418 and puramycin.

5. Peptides

a) Protein variants

172. As discussed herein there are numerous variants of the disclosed organism proteins that are known and herein contemplated. In addition, to the known functional Thraustochytriales strain there are derivatives of the Thraustochytriales proteins which also function in the disclosed methods and compositions. Protein variants and derivatives are well understood to those of skill in the art and in can involve amino acid sequence modifications. For example, amino acid sequence modifications typically fall into one or more of three classes: substitutional, insertional

or deletional variants. Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues. Immunogenic fusion protein derivatives, such as those described in the examples, are made by fusing a polypeptide sufficiently large to confer immunogenicity to the target sequence by cross-linking in vitro or by recombinant cell culture transformed with DNA encoding the fusion. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. Typically, no more than about from 2 to 6 residues are deleted at any one site within the protein molecule. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example M13 primer mutagenesis and PCR mutagenesis. Amino acid substitutions are typically of single residues, but can occur at a number of different locations at once; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. The mutations must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Tables 1 and 2 and are referred to as conservative substitutions.

173. Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those in Table 2, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the protein properties will be those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g.,

phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine, in this case, (e) by increasing the number of sites for sulfation and/or glycosylation.

TABLE 1: Amino Acid Abbreviations

Amino Acid	Abbreviations
Alanine	Ala A
Arginine	Arg R
Asparagine	Asn N
Aspartic acid	Asp D
Cysteine	Cys C
Glutamine	Gln Q
Glutamic acid	Glu E
Glycine	Gly G
Histidine	His H
Isoleucine	Ile I
Leucine	Leu L
Lysine	Lys K
Methionine	Met M
Phenylalanine	Phe F
Proline	Pro P
Serine	Ser S
Threonine	Thr T
Tryptophan	Trp W
Tyrosine	Tyr Y
Valine	Val V

5

TABLE 2: Amino Acid Substitutions

Original Residue	Exemplary Conservative Substitutions*
Ala	Ser
Arg	Lys; Gln
Asn	Gln; His
Asp	Glu
Cys	Ser
Gln	Asn; Lys
Glu	Asp
Gly	Pro
His	Asn; Gln
Ile	Leu; Val
Leu	Ile; Val
Lys	Arg; Gln
Met	Leu; Ile
Phe	Met; Leu; Tyr
Pro	Gly
Ser	Thr
Thr	Ser
Trp	Tyr
Tyr	Trp; Phe
Val	Ile; Leu

* Others are known in the art

174. For example, the replacement of one amino acid residue with another that is biologically and/or chemically similar is known to those skilled in the art as a conservative substitution. For example, a conservative substitution would be replacing one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as, for example, Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe,

10

Tyr. Such conservatively substituted variations of each explicitly disclosed sequence are included within the mosaic polypeptides provided herein.

175. Substitutional or deletional mutagenesis can be employed to insert sites for N-glycosylation (Asn-X-Thr/Ser) or O-glycosylation (Ser or Thr). Deletions of cysteine or other labile residues also may be desirable. Deletions or substitutions of potential proteolysis sites, e.g. Arg, is accomplished for example by deleting one of the basic residues or substituting one by glutamyl or histidyl residues.

176. Certain post-translational derivatizations are the result of the action of recombinant host cells on the expressed polypeptide. Glutamyl and asparaginyl residues are frequently post-translationally deamidated to the corresponding glutamyl and asparyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the o-amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, *Proteins: Structure and Molecular Properties*, W. H. Freeman & Co., San Francisco pp 79-86, 1983), acetylation of the N-terminal amine and, in some instances, amidation of the C-terminal carboxyl.

177. It is understood that one way to define the variants and derivatives of the disclosed proteins herein is through defining the variants and derivatives in terms of homology/identity to specific known sequences. Specifically disclosed are variants of proteins herein disclosed which have at least, 60%, 70% or 75% or 80% or 85% or 90% or 95% homology to the stated sequence. Those of skill in the art readily understand how to determine the homology of two proteins. For example, the homology can be calculated after aligning the two sequences so that the homology is at its highest level.

178. Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman *Adv. Appl. Math.* 2: 482, 1981, by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48: 443, 1970, by the search for similarity method of Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85: 2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection.

179. The same types of homology can be obtained for nucleic acids by for example the algorithms disclosed in Zuker, M. *Science* 244:48-52, 1989, Jaeger et al. *Proc. Natl. Acad. Sci.*

USA 86:7706-7710, 1989, Jaeger et al. *Methods Enzymol.* 183:281-306, 1989 which are herein incorporated by reference for at least material related to nucleic acid alignment.

180. It is understood that the description of conservative mutations and homology can be combined together in any combination, such as embodiments that have at least 70%
5 homology to a particular sequence wherein the variants are conservative mutations.

181. As this specification discusses various proteins and protein sequences it is understood that the nucleic acids that can encode those protein sequences are also disclosed. This would include all degenerate sequences related to a specific protein sequence, i.e. all nucleic acids having a sequence that encodes one particular protein sequence as well as all
10 nucleic acids, including degenerate nucleic acids, encoding the disclosed variants and derivatives of the protein sequences. Thus, while each particular nucleic acid sequence may not be written out herein, it is understood that each and every sequence is in fact disclosed and described herein through the disclosed protein sequence. It is also understood that while no amino acid sequence indicates what particular DNA sequence encodes that protein within an organism, where
15 particular variants of a disclosed protein are disclosed herein, the known nucleic acid sequence that encodes that protein in the particular strain from which that protein arises is also known and herein disclosed and described.

182. It is understood that there are numerous amino acid and peptide analogs which can be incorporated into the disclosed compositions. For example, there are numerous D amino
20 acids or amino acids which have a different functional substituent than the amino acids shown in Table 1 and Table 2. The opposite stereo isomers of naturally occurring peptides are disclosed, as well as the stereo isomers of peptide analogs. These amino acids can readily be incorporated into polypeptide chains by charging tRNA molecules with the amino acid of choice and engineering genetic constructs that utilize, for example, amber codons, to insert the analog
25 amino acid into a peptide chain in a site specific way (Thorson et al., *Methods in Mol. Biol.* 77:43-73, 1991, Zoller, *Curr. Opin. Biotech.*, 3:348-354, 1992; Ibba, *Biotechnol. Genet. Eng.* 13:197-216, 1995, Cahill et al., *Trends Biochem. Sci.*, 14:400-403, 1989; Benner, *Trends. Biotechnol.*, 12:158-163, 1994) all of which are herein incorporated by reference at least for material related to amino acid analogs).

30 183. Molecules can be produced that resemble peptides, but which are not connected via a natural peptide linkage. For example, linkages for amino acids or amino acid analogs can include $\text{CH}_2\text{NH--}$, $\text{--CH}_2\text{S--}$, $\text{--CH}_2\text{--CH}_2\text{--}$, --CH=CH-- (cis and trans), $\text{--COCH}_2\text{--}$, $\text{--CH(OH)CH}_2\text{--}$, and $\text{--CHH}_2\text{SO--}$ (These and others can be found in Spatola, A. F. in *Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins*, B. Weinstein, eds., Marcel Dekker,

New York, p. 267, 1983; Spatola, A. F., Vega Data (March 1983), Vol. 1, Issue 3, Peptide Backbone Modifications (general review); Morley, *Trends Pharm. Sci.* 463-468, 1980; Hudson, D. et al., *Int. J. Pept. Prot. Res.* 14:177-185, 1979 (--CH₂NH--, CH₂CH₂--); Spatola et al. *Life Sci.* 38:1243-1249, 1986 (--CH H₂--S); Hann J. *Chem. Soc. Perkin Trans. I* 307-314, 1982 (--CH--CH--, cis and trans); Almquist et al. *J. Med. Chem.* 23:1392-1398, 1980 (--COCH₂--); Jennings-White et al. *Tetrahedron Lett.*, 23:2533, 1982 (--COCH₂--); Szelke et al. *European Appln.*, EP 45665 CA: 97:39405, 1982 (--CH(OH)CH₂--); Holladay et al. *Tetrahedron Lett.* 24:4401-4404, 1983 (--C(OH)CH₂--); and Hruby *Life Sci.* 31:189-199, 1982 (--CH₂--S--); each of which is incorporated herein by reference. A particularly preferred non-peptide linkage is --CH₂NH--. It is understood that peptide analogs can have more than one atom between the bond atoms, such as β -alanine, γ -aminobutyric acid, and the like.

184. Amino acid analogs and analogs and peptide analogs often have enhanced or desirable properties, such as, more economical production, greater chemical stability, enhanced pharmacological properties (half-life, absorption, potency, efficacy, etc.), altered specificity (e.g., a broad-spectrum of biological activities), reduced antigenicity, and others.

185. D-amino acids can be used to generate more stable peptides, because D amino acids are not recognized by peptidases and such. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) can be used to generate more stable peptides. Cysteine residues can be used to cyclize or attach two or more peptides together. This can be beneficial to constrain peptides into particular conformations. (Rizo and Gierasch *Ann. Rev. Biochem.* 61:387, 1992, incorporated herein by reference).

6. Supplements

186. Also disclosed herein are nutritional supplements. A nutritional supplement is any compound or composition that can be administered to or taken by a subject to provide, supply, or increase a nutrient(s) (e.g., vitamin, mineral, essential trace element, amino acid, peptide, nucleic acid, oligonucleotide, lipid, cholesterol, steroid, carbohydrate, and the like). In one aspect, disclosed herein are nutritional supplements comprising any of the compounds disclosed herein. For example, a nutritional supplement can comprise any of the lipids disclosed herein. The fatty acid residues of these lipids can be any fatty acid as disclosed herein (e.g., unsaturated or saturated fatty acid residues).

187. The nutritional supplement can comprise any amount of the compounds disclosed herein, but will typically contain an amount determined to supply a subject with a desired dose of a benzenediol derivative (e.g., CoQ₁₀) and/or fatty acids. The exact amount of compound

required in the nutritional supplement will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the dietary deficiency being treated, the particular mode of administration, and the like. Thus, it is not possible to specify an exact amount for every nutritional supplement. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein. In one specific example, a nutritional supplement can comprise from about 0.05 to about 20%, from about 1 to about 7.5%, or from about 3 to about 5% by weight of the compound. In another example, the nutritional supplement can comprise from about 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, or 20.0% by weight of the compound, where any of the stated values can form an upper or lower endpoint when appropriate. In another aspect, when the nutritional supplement, the supplement can be composed of up to 100% of the supplement.

188. The nutritional supplement can also comprise other nutrient(s) such as vitamins trace elements, minerals, and the like. Further, the nutritional supplement can comprise other components such as preservatives, antimicrobials, anti-oxidants, chelating agents, thickeners, flavorings, diluents, emulsifiers, dispersing aids, and/or binders.

189. The nutritional supplements are generally taken orally and can be in any form suitable for oral administration. For example, a nutritional supplement can typically be in a tablet, gel-cap, capsule, liquid, sachets, or syrup form.

7. Delivery Devices

190. Any of the compounds described herein can be incorporated into a delivery device. Examples of delivery devices include, but are not limited to, microcapsules, microspheres, nanospheres or nanoparticles, liposomes, noisome, nanoerythroosome, solid-liquid nanoparticles, gels, gel capsules, tablets, lotions, creams, sprays, or emulsions. Other examples of delivery devices that are suitable for non-oral administration include pulmospheres. Examples of particular delivery devices useful herein are described below.

191. The disclosed compounds can be incorporated into liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The disclosed compositions in liposome form can contain, in addition to a compound disclosed herein, stabilizers, preservatives, excipients, and the like.

Examples of suitable lipids are the phospholipids and the phosphatidylcholines (lecithins), both natural and synthetic. Methods of forming liposomes are known in the art. *See, e.g.*, Prescott, Ed., *Methods in Cell Biology*, Volume XIV, Academic Press, New York, p. 33 et seq., 1976, which is hereby incorporated by reference herein for its teachings of liposomes and their
5 preparation.

192. In other examples, the liposomes can be cationic liposomes (*e.g.*, DOTMA, DOPE, DC cholesterol) or anionic liposomes. Liposomes can further comprise proteins to facilitate targeting a particular cell, if desired. Administration of a composition comprising a compound and a cationic liposome can be administered to the blood afferent to a target organ or
10 inhaled into the respiratory tract to target cells of the respiratory tract. Regarding liposomes, *see e.g.*, Brigham, *et al.*, *Am J Resp Cell Mol Biol* 1:95-100, 1989; Felgner, *et al.*, *Proc Natl Acad Sci USA* 84:7413-7, 1987; and U.S. Pat. No. 4,897,355, which are incorporated by reference herein for their teachings of liposomes. As one example, delivery can be via a liposome using commercially available liposome preparations such as LIPOFECTIN, LIPOFECTAMINE
15 (GIBCO-BRL, Inc., Gaithersburg, MD), SUPERFECT (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM (Promega Biotec, Inc., Madison, WI), as well as other liposomes developed according to procedures standard in the art. Liposomes where the diffusion of the compound or delivery of the compound from the liposome is designed for a specific rate or dosage can also be used.

20 193. As described herein, noisomes are delivery devices that can be used to deliver the compositions disclosed herein. Noisomes are multilamellar or unilamellar vesicles involving non-ionic surfactants. An aqueous solution of solute is enclosed by a bilayer resulting from the organization of surfactant macromolecules. Similar to liposomes, noisomes are used in targeted delivery of, for example, anticancer drugs, including methotrexate, doxorubicin, and
25 immunoadjuvants. They are generally understood to be different from transferosomes, vesicles prepared from amphiphilic carbohydrate and amino group containing polymers, *e.g.*, chitosan.

194. As described herein, nanoerythrocytes are delivery devices that can be used to deliver the compositions disclosed herein. Nanoerythrocytes are nano-vesicles made of red
30 blood cells via dialysis through filters of defined pore size. These vesicles can be loaded with a diverse array of biologically active molecules, including proteins and the compositions disclosed herein. They generally serve as ideal carriers for antineoplastic agents like bleomycin, actinomycin D, but can be used for steroids, other lipids, etc.

195. Artificial red blood cells, as described herein, are further delivery devices that can be used to deliver the compositions disclosed herein. Artificial red blood cells can be generated

by interfacial polymerization and complex emulsion methods. Generally, the "cell" wall is made of polyphthaloyl L-lysine polymer/polystyrene and the core is made of a hemoglobin solution from sheep hemolysate. Hemoglobin loaded microspheres typically have particle sizes of from about 1 to about 10 μm . Their size, flexibility, and oxygen carrying capacity is similar to red blood cells.

196. Solid-lipid nanoparticles, as described herein, are other delivery devices that can be used to deliver the compositions disclosed herein. Solid-lipid nanoparticles are nanoparticles, which are dispersed in an aqueous surfactant solution. They are comprised of a solid hydrophobic core having a monolayer of a phospholipid coating and are usually prepared by high-pressure homogenization techniques. Immunomodulating complexes (ISCOMS) are examples of solid-lipid nanoparticles. They are cage-like 40 nm supramolecular assemblies comprising of phospholipid, cholesterol, and hydrophobic antigens and are used mostly as immunoadjuvants. For instance, ISCOMs are used to prolong blood-plasma levels of subcutaneously injected cyclosporine.

197. Microspheres and micro-capsules, as described herein, are yet other delivery devices that can be used to deliver the compositions disclosed herein. In contrast to liposomal delivery systems, microspheres and micro-capsules typically do not have an aqueous core but a solid polymer matrix or membrane. These delivery devices are obtained by controlled precipitation of polymers, chemical cross-linking of soluble polymers, and interfacial polymerization of two monomers or high-pressure homogenization techniques. The encapsulated compound is gradually released from the depot by erosion or diffusion from the particles. Successful formulations of short acting peptides, such as LHRH agonists like leuprorelin and triptoreline, have been developed. Poly(lactide co-glycolide (PLGA) microspheres are currently used as monthly and three monthly dosage forms in the treatment of advanced prostate cancer, endometriosis, and other hormone responsive conditions. Leuprolide, an LHRH superagonist, was incorporated into a variety of PLGA matrices using a solvent extraction/evaporation method. As noted, all of these delivery devices can be used in the methods disclosed herein.

198. Pulmospheres are still other examples of delivery devices that can be used herein. Pulmospheres are hollow porous particles with a low density (less than about 0.1 g mL^{-1}). Pulmospheres typically have excellent re-dispersibility and are usually prepared by supercritical fluid condensation technology. Co-spray-drying with certain matrices, such as carbohydrates, human serum albumin, etc., can improve the stability of proteins and peptides (e.g., insulin) and other biomolecules for pulmonary delivery. This type of delivery could be also accomplished

with micro-emulsions and lipid emulsions, which are ultra fine, thin, transparent oil-in-water (o/w) emulsions formed spontaneously with no significant input of mechanical energy. In this technique, an emulsion can be prepared at a temperature, which must be higher than the phase inversion temperature of the system. At elevated temperature the emulsion is of water-in-oil (w/o) type and as it cools at the phase inversion temperature, this emulsion is inverted to become o/w. Due to their very small inner phase, they are extremely stable and used for sustained release of steroids and vaccines. Lipid emulsions comprise a neutral lipid core (*i.e.*, triglycerides) stabilized by a monolayer of amphiphilic lipid (*i.e.*, phospholipid) using surfactants like egg lecithin triglycerides and miglyol. They are suitable for passive and active targeting.

199. There are other oral delivery systems under investigation that are based on osmotic pressure modulation, pH modulation, swelling modulation, altered density and floating systems, mucoadhesiveness etc. These formulations and time-delayed formulations to deliver drugs in accordance with circadian rhythm of disease that are currently in use or investigation can be applied for delivery of the compositions disclosed herein.

200. In one particular aspect disclosed herein, the disclosed compounds, including nutritional supplement and pharmaceutical formulations thereof, can be incorporated into microcapsules as described herein.

201. In one aspect disclosed herein, the disclosed compounds can be incorporated into microcapsules. In one aspect, the microcapsule comprises an agglomeration of primary microcapsules and the chromium compounds described herein, each individual primary microcapsule having a primary shell, wherein the chromium compound is encapsulated by the primary shell, wherein the agglomeration is encapsulated by an outer shell. These microcapsules are referred to herein as "multicore microcapsules."

202. In another aspect, described herein are microcapsules comprising a chromium compound, a primary shell, and a secondary shell, wherein the primary shell encapsulates the chromium compound, and the secondary shell encapsulates the loading substance and primary shell. These microcapsules are referred to herein as "single-core microcapsules."

203. Optionally, other loading substances can be encapsulated with the chromium compound. The loading substance can be any substance that is not entirely soluble in the aqueous mixture. In one aspect, the loading substance is a solid, a hydrophobic liquid, or a mixture of a solid and a hydrophobic liquid. In another aspect, the loading substance comprises a grease, an oil, a lipid, a drug (*e.g.*, small molecule), a biologically active substance, a nutritional supplement (*e.g.*, vitamins), a flavor compound, or a mixture thereof. Examples of oils include, but are not limited to, animal oils (*e.g.*, fish oil, marine mammal oil, etc.), vegetable

oils (e.g., canola or rapeseed), mineral oils, derivatives thereof or mixtures thereof. The loading substance can be a purified or partially purified oily substance such as a fatty acid, a triglyceride or ester thereof, or a mixture thereof. In another aspect, the loading substance can be a carotenoid (e.g., lycopene), a satiety agent, a flavor compound, a drug (e.g., a water insoluble drug), a particulate, an agricultural chemical (e.g., herbicides, insecticides, fertilizers), or an aquaculture ingredient (e.g., feed, pigment).

204. In one aspect, the loading substance can be an omega-3 fatty acid. Examples of omega-3 fatty acids include, but are not limited to, α -linolenic acid (18:3n3), octadecatetraenoic acid (18:4n3), eicosapentaenoic acid (20:5n3) (EPA), docosahexaenoic acid (22:6n3) (DHA), docosapentaenoic acid (22:5n3) (DPA), eicosatetraenoic acid (20:4n3), uncosapentaenoic acid (21:5n3), docosapentaenoic acid (22:5n3) and derivatives thereof and mixtures thereof. Many types of derivatives of omega-3 fatty acids are well known in the art. Examples of suitable derivatives include, but are not limited to, esters, such as phytosterol esters, branched or unbranched C₁-C₃₀ alkyl esters, branched or unbranched C₂-C₃₀ alkenyl esters, or branched or unbranched C₃-C₃₀ cycloalkyl esters such as phytosterol esters and C₁-C₆ alkyl esters. Sources of oils can be derived from aquatic organisms (e.g., anchovies, capelin, Atlantic cod, Atlantic herring, Atlantic mackerel, Atlantic menhaden, salmonids, sardines, shark, tuna, etc) and plants (e.g., flax, vegetables, etc) and microorganisms (e.g., fungi and algae).

205. In one aspect, the loading substance can contain an antioxidant. Examples of antioxidants include, but are not limited to, vitamin E, CoQ₁₀, tocopherols, lipid soluble derivatives of more polar antioxidants such as ascorbyl fatty acid esters (e.g., ascorbyl palmitate), plant extracts (e.g., rosemary, sage and oregano oils), algal extracts, and synthetic antioxidants (e.g., BHT, TBHQ, ethoxyquin, alkyl gallates, hydroquinones, tocotrienols).

206. A number of different polymers can be used to produce the shell layers of the single and multicore microcapsules. Examples of such polymers include, but are not limited to, a protein, a polyphosphate, a polysaccharide, or a mixture thereof. In another aspect, the shell material used to prepare the single- and multicore microcapsules further comprises In another aspect, the shell material used to prepare the single- and multicore microcapsules further comprises gelatin type A, gelatin type B, polyphosphate, gum arabic, alginate, chitosan, carrageenan, pectin, starch, modified starch, alfa-lactalbumin, beta-lactoglobulin, ovalbumin, polysorbition, maltodextrins, cyclodextrins, cellulose, methyl cellulose, ethyl cellulose, hydropropylmethylcellulose, carboxymethylcellulose, milk protein, whey protein, soy protein, canola protein, albumin, chitin, polylactides, poly-lactide-co-glycolides, derivatized chitin, chitosan, poly-lysine, various inorganic-organic composites, or any mixture thereof. It is also

contemplated that derivatives of these polymers can be used as well. In another aspect, the polymer can be kosher gelatin, non-kosher gelatin, Halal gelatin, or non-Halal gelatin.

207. In one aspect, one or more of the shell layers in the single and multicore microcapsules comprises gelatin having a Bloom number less than 50. This gelatin is referred to herein as "low Bloom gelatin." The Bloom number describes the gel strength formed at 10°C with a 6.67% solution gelled for 18 hours. In one aspect, the low Bloom gelatin has a Bloom number less than 40, less than 30, less than 20, or less than 10. In another aspect, the gelatin has a Bloom number of 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0, where any two values can be used to produce a range. In another aspect, the low Bloom gelatin is in both the primary shell and the outer shell of the multicore microcapsule. In one aspect, the low Bloom gelatin is gelatin type A. In another aspect, the low Bloom gelatin is gelatin type A produced by Kenney & Ross Ltd., R.R. #3 Shelburne, NS Canada. In another aspect, gelatin having a Bloom number of zero is in both the primary shell and the outer shell of the multicore microcapsule.

208. In one aspect, the material used to make the shells of the single- or multicore microcapsules is a two-component system made from a mixture of two different types of polymers. In one aspect, the material is a complex coacervate between the polymer components. Complex coacervation is caused by the interaction between two oppositely charged polymers. In one aspect, the shell material used to produce the single and multicore microcapsules is composed of (1) low Bloom gelatin and (2) gelatin type B, polyphosphate, gum arabic, alginate, chitosan, carrageenan, pectin, carboxymethylcellulose, whey protein, soy protein, canola protein, albumin, or a mixture thereof. The molar ratio of the different polymers can vary. For example, the molar ratio of low Bloom gelatin to the other polymer component is from 1:5 to 15:1. For example, when low Bloom gelatin and polyphosphate are used, the molar ratio of low Bloom gelatin to polyphosphate is about 8:1 to about 12:1; when low Bloom gelatin and gelatin type B are used, the molar ratio is 2:1 to 1:2; and when low Bloom gelatin and alginate are used, the molar ratio is 3:1 to 8:1.

209. Processing aids can be included in the shell material (e.g., primary or outer shells). Processing aids can be used for a variety of reasons. For example, they may be used to promote agglomeration of the primary microcapsules, stabilize the emulsion system, improve the properties of the outer shells, control microcapsule size and/or to act as an antioxidant. In one aspect, the processing aid can be an emulsifier, a fatty acid, a lipid, a wax, a microbial cell (e.g., yeast cell lines), a clay, or an inorganic compound (e.g., calcium carbonate). Not wishing to be bound by theory, these processing aids can improve the barrier properties of the microcapsules. In one aspect, one or more antioxidants can be added to the shell material. Antioxidant

properties are useful both during the process (e.g. during coacervation and/or spray drying) and in the microcapsules after they are formed (i.e. to extend shelf-life, etc). Preferably a small number of processing aids that perform a large number of functions can be used. In one aspect, the antioxidant can be a phenolic compound, a plant extract, or a sulphur-containing amino acid.

5 In one aspect, ascorbic acid (or a salt thereof such as sodium or potassium ascorbate) can be used to promote agglomeration of the primary microcapsules, to control microcapsule size and to act as an antioxidant. The antioxidant can be used in an amount of about 100 ppm to about 12,000 ppm, or from about 1,000 ppm to about 5,000 ppm. Other processing aids such as, for example, metal chelators, can be used as well. For example, ethylene diamine tetraacetic acid
10 can be used to bind metal ions, which can reduce the catalytic oxidation of the loading substance.

210. In one aspect, the primary microcapsules (primary shells) have an average diameter of about 40 nm to about 10 μm , 0.1 μm to about 10 μm , 1 μm to about 10 μm , 1 μm to about 8 μm , 1 μm to about 6 μm , 1 μm to about 4 μm , or 1 μm to about 2 μm , or 1 μm . In
15 another aspect, the multicore microcapsules can have an average diameter of from about 1 μm to about 2000 μm , 20 μm to about 1000 μm , from about 20 μm to about 100 μm , or from about 30 μm to about 80 μm . In another aspect, the single-core microcapsules have an outer diameter of from 1 μm to 2,000 μm .

211. The microcapsules described herein generally have a combination of high payload
20 and structural strength. For example, payloads of loading substance can be from 20% to 90%, 50% to 70% by weight, or 60% by weight of the single or multicore microcapsules.

212. In one aspect, the methods disclosed in U.S. Patent Application Publication No. 2003/0193102, which is incorporated by reference in its entirety, can be used to encapsulate the chromium compounds described herein. It is also contemplated that one or more additional shell
25 layers can be placed on the outer shell of the single or multicore microcapsules. In one aspect, the techniques described in International Publication No. WO 2004/041251 A1, which is incorporated by reference in its entirety, can be used to add additional shell layers to the single and multicore microcapsules.

a) Pharmaceutical and nutraceutical compositions

30 213. These lipids and antioxidants are targeted for use in animal feeds, pharmaceuticals, nutraceuticals (especially infant formula) as well as in the industry. This is to also include nutraceutical forms of delivery such as gel capsules and the like, common microencapsulations, etc.

214. As described above, the compositions can also be administered *in vivo* in a pharmaceutically acceptable carrier. By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject, along with the nucleic acid or vector, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.

215. The compositions may be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, extracorporeally, topically or the like, including topical intranasal administration or administration by inhalant. As used herein, "topical intranasal administration" means delivery of the compositions into the nose and nasal passages through one or both of the nares and can comprise delivery by a spraying mechanism or droplet mechanism, or through aerosolization of the nucleic acid or vector. Administration of the compositions by inhalant can be through the nose or mouth via delivery by a spraying or droplet mechanism. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation. The exact amount of the compositions required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the allergic disorder being treated, the particular nucleic acid or vector used, its mode of administration and the like. Thus, it is not possible to specify an exact amount for every composition. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.

216. Parental administration of the composition, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Patent No. 3,610,795, which is incorporated by reference herein.

217. The materials may be in solution, suspension (for example, incorporated into microparticles, liposomes, or cells). These may be targeted to a particular cell type via antibodies, receptors, or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., *Bioconjugate Chem.*, 2:447-451,1991; Bagshawe, K.D., *Br. J. Cancer*, 60:275-281,1989; Bagshawe, et al., *Br. J. Cancer*, 58:700-703,1988; Senter, et al., *Bioconjugate Chem.*, 4:3-9,1993; Battelli, et al., *Cancer*

Immunol. Immunother., 35:421-425,1992; Pietersz and McKenzie, *Immunolog. Reviews*, 129:57-80,1992; and Roffler, et al., *Biochem. Pharmacol.*, 42:2062-2065,1991). Vehicles such as "stealth" and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic retroviral targeting of murine glioma cells *in vivo*. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Hughes et al., *Cancer Research*, 49:6214-6220,1989); and Litzinger and Huang, *Biochimica et Biophysica Acta*, 1104:179-187,1992). In general, receptors are involved in pathways of endocytosis, either constitutive or ligand induced.

These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes. The internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor-level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis has been reviewed (Brown and Greene, *DNA and Cell Biology* 10:399-409,1991).

(1) Pharmaceutically Acceptable Carriers

218. The compositions, including antibodies, can be used therapeutically in combination with a pharmaceutically acceptable carrier.

219. Suitable carriers and their formulations are described in *Remington: The Science and Practice of Pharmacy* (19th ed.) ed. A.R. Gennaro, Mack Publishing Company, Easton, PA 1995. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-acceptable carrier include, but are not limited to, saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered.

220. Pharmaceutical carriers are known to those skilled in the art. These most typically would be standard carriers for administration of drugs to humans, including solutions such as

sterile water, saline, and buffered solutions at physiological pH. The compositions can be administered intramuscularly or subcutaneously. Other compounds will be administered according to standard procedures used by those skilled in the art.

221. Pharmaceutical compositions may include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice. Pharmaceutical compositions may also include one or more active ingredients such as antimicrobial agents, antiinflammatory agents, anesthetics, and the like.

222. The pharmaceutical composition may be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Administration may be topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip, subcutaneous, intraperitoneal or intramuscular injection. The disclosed antibodies can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.

223. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.

224. Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

225. Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable.

226. Some of the compositions may potentially be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide,

potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.

(2) Therapeutic Uses

227. Effective dosages and schedules for administering the compositions may be determined empirically, and making such determinations is within the skill in the art. The dosage ranges for the administration of the compositions are those large enough to produce the desired effect in which the symptoms disorder are effected. The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient, route of administration, or whether other drugs are included in the regimen, and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any counterindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. For example, guidance in selecting appropriate doses for antibodies can be found in the literature on therapeutic uses of antibodies, e.g., Handbook of Monoclonal Antibodies, Ferrone et al., eds., Nokes Publications, Park Ridge, N.J., (1985) ch. 22 and pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, Haber et al., eds., Raven Press, New York (1977) pp. 365-389. A typical daily dosage of the antibody used alone might range from about 1 µg/kg to up to 100 mg/kg of body weight or more per day, depending on the factors mentioned above.

b) Targeted delivery

228. The disclosed liposomes and microcapsules can be targeted to a particular cell type, such as islets cells, via antibodies, receptors, or receptor ligands. The following references are examples of the use of this technology to target specific tissue (Senter, *et al.*, *Bioconjugate Chem* 2:447-51, 1991; Bagshawe, *Br J Cancer* 60:275-81, 1989; Bagshawe, *et al.*, *Br J Cancer* 58:700-3, 1988; Senter, *et al.*, *Bioconjugate Chem* 4:3-9, 1993; Battelli, *et al.*, *Cancer Immunol Immunother* 35:421-5, 1992; Pietersz and McKenzie, *Immunolog Reviews* 129:57-80, 1992; and Roffler, *et al.*, *Biochem Pharmacol* 42:2062-5, 1991). These techniques can be used for a variety of other specific cell types.

8. Foodstuffs

229. Also disclosed herein are foodstuffs comprising any of the microcapsules and emulsions disclosed herein. By "foodstuff" is meant any article that can be consumed (e.g., eaten, drank, or ingested) by a subject. In one aspect, the microcapsules can be used as nutritional supplements to a foodstuff. For example, the microcapsules and emulsions can be

loaded with vitamins, omega-3 fatty acids, and other compounds that provide health benefits. In one aspect, the foodstuff is a baked good, a pasta, a meat product, a frozen dairy product, a milk product, a cheese product, an egg product, a condiment, a soup mix, a snack food, a nut product, a plant protein product, a hard candy, a soft candy, a poultry product, a processed fruit juice, a granulated sugar (e.g., white or brown), a sauce, a gravy, a syrup, a nutritional bar, a beverage, a dry beverage powder, a jam or jelly, a fish product, or pet companion food. In another aspect, the foodstuff is bread, tortillas, cereal, sausage, chicken, ice cream, yogurt, milk, salad dressing, rice bran, fruit juice, a dry beverage powder, rolls, cookies, crackers, snack food, fruit pies, or cakes.

9. Chips and microarrays

230. Disclosed are chips where at least one address is the sequences or part of the sequences set forth in any of the nucleic acid sequences disclosed herein. Also disclosed are chips where at least one address is the sequences or portion of sequences set forth in any of the peptide sequences disclosed herein.

231. Also disclosed are chips where at least one address is a variant of the sequences or part of the sequences set forth in any of the nucleic acid sequences disclosed herein. Also disclosed are chips where at least one address is a variant of the sequences or portion of sequences set forth in any of the peptide sequences disclosed herein.

10. Computer readable mediums

232. It is understood that the disclosed nucleic acids and proteins can be represented as a sequence consisting of the nucleotides of amino acids. There are a variety of ways to display these sequences, for example the nucleotide guanosine can be represented by G or g. Likewise the amino acid valine can be represented by Val or V. Those of skill in the art understand how to display and express any nucleic acid or protein sequence in any of the variety of ways that exist, each of which is considered herein disclosed. Specifically contemplated herein is the display of these sequences on computer readable mediums, such as, commercially available floppy disks, tapes, chips, hard drives, compact disks, and video disks, or other computer readable mediums. Also disclosed are the binary code representations of the disclosed sequences. Those of skill in the art understand what computer readable mediums. Thus, computer readable mediums on which the nucleic acids or protein sequences are recorded, stored, or saved.

233. Disclosed are computer readable mediums comprising the sequences and information regarding the sequences set forth herein.

11. Kits

234. Disclosed herein are kits that are drawn to reagents that can be used in practicing the methods disclosed herein or in using or keeping the compositions disclosed herein. The kits can include any reagent or combination of reagent discussed herein or that would be understood to be required or beneficial in the practice of the disclosed methods. For example, the kits could include one or more of the eukaryotic microorganisms disclosed herein along with, for example, media for their maintenance. The kits could also include, for example, the lipids or antioxidants, along with means for using or administering these.

12. Compositions with similar functions

235. It is understood that the compositions disclosed herein have certain functions, such as producing certain ratios of lipids. Disclosed herein are certain structural, genetic, and functional requirements for performing the disclosed functions, and it is understood that there are a variety of structures, genetic backgrounds, and functional backgrounds which can perform the same function which are related to the disclosed structures, and that these structures will ultimately achieve the same result, for example production of a certain ration of lipids.

D. Methods of making the compositions

236. The compositions disclosed herein and the compositions necessary to perform the disclosed methods can be made using any method known to those of skill in the art for that particular reagent or compound unless otherwise specifically noted.

1. Nucleic acid synthesis

237. For example, the nucleic acids, such as, the oligonucleotides to be used as primers can be made using standard chemical synthesis methods or can be produced using enzymatic methods or any other known method. Such methods can range from standard enzymatic digestion followed by nucleotide fragment isolation (see for example, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Edition (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) Chapters 5, 6) to purely synthetic methods, for example, by the cyanoethyl phosphoramidite method using a Milligen or Beckman System 1Plus DNA synthesizer (for example, Model 8700 automated synthesizer of Milligen-Bioscience, Burlington, MA or ABI Model 380B). Synthetic methods useful for making oligonucleotides are also described by Ikuta *et al.*, *Ann. Rev. Biochem.* 53:323-356, 1984, (phosphotriester and phosphite-triester methods), and Narang *et al.*, *Methods Enzymol.*, 65:610-620, 1980, (phosphotriester method). Protein nucleic acid molecules can be made using known methods such as those described by Nielsen *et al.*, *Bioconjug. Chem.* 5:3-7, 1994.

2. Peptide synthesis

238. One method of producing the disclosed proteins is to link two or more peptides or polypeptides together by protein chemistry techniques. For example, peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using either Fmoc (9-fluorenylmethyloxycarbonyl) or Boc (*tert*-butyloxycarbonyl) chemistry. (Applied Biosystems, Inc., Foster City, CA). One skilled in the art can readily appreciate that a peptide or polypeptide corresponding to the disclosed proteins, for example, can be synthesized by standard chemical reactions. For example, a peptide or polypeptide can be synthesized and not cleaved from its synthesis resin whereas the other fragment of a peptide or protein can be synthesized and subsequently cleaved from the resin, thereby exposing a terminal group which is functionally blocked on the other fragment. By peptide condensation reactions, these two fragments can be covalently joined via a peptide bond at their carboxyl and amino termini, respectively, to form an antibody, or fragment thereof. (Grant GA (1992) *Synthetic Peptides: A User Guide*. W.H. Freeman and Co., N.Y. (1992); Bodansky M and Trost B., Ed. (1993) *Principles of Peptide Synthesis*. Springer-Verlag Inc., NY (which is herein incorporated by reference at least for material related to peptide synthesis). Alternatively, the peptide or polypeptide is independently synthesized *in vivo* as described herein. Once isolated, these independent peptides or polypeptides may be linked to form a peptide or fragment thereof via similar peptide condensation reactions.

239. For example, enzymatic ligation of cloned or synthetic peptide segments allow relatively short peptide fragments to be joined to produce larger peptide fragments, polypeptides or whole protein domains (Abrahmsen L et al., *Biochemistry*, 30:4151, 1991). Alternatively, native chemical ligation of synthetic peptides can be utilized to synthetically construct large peptides or polypeptides from shorter peptide fragments. This method consists of a two step chemical reaction (Dawson et al. *Science*, 266:776-779, 1994). The first step is the chemoselective reaction of an unprotected synthetic peptide--thioester with another unprotected peptide segment containing an amino-terminal Cys residue to give a thioester-linked intermediate as the initial covalent product. Without a change in the reaction conditions, this intermediate undergoes spontaneous, rapid intramolecular reaction to form a native peptide bond at the ligation site (Baggiolini M et al. *FEBS Lett.* 307:97-101, 1992; Clark-Lewis I et al., *J. Biol. Chem.*, 269:16075, 1994; Clark-Lewis I et al., *Biochemistry*, 30:3128, 1991; Rajarathnam K et al., *Biochemistry* 33:6623-30, 1994).

240. Alternatively, unprotected peptide segments are chemically linked where the bond formed between the peptide segments as a result of the chemical ligation is an unnatural

(non-peptide) bond (Schmolzer, M. et al. *Science*, 256:221, 1992). This technique has been used to synthesize analogs of protein domains as well as large amounts of relatively pure proteins with full biological activity (de Lisle-Milton RC et al., *Techniques in Protein Chemistry IV*. Academic Press, New York, pp. 257-267, 1992).

5 3. Processes for making the compositions

241. Disclosed are processes for making the compositions as well as making the intermediates leading to the compositions. For example, disclosed are eukaryotic microorganisms which can produce desired lipids and antioxidants as well as methods for isolating and purifying the desired lipids and antioxidants. There are a variety of methods that can be used for making these compositions, such as synthetic chemical methods and standard molecular biology methods. It is understood that the methods of making these and the other disclosed compositions are specifically disclosed.

242. Disclosed are cells produced by the process of transforming the cell with any nucleic acid. Disclosed are cells produced by the process of transforming the cell with any of the non-naturally occurring disclosed nucleic acids.

243. Disclosed are any of the lipids produced by the disclosed eukaryotic microorganisms. Disclosed are any peptides produced by the process of expressing the peptide in the disclosed organisms. Methods of using the compositions.

4. Methods of using the compositions as research tools

244. The disclosed compositions can be used in a variety of ways as research tools and of the production of, for example, lipids and antioxidants.

245. The disclosed compositions can be used as discussed herein as either reagents in micro arrays or as reagents to probe or analyze existing microarrays. The disclosed compositions can be used in any known method for isolating or identifying single nucleotide polymorphisms. The compositions can also be used in any method for determining allelic analysis of for example, the strains of the organisms disclosed herein, particularly allelic analysis as it relates to the production of lipids and antioxidants. The compositions can also be used in any known method of screening assays, related to chip/microarrays. The compositions can also be used in any known way of using the computer readable embodiments of the disclosed compositions, for example, to study relatedness or to perform molecular modeling analysis related to the disclosed compositions.

5. Methods of gene modification and gene disruption

246. The disclosed compositions and methods can be used for targeted gene disruption and modification in any animal that can undergo these events. Gene modification and gene

disruption refer to the methods, techniques, and compositions that surround the selective removal or alteration of a gene or stretch of chromosome in an organism, such as the eukaryotes disclosed herein, in a way that propagates the modification through the replication of the organism. In general, for example, a cell is transformed with a vector which is designed to homologously recombine with a region of a particular chromosome or nucleic acid contained within the cell, as for example, described herein. This homologous recombination event can produce a chromosome which has exogenous DNA introduced, for example in frame, with the surrounding DNA. This type of protocol allows for very specific mutations, such as point mutations, to be introduced into the genome contained within the cell. Methods for performing this type of homologous recombination are disclosed herein.

V. SPECIFIC EMBODIMENTS

247. Disclosed herein is a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1. The eukaryotic microorganism can produce unsaturated fatty acids having a profile shown in figure 2. The eukaryotic microorganism can be from the phylum Labyrinthulomycota, the class Labyrinthulomycetes, the subclass Thraustochytridae, the order Thraustochytriales, the family Thraustochytriaceae, and/or the genus *Thraustochytrium*. The eukaryotic microorganism can be *Thraustochytrium* sp., *Thraustochytrium aureum*, *Thraustochytrium roseum*, or *Thraustochytrium striatum*. The eukaryotic microorganism can also be from the family Thraustochytriaceae and can have ATCC accession number 20888, 20889, 20890, 20891, or 20892.

248. Also disclosed herein is a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, wherein the microorganism is from the genus *Schizochytrium*. The eukaryotic microorganism can be *Schizochytrium* sp.

249. Also disclosed herein is a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, wherein the eukaryotic microorganism comprises an omega 3 or omega 6 fatty acid. The eukaryotic microorganism can also comprises DHA or DPA.

250. Also disclosed herein is a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, wherein the microorganism produces a lipid or fatty acid fraction of at least about 4 wt.% to 6 wt.%. The lipid can comprise DHA. The lipid composition can also comprise from about 25 wt.% fatty acid fraction to about 40 wt.% fatty acid fraction of n-3 DHA, from about 6 wt.%

fatty acid fraction to about 10 wt.% fatty acid fraction of n-6 DPA, and from about 0 wt.% fatty acid fraction to about 3 wt.% fatty acid fraction of n-3 EPA.

251. Also disclosed is a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1. The composition can further comprise a medium and/or nutrients.

252. Also disclosed is a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, wherein the composition is a biomass. The eukaryotic microorganism of the composition can be from the phylum Labyrinthulomycota, the class Labyrinthulomycetes, the subclass Thraustochytridae, the order Thraustochytriales, the family Thraustochytriaceae, or the genus *Thraustochytrium*. The eukaryotic microorganism can be *Thraustochytrium* sp., *Thraustochytrium aureum*, *Thraustochytrium roseum*, or *Thraustochytrium striatum*. The eukaryotic microorganism can also be from the family Thraustochytriaceae and can have ATCC accession number 20888, 20889, 20890, 20891, or 20892.

253. Also disclosed is a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, wherein the microorganism is from the genus *Schizochytrium*. The eukaryotic microorganism can be *Schizochytrium* sp.

254. Also disclosed is a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, wherein the eukaryotic microorganism produces unsaturated fatty acids having a profile shown in figure 2. The unsaturated fatty acid can comprise an omega 3 or omega 6 fatty acid. The unsaturated fatty acid can also comprise DHA or DPA.

255. Also disclosed is a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, wherein the eukaryotic microorganism can produce a lipid or fatty acid fraction of at least about 4 wt.% to 6 wt.%. The lipid can comprise DHA. The lipid can also comprise from about 25 wt.% fatty acid fraction to about 40 wt.% fatty acid fraction of n-3 DHA, from about 6 wt.% fatty acid fraction to about 10 wt.% fatty acid fraction of n-6 DPA, and from about 0 wt.% fatty acid fraction to about 3 wt.% fatty acid fraction of n-3 EPA.

256. Also disclosed is a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 80% identity to the sequence set forth in SEQ ID NO:1

257. Also disclosed is a composition comprising from about 25 wt.% fatty acid fraction to about 40 wt.% fatty acid fraction of n-3 DHA, from about 6 wt.% fatty acid fraction to about 10 wt.% fatty acid fraction of n-6 DPA, and from about 0 wt.% fatty acid fraction to about 3 wt.% fatty acid fraction of n-3 EPA.

5 258. Also disclosed is a method of preparing a lipid composition, the method comprising: culturing the eukaryotic microorganism described herein, in a heterotrophic medium, and isolating the lipid composition. Also disclosed is a lipid composition prepared according to this method.

10 259. Also disclosed is a delivery device comprising a any of the compositions described above. For example, disclosed is a delivery device comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1. The delivery device can comprise a microcapsule, a microsphere, a nanosphere or nanoparticle, a liposome, a noisome, a nanoerythroosome, a solid-liquid nanoparticle, a leuprolide, a gel, a gel capsule, a tablet, a lotion,
15 a cream, a spray, an emulsion, or a powder.

20 260. Also disclosed is a microcapsule, comprising an agglomeration of primary microcapsules and a loading substance, each individual primary microcapsule having a primary shell, wherein the loading substance comprises any of the compositions described above, and is encapsulated by the primary shell, and wherein the agglomeration is encapsulated by an outer
25 shell. The primary shell and/or outer shell can comprise a surfactant, gelatin, polyphosphate, polysaccharide, or a mixture thereof. The primary shell and/or outer shell can also comprise gelatin type B, polyphosphate, gum arabic, alginate, chitosan, carrageenan, pectin, starch, modified starch, alfa-lactalbumin, beta-lactoglobulin, ovalbumin, polysorbition, maltodextrin, cyclodextrin, cellulose, methyl cellulose, ethyl cellulose, hydropropylmethylcellulose,
30 carboxymethylcellulose, milk protein, whey protein, soy protein, canola protein, albumin, kosher gelatin, non-kosher gelatin, Halal gelatin, non-Halal gelatin, or a mixture thereof. The primary shell and/or outer shell can also comprise a complex coacervate, gelatin type A, fish gelatin, a gelatin with a Bloom number of from about 0 to about 300, a gelatin with a Bloom number of from about 0 to about 50, a gelatin with a Bloom number of from about 51 to about 300, a
35 gelatin with a Bloom number of about 0, about 210, about 220, or about 240, a coacervate of gelatin and polyphosphate.

261. The loading substance of the disclosed microcapsules can comprise oil from *Thraustochytrium*, *Schizochytrium*, or a mixture thereof. The loading substance can be from about 20% to about 90% or 50% to about 70% by weight of the microcapsule.

~~262. The outer shell of the disclosed~~ microcapsules can have an average diameter of from about 1 μm to about 2,000 μm , about 20 μm to about 1,000 μm , about 30 μm to about 80 μm , about 40 nm to about 10 μm , or about 0.1 μm to about 5 μm .

263. Also disclosed is a nutritional supplement that comprises any of the compositions, delivery devices, or microcapsules described above. The disclosed nutritional supplements can be in the form of a tablet, gel-cap, capsule, liquid, or syrup.

264. Also disclosed is a foodstuff that comprises any of the compositions, delivery devices, or microcapsules described above. The foodstuff can be a baked good, a pasta, a meat product, a frozen dairy product, a milk product, a cheese product, an egg product, a condiment, a soup mix, a snack food, a nut product, a plant protein product, a hard candy, a soft candy, a poultry product, a processed fruit juice, a granulated sugar, a sauce, a gravy, a syrup, a nutritional bar, a beverage, a dry beverage powder, a jam or jelly, an infant formula, or a baby food. The foodstuff can also be a fish product, a companion pet food, a livestock or an aquaculture feed. The foodstuff can also be bread, tortillas, cereal, sausage, chicken, ice cream, yogurt, milk, salad dressing, rice bran, fruit juice, a dry beverage powder, rolls, cookies, crackers, fruit pies, or cakes.

265. Also disclosed is a method of delivering a composition to a subject, comprising administering to the subject any of the compositions, delivery devices, microcapsules, or foodstuffs described above. The subject can be a mammal. The subject can also be a human.

266. Also disclosed is a use of any of the microcapsules described above and to prepare a medicament for delivering a loading substance to a subject.

267. Also disclosed is a method of lowering cholesterol levels, triglyceride levels, or a combination thereof in a subject, comprising the step of administering to the subject an effective amount of any of the compositions, delivery devices, microcapsules, nutritional supplements, or foodstuffs described above.

268. Also disclosed is a method of supplementing essential trace elements in a subject, the method comprising the step of administering to the subject an effective amount of any of the compositions, delivery devices, microcapsules, nutritional supplements, or foodstuffs described above, wherein the composition, delivery device, microcapsule, supplement, and foodstuff comprises an essential trace element.

269. Also disclosed is a method of improving insulin sensitivity in a subject, comprising the step of administering to the subject an effective amount of any of the compositions, delivery devices, microcapsules, nutritional supplements, or foodstuffs described above.

~~270. Also disclosed is a method of reducing hyperglycemia in a subject, comprising the step of administering to the subject an effective amount of of any of the compositions, delivery devices, microcapsules, nutritional supplements, or foodstuffs described above.~~

271. Also disclosed is a method of reducing hypercholesterolemia in a subject, comprising the step of administering to the subject an effective amount of any of the compositions, delivery devices, microcapsules, nutritional supplements, or foodstuffs described above.

272. Also disclosed is a method of reducing body fat in a subject, comprising the step of administering to the subject an effective amount of any of the compositions, delivery devices, microcapsules, nutritional supplements, or foodstuffs described above.

273. Also disclosed is a method of promoting weight loss in a subject, comprising the step of administering to the subject an effective amount of any of the compositions, delivery devices, microcapsules, nutritional supplements, or foodstuffs described above.

274. Also disclosed is a method of treating or preventing diabetes in a subject, comprising the step of administering to the subject an effective amount of any of the compositions, delivery devices, microcapsules, nutritional supplements, or foodstuffs described above.

275. Also disclosed is a pharmaceutical formulation comprising any of the compositions, delivery devices, or microcapsules described above, and a pharmaceutical carrier.

276. Also disclosed is a foodstuff comprising comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1. The foodstuff can be a baked good, a pasta, a meat product, a frozen dairy product, a milk product, a cheese product, an egg product, a condiment, a soup mix, a snack food, a nut product, a plant protein product, a hard candy, a soft candy, a poultry product, a processed fruit juice, a granulated sugar, a sauce, a gravy, a syrup, a nutritional bar, a beverage, a dry beverage powder, a jam or jelly, an infant formula, or a baby food. The foodstuff can also be a fish product, or pet companion food, a livestock or an aquaculture feed. The foodstuff can also be bread, tortillas, cereal, sausage, chicken, ice cream, yogurt, milk, salad dressing, rice bran, fruit juice, a dry beverage powder, rolls, cookies, crackers, fruit pies, or cakes.

277. Also disclosed is a method of lowering cholesterol levels, triglyceride levels, or a combination thereof in a subject, comprising the step of administering an effective amount of a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a nutritional

~~supplement comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a delivery device comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, or a foodstuff comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1.~~

278. Also disclosed is a method of supplementing essential trace elements in a subject, the method comprising the step of administering an effective amount of a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a nutritional supplement comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a delivery device comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, or a foodstuff comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1.

279. Also disclosed is a method improving insulin sensitivity in a subject, comprising the step of administering an effective amount of a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a nutritional supplement comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a delivery device comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, or a foodstuff comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1.

280. Also disclosed is a method of reducing hyperglycemia in a subject, comprising the step of administering an effective amount of a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a nutritional supplement comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a delivery device comprising a

~~composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, or a foodstuff comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1.~~

5 281. Also disclosed is a method of reducing hypercholesterolemia in a subject, comprising the step of administering an effective amount of a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a nutritional supplement comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S
10 sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a delivery device comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, or a foodstuff comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ
15 ID NO:1.

282. Also disclosed is a method of reducing body fat in a subject, comprising the step of administering an effective amount of a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a nutritional supplement comprising a composition comprising a
20 eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a delivery device comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, or a foodstuff comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S
25 sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1..

283. Also disclosed is a method of promoting weight loss in a subject, comprising the step of administering an effective amount of a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a nutritional supplement comprising a composition
30 comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a delivery device comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, or a foodstuff

comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1..

284. Also disclosed is a method of treating or preventing diabetes in a subject, comprising the step of administering an effective amount of a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a nutritional supplement comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, a delivery device comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1, or a foodstuff comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1..

285. Also disclosed is a pharmaceutical formulation comprising a composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1.

VI. Examples

286. The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the disclosure. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at ambient temperature, and pressure is at or near atmospheric.

1. Example 1 Isolation of *ONC-T18 Thraustochytrium* sp. strain

287. Classical bacteriological strain purification techniques were employed in order to isolate *ONC-T18* from mangrove leaves collected at Advocate Harbor, Nova Scotia. *ONC-T18* was serially cultured at 25°C on a nutrient medium agar containing 5 g L⁻¹ glucose, 2 g L⁻¹ peptone, 2 g L⁻¹ yeast extract and 15.0 g L⁻¹ agar to 1L of 0.2 µm filtered sea water until purity was assured. Subsequently, a liquid medium containing 15% artificial sea water (trophic marine), supplemented with a nitrogen and carbon source, being 60 g L⁻¹ glucose and 10 g L⁻¹ yeast extract, respectively, was prepared. This medium (50 ml of medium in 250 ml flasks) was inoculated with *ONC-T18*, then incubated at 25°C and aerated via shaking at 120 rpm.

288. ~~ONC-T18~~ was separated from medium via centrifugation, with cellular biomass then washed, recentrifuged and freeze dried to completion. Cellular biomass was then weighed in order to determine culture efficiencies with biomass per liter medium values recorded. Extraction of lipid fraction from biomass and subsequent fatty acid methyl ester separation was performed using the Bligh & Dyer method. Transesterification was performed by transferring freeze dried cellular material to a 10 ml screw-top test tube and adding 10% methanolic HCl and dichloromethane to the tube, with the mixture allowed to react for 2 hours at 90°C. Fatty acid methyl esters were then extracted via addition of hexane:chloroform, and the methyl ester component measured via gas chromatography (FID) in order to determine the fatty acid profile of each microorganism and the symbiotic community (ONC-T18). Concentrations of each fatty acid methyl ester (C14:0 to C22:6) were determined by comparison of the GC peak areas of two internal standards (C19:0 and C23:0) added in defined amounts both at the beginning (C23:0) and end (C19:0) of the transesterification process. The total amount of fatty acids per gram of dried cell biomass and the percentage content of each fatty acid, calculated using this method, are shown in figure 2.

289. From analysis of these results, in conjunction with those shown in Figure 1, it can be seen that ONC-T18 demonstrated the ability to produce increased amounts of DHA, as well as marked quantities of EPA and DPA. ONC-T18, produces of approximately 25% DHA, 8.0 % (n-6) DPA and 1.0 % EPA within this non-optimized fermentation medium. Subsequently, ONC-T18 was chosen on the basis of a combination of economically desirable characteristics: (1) capable of maximal heterotrophic growth (compared to control strains); (2) contain a high percentage of omega-3 highly unsaturated fatty acids; (3) capable of growth on inexpensive nutrients; (4) thermotolerance, and are (5) euryhaline.

290. In addition, multiple different strains of oil producing microbes were compared to ONC-T18. Each of these microbes is believed to comprise a Thraustochyrid, and produces oil in the amounts shown in Table 3.

Table 3, [] = mg/g

	[] DHA	[] EPA	Total Lipid	Weight (g)
MYA-1381	127.96	5.52	216.37	1.80
ATCC-20891	37.97	7.14	67.34	1.30
ONC-T01	5.18	7.76	50.82	0.40
ONC-T02	31.84	4.20	52.88	0.50
ONC-T03	24.87	6.97	75.00	0.60
ONC-T04	14.39	4.49	41.74	0.90
ONC-T05	11.37	3.97	34.89	0.10
ONC-T06	27.80	6.71	63.87	0.10
ONC-T07	33.02	5.49	61.81	0.50
ONC-T08	24.48	4.83	53.35	0.80

ONC-T09	63.82	4.25	109.12	0.80
ONC-T10	22.22	4.93	40.99	0.10
ONC-T11	18.37	21.25	214.98	0.80
ONC-T12	57.96	9.03	96.26	0.60
ONC-T13	12.90	4.57	39.52	1.30
ONC-T14	15.99	5.16	36.46	0.50
ONC-T15	15.53	5.11	37.72	0.50
ONC-T16	18.02	5.55	42.12	0.50
ONC-T17	36.43	4.34	94.26	0.30
ONC-T18	83.63	2.76	321.14	2.30
ONC-T19	34.71	8.07	66.14	0.60
ONC-T20	19.28	6.94	66.74	0.10
ONC-T21				
ONC-T22	22.72	3.26	47.58	0.60
ONC-T23				
ONC-T24	11.73	3.56	33.56	0.70
ONC-T25	26.99	6.11	45.67	0.60
ONC-T26	14.50	6.43	39.22	0.60
ONC-T27	26.83	7.75	61.87	0.70
ONC-T28	16.62	6.02	38.28	0.90
ONC-T29	14.67	4.91	34.48	0.80
ONC-T30	16.56	5.42	81.88	0.80
ONC-T31	13.36	5.74	44.86	0.30
ONC-T32	19.12	6.56	53.29	0.20
ONC-T33				
ONC-T34	18.92	5.98	53.36	0.60
ONC-T35				
ONC-T36				
ONC-T37	35.69	11.06	82.73	0.10
ONC-T38	22.73	10.94	51.56	0.10
ONC-T39				
ONC-T40	26.87	8.83	67.87	0.80
ONC-T41	22.85	6.65	52.63	0.50
ONC-T42	33.65	9.22	83.93	0.80
ONC-T43	12.49	3.25	37.93	0.80
ONC-T44	11.71	2.93	55.05	1.10
ONC-T45	26.08	7.95	70.45	0.70
ONC-T46	33.34	6.27	63.76	0.30
ONC-T47	10.01	4.77	68.02	0.70
ONC-T48	26.23	3.95	69.06	0.60
ONC-T49	16.64	4.89	39.76	0.30
ONC-T50	13.64	4.56	40.30	1.00
ONC-T51				
ONC-T52	26.57	4.55	41.36	0.60
ONC-T53	11.40	3.56	29.20	0.70
ONC-T54	10.34	3.18	29.31	0.70
ONC-T55				
ONC-T56				
ONC-T57				
ONC-T58	10.30	3.13	27.10	0.70
ONC-T59				
ONC-T60	27.71	7.01	66.84	0.30
ONC-T61	15.72	5.62	52.56	0.40
ONC-T62				
ONC-T63	20.17	8.25	62.58	0.60
ONC-T64	12.16	2.97	44.73	1.10
ONC-T65				

ONC-T66				
ONC-T67	23.71	5.63	43.24	0.50
ONC-T68	22.72	6.10	41.37	0.50

291. It is understood that just as for ONC-T18, as described herein, a set of oil producing microbes as represented by the oil producing capabilities disclosed herein are disclosed, such as by a percentage of DHA to total oil production, or by total DHA production, for example.

2. Example 2 Identification eukaryotic *Thraustochytrium* species of ONC-T18 using genetic techniques

292. Using polymerase chain reaction (PCR) techniques and primers targeting the 18S ribosomal RNA gene, being universal for all eukaryotic species, it was possible to generate PCR products of the structural genes of the eukaryotic microorganism isolated from ONC-T18 (as per example 1). PCR products were then sequenced and designated SEQ ID NO:1 for the eukaryotic species (see figure 2).

293. Comparison of SEQ ID NO:1 with nucleic acid sequences found in the genomic database, GenBank (National Centre for Biotechnology Information, National Institute of Health, Bethesda, MD, USA) using the BLAST (Basic local alignment search tool) algorithm identified SEQ ID NO:1 as being most related to *Thraustochytrium striatum* [AF265338] (97.5% similarity).

294. BLAST results for ONC-T18 *Thraustochytrium* sp. are shown below.

Sequences producing significant alignments:	Score (bits)	E Value
gi 14279326 gb AF265338.1 Thraustochytrium striatum small subun...	2126	0.0
gi 50508012 dbj AB183657.1 Thraustochytriidae sp. MBIC11072 gen...	2121	0.0
gi 54778780 gb AY773276.1 Thraustochytriidae sp. FJN-10 18S rib...	1857	0.0
gi 50508019 dbj AB183664.1 Thraustochytriidae sp. MBIC11093 gen...	1828	0.0
gi 38524571 dbj AB126669.1 Thraustochytrium sp. CHN-1 gene for ...	1748	0.0
gi 24817740 dbj AB073308.2 Thraustochytriidae sp. N1-27 gene fo...	1628	0.0
gi 50508018 dbj AB183663.1 Thraustochytriidae sp. MBIC11092 gen...	1257	0.0
gi 50508017 dbj AB183662.1 Thraustochytriidae sp. MBIC11091 gen...	1257	0.0
gi 50508015 dbj AB183660.1 Thraustochytriidae sp. MBIC11084 gen...	1255	0.0
gi 50508011 dbj AB183656.1 Thraustochytriidae sp. MBIC11070 gen...	1255	0.0
gi 50508016 dbj AB183661.1 Thraustochytriidae sp. MBIC11086 gen...	1249	0.0
gi 15823623 dbj AB052555.1 Schizochytrium sp. KH105 gene for 18...	1245	0.0
gi 50508013 dbj AB183658.1 Thraustochytriidae sp. MBIC11075 gen...	1227	0.0
gi 50508010 dbj AB183655.1 Thraustochytriidae sp. MBIC11067 gen...	1213	0.0
gi 54303872 gb AY758384.1 Schizochytrium sp. FJU-512 18S riboso...	1158	0.0
gi 14279326 gb AF265338.1 AF265338 Thraustochytrium striatum sma...	1106	0.0
gi 6492308 gb AF155209.1 AF155209 Labyrinthulid quahog parasite ...	765	0.0
gi 16209570 gb AY052644.1 Labyrinthulid quahog parasite QPX sma...	757	0.0
gi 9755031 gb AF261664.1 AF261664 Labyrinthulid quahog parasite ...	757	0.0
gi 58176547 gb AY870336.1 Thraustochytriidae sp. Fng1 18S ribos...	735	0.0
gi 67624914 dbj AB191425.1 Uncultured eukaryote gene for small ...	724	0.0
gi 5509891 dbj AB022112.1 Thraustochytrium striatum gene for 18...	724	0.0
gi 561884 gb L34054.1 ULKRRE Ulkenia profunda 18S ribosomal RNA ...	702	0.0
gi 50508014 dbj AB183659.1 Thraustochytriidae sp. MBIC11077 gen...	686	0.0
gi 50508008 dbj AB183653.1 Thraustochytriidae sp. MBIC11060 gen...	686	0.0
gi 50508009 dbj AB183654.1 Thraustochytriidae sp. MBIC11063 gen...	658	0.0
gi 41391986 emb AJ535188.1 Pleurosira cf. laevis 18S rRNA gene,...	634	e-178
gi 28316562 gb AF525670.1 Pleurosira laevis small subunit ribos...	634	e-178
gi 5509889 dbj AB022110.1 Thraustochytrium aureum gene for 18S ...	634	e-178
gi 561883 gb L34668.1 TUKRRE Thraustochytrium kinnei 18S ribosom...	628	e-176
gi 5509894 dbj AB022115.1 Ulkenia radiata gene for 18S rRNA	624	e-175
gi 5509893 dbj AB022114.1 Ulkenia profunda gene for 18S rRNA	624	e-175

	gi	5509895	dbj	AB022116.1	Ulkenia visurgensis gene for 18S rRNA	603	e-169
	gi	9027563	gb	AF257315.2	Thraustochytriidae sp. BS2 18S ribosom...	589	e-164
	gi	5509886	dbj	AB022107.1	Schizochytrium limacinum gene for 18S...	581	e-162
5	gi	48727879	gb	AY620254.1	Metromonas simplex clone TC-S small s...	571	e-159
	gi	33309650	gb	AF411282.1	Unidentified cercozoan 18S ribosomal ...	569	e-158
	gi	28076844	gb	AF530543.1	Uncultured eukaryote clone AT4-68 18S...	531	e-147
	gi	30144485	gb	AY256273.1	Uncultured eukaryote isolate E170 sma...	517	e-143
	gi	30144529	gb	AY256317.1	Uncultured eukaryote isolate D107 sma...	507	e-140
10	gi	14579477	gb	AF363207.1	Eukaryote marine clone ME1-24 18S rib...	505	e-139
	gi	39578677	gb	AY426906.1	Uncultured marine eukaryote clone BL0...	504	e-139
	gi	39981869	gb	AY381216.1	Uncultured eukaryote clone BL010625.3...	504	e-139
	gi	73533408	gb	DQ103811.1	Uncultured marine eukaryote clone M4_...	504	e-139
	gi	73533402	gb	DQ103805.1	Uncultured marine eukaryote clone M3_...	504	e-139
	gi	73533389	gb	DQ103792.1	Uncultured marine eukaryote clone M2_...	504	e-139
15	gi	73533382	gb	DQ103785.1	Uncultured marine eukaryote clone M1_...	504	e-139
	gi	30144534	gb	AY256322.1	Uncultured eukaryote isolate D179 sma...	504	e-139
	gi	24817738	dbj	AB073305.2	Thraustochytriidae sp. H1-14 gene fo...	504	e-139
	gi	30268157	emb	AJ519935.1	AST519935 Aplanochytrium stocchinoi p...	504	e-139
20	gi	58531881	gb	AY882527.1	Uncultured marine eukaryote clone T41...	504	e-139
	gi	463127	gb	L27634.1	LADDIRRNA Labyrinthuloides minuta 16S-like...	504	e-139
	gi	39981839	gb	AY381186.1	Uncultured eukaryote clone OR000415.1...	502	e-138
	gi	39981824	gb	AY381171.1	Uncultured eukaryote clone HE001005.1...	502	e-138
	gi	18026024	gb	AY046848.1	Uncultured eukaryote isolate C3_E019 ...	502	e-138
25	gi	18026022	gb	AY046846.1	Uncultured eukaryote isolate C3_E017 ...	502	e-138
	gi	18026014	gb	AY046838.1	Uncultured eukaryote isolate C3_E008 ...	502	e-138
	gi	18026008	gb	AY046832.1	Uncultured eukaryote isolate C3_E002 ...	502	e-138
	gi	18025980	gb	AY046804.1	Uncultured eukaryote isolate C2_E014 ...	502	e-138
	gi	18025969	gb	AY046793.1	Uncultured eukaryote isolate C2_E002 ...	502	e-138
30	gi	18025801	gb	AY046625.1	Uncultured eukaryote isolate C1_E024 ...	502	e-138
	gi	67624915	dbj	AB191426.1	Uncultured eukaryote gene for small ...	502	e-138
	gi	67624913	dbj	AB191424.1	Uncultured eukaryote gene for small ...	502	e-138
	gi	67624912	dbj	AB191423.1	Uncultured eukaryote gene for small ...	502	e-138
	gi	39981861	gb	AY381208.1	Uncultured eukaryote clone BL010320.1...	500	e-138
35	gi	14349249	dbj	AB052556.1	Thraustochytrium sp. KK17-3 gene for...	500	e-138
	gi	20218962	dbj	AB073307.1	Thraustochytriidae sp. M4-103 gene f...	498	e-137
	gi	59709960	gb	AY916582.1	Uncultured eukaryote clone Zeuk76 18S...	496	e-136
	gi	18025960	gb	AY046784.1	Uncultured eukaryote isolate A3_E043 ...	496	e-136
	gi	18025789	gb	AY046613.1	Uncultured eukaryote isolate C1_E009 ...	496	e-136
40	gi	30144548	gb	AY256336.1	Uncultured eukaryote isolate D278 sma...	496	e-136
	gi	2138106	gb	U59933.1	U59933 Scybalium jamaicense 18S ribosomal...	496	e-136
	gi	53828186	gb	AY744948.1	Phytophthora palmivora isolate 88108 ...	494	e-136
	gi	60687349	gb	AY821976.1	Uncultured oomycete clone CV1_B2_5 sm...	494	e-136
	gi	60687347	gb	AY821974.1	Uncultured Phytophthora-like oomycete...	494	e-136
45	gi	60687342	gb	AY821969.1	Uncultured oomycete clone CV1_B1_49 s...	494	e-136
	gi	39981870	gb	AY381217.1	Uncultured eukaryote clone BL010625.3...	494	e-136
	gi	39981864	gb	AY381211.1	Uncultured eukaryote clone BL010320.2...	494	e-136
	gi	39981860	gb	AY381207.1	Uncultured eukaryote clone BL010320.6...	494	e-136
	gi	39981844	gb	AY381191.1	Uncultured eukaryote clone BL000921.1...	494	e-136
50	gi	18026046	gb	AY046870.1	Uncultured eukaryote isolate C3_E044 ...	494	e-136
	gi	18026039	gb	AY046863.1	Uncultured eukaryote isolate C3_E035 ...	494	e-136
	gi	18026031	gb	AY046855.1	Uncultured eukaryote isolate C3_E026 ...	494	e-136
	gi	42412527	gb	AY486144.1	Pythium insidiosum 18S ribosomal RNA ...	494	e-136
	gi	73533425	gb	DQ103828.1	Uncultured marine eukaryote clone M2_...	494	e-136
55	gi	34576227	gb	AY129064.1	Uncultured marine eukaryote UEPAC45p4...	494	e-136
	gi	30144522	gb	AY256310.1	Uncultured eukaryote isolate D85 smal...	494	e-136
	gi	30144521	gb	AY256309.1	Uncultured eukaryote isolate D84 smal...	494	e-136
	gi	30144518	gb	AY256306.1	Uncultured eukaryote isolate D79 smal...	494	e-136
	gi	30144475	gb	AY256263.1	Uncultured eukaryote isolate E106 sma...	494	e-136
60	gi	30144473	gb	AY256261.1	Uncultured eukaryote isolate E94 smal...	494	e-136
	gi	21954246	gb	AY116220.1	Uncultured eukaryote clone ANT12-26 l...	494	e-136
	gi	41393027	emb	AJ535176.1	LMI535176 Leptocylindrus minimum 18S ...	494	e-136
	gi	53693111	gb	AY742743.1	Phytophthora tropicalis isolate.129F-...	494	e-136
	gi	53693108	gb	AY742759.1	Pythium vexans isolate Pyv6-2 18S rib...	494	e-136
65	gi	53693105	gb	AY742756.1	Pythium splendens isolate 117 18S rib...	494	e-136
	gi	53693104	gb	AY742755.1	Pythium aphanidermatum 18S ribosomal ...	494	e-136
	gi	53693097	gb	AY742748.1	Phytophthora capsici isolate 98110 18...	494	e-136
	gi	53693096	gb	AY742747.1	Phytophthora tropicalis isolate 23047...	494	e-136
	gi	53693094	gb	AY742745.1	Phytophthora palmivora isolate 8829 l...	494	e-136
70	gi	58531862	gb	AY882508.1	Uncultured marine eukaryote clone T53...	494	e-136

3. Example 3: Optimized production of biomass using strain ONC-T18

295. Production of microbial derived (or single celled) oils are dependent on a variety of process variables, such as initial inoculum level, type of substrate, media composition, temperature and pH. Specifically, microbial-based production of highly unsaturated fatty acids using *Thraustochytrid* strains, shows a direct correlation between biomass and fatty acid

production. Consequently, an understanding of the basic needs or optimization of parameters is an important factor in achieving maximum output. Therefore, in order to determine the best medium for production of increased fatty acid quantities, initial biomass optimization experiments were undertaken. Specifically, the recently developed Taguchi method (Joseph J and Piganatiells JR, *IIE Trans* 20:247-254, 1998), based on orthogonal arrays, was used in order to determine the optimum medium configuration for increased optical density (directly related to biomass production). In this instance, the Taguchi method was used to gain an understanding of the cumulative effects of the variables that pose an impact on biomass production. The effects of variations in nitrogen (yeast extract, peptone, L-glutamate), carbon (glucose) and salt concentration (artificial sea salt) had on biomass production. Therefore, a variety of liquid media were prepared with varying amounts of yeast extract, peptone and L-glutamate (0, 4, 10, 20, 50 g L⁻¹) as relates to varying amounts of glucose and sea salt solution (5, 40, 100, 160, 200 g L⁻¹ and 0, 6, 20, 30, 40 g L⁻¹, respectively). Concentrations were calculated according to a L²⁵ orthogonal array in such a way that nitrogen medium of choice was discerned through the use of signal to noise ratio (SNL) analysis at 48 and 120 hrs, using the following formula:

$$SNL = -10 \log \left[\frac{1}{n} \sum_{i=1}^n \frac{1}{y_i^2} \right]$$

where, n = number of levels and y = yield (average OD₆₀₀ from triplicate experiments).

296. Results from these experiments (which specifically target biomass considerations), as shown within figure 2 below, demonstrated that the rate of nitrogen utilization by ONC-T18 as relates to optical density (OD₆₀₀) was peptone, then yeast extract followed by L-glutamate. However, based on growth maxima the best nitrogen sources for increase biomass production was yeast extract, then peptone, followed by L-glutamate. Furthermore, through the use of similar experiments with variations in glucose and salinity (sea salt concentration), the optimal and cheapest medium composition for the production of ONC-T18 biomass was within a medium comprising 2 g L⁻¹ yeast extract, 8 g L⁻¹ MSG, 60 g L⁻¹ glucose and 6 g L⁻¹ sea salt.

4. Example 4: Optimized production of docosahexaenoic acid (DHA) by strain ONC-T18

297. Media consisting of a nitrogen source (either peptone, yeast extract, L-glutamate (MSG) or combinations of these) and a carbon source (glucose), in a saline (artificial sea water) solution, were prepared in order to determine the best media composition for optimal biomass and DHA production in a similar manner to that described in Example 3 (shown in Table 4). After cultivation at 25°C and 130 rpms over 3 days, biomass, total fatty acid per liter of medium, percent content of fatty acids by weight, percent content of DHA in total fatty acids and the

amount of DHA per liter of medium were determined via gas chromatography as per method described in example 1, and herein, and shown in Table 4 below.

298. In this case, DHA was confirmed by comparison to known standards of DHA using gas chromatography mass spectrometry and peak locking methods. Findings from experimental package ①, where variations in both natural and organic forms of nitrogen were investigated, showed that the optimal media composition should contain between 4.0 and 6.0 g L⁻¹ of both yeast extract and L-glutamate for optimal biomass and DHA production. Experimental package ②, on the other hand, which investigated changes in the composition of sodium added to the medium showed optimal DHA production and biomass production when artificial sea salt is used. Moreover, experimental package ③, in which the concentration of sodium within the medium was varied, depicted maxima for DHA and biomass production between 5 and 15% artificial seawater L⁻¹ dH₂O. Results from experimental package ④, where variations in glucose levels were evaluated, demonstrated that the range of 40 to less than 160 g L⁻¹ glucose translated into optimal biomass and DHA production. Finally, results of experimental package ⑤ indicate that ONC-T18 produced equivalent values for both cellular biomass and DHA concentration, when glucose or glycerol were used as carbon sources.

Table 4: Results of DHA production optimization experiments with respect to variations in medium compositions.

	Exp No.	Carbon Sources		Salt types		Nitrogen Sources		Total fatty acids (g L ⁻¹)	Percent fatty acids (wt %)	Percent content DHA (wt %)	Amount of DHA (g L ⁻¹)
		Carbon source used	Amount added (g L ⁻¹)	Salt mix used	Amount added (% salinity)	Yeast extract (g L ⁻¹)	MSG (g L ⁻¹)				
①	401	Glucose	60.0	Sea salt	15.0	10.0	0.0	7.7	34.53	20.20	1.5579
	402	Glucose	60.0	Sea salt	15.0	8.0	2.0	10.0	44.01	17.09	1.7156
	403	Glucose	60.0	Sea salt	15.0	6.0	4.0	11.5	50.69	16.23	1.8624
	404	Glucose	60.0	Sea salt	15.0	4.0	6.0	16.9	69.07	24.19	4.0877
	405	Glucose	60.0	Sea salt	15.0	2.0	8.0	21.3	81.73	20.99	4.4752
	406	Glucose	60.0	Sea salt	15.0	15.0	0.0	10.0	0.15	1.97	28.81
②	407	Glucose	60.0	Sea salt	15.0	10.0	0.0	13.2	58.92	31.44	4.1362
	408	Glucose	60.0	NaCl	15.0	10.0	0.0	9.6	63.75	38.45	3.7009
	409	Glucose	60.0	NaSO ₄	15.0	10.0	0.0	0.05	1.41	20.14	0.0109
③	410	Glucose	60.0	Sea salt	5.0	10.0	0.0	14.6	59.23	31.44	4.6004
	411	Glucose	60.0	Sea salt	15.0	10.0	0.0	10.8	51.01	26.17	2.8144
	412	Glucose	60.0	Sea salt	37.5	10.0	0.0	15.9	69.32	25.32	4.0194
	413	Glucose	60.0	Sea salt	75.0	10.0	0.0	10.8	61.02	25.25	2.7356
	414	Glucose	60.0	Sea salt	100.0	10.0	0.0	11.8	68.21	24.02	2.8290
	415	Glucose	60.0	Sea salt	125.0	10.0	0.0	11.2	59.63	22.56	2.5256
④	416	Glucose	5.0	Sea salt	15.0	10.0	0.0	0.63	5.21	29.18	0.1844
	417	Glucose	20.0	Sea salt	15.0	10.0	0.0	4.06	29.59	24.01	0.9752
	418	Glucose	40.0	Sea salt	15.0	10.0	0.0	9.91	59.39	23.88	2.3665
	419	Glucose	60.0	Sea salt	15.0	10.0	0.0	10.76	51.01	26.17	2.8144
	420	Glucose	100.0	Sea salt	15.0	10.0	0.0	12.79	69.50	31.55	4.0344
	421	Glucose	160.0	Sea salt	15.0	10.0	0.0	1.00	9.40	30.01	0.3013
⑤	422	Glucose	5.0	Sea salt	15.0	10.0	0.0	0.62	12.74	29.86	0.1866
	423	Glycerol	5.0	Sea salt	15.0	10.0	0.0	0.52	18.84	35.07	0.1836

5. Example 5: Optimal time for harvesting of ONC-T18 for maximal DHA production

299. ONC-T18 was cultured under the same media composition and conditions as those shown within example 1. Of interest in this particular instance is the time at which ONC-T18 should be harvested in order to gain the maximal amounts of DHA, DPA and EPA as well as taking into account the time necessary to gain said amounts (see figure 3).

300. Time course experimental results showed that the optimal time for harvesting ONC-T18 for optimal DHA production within flask and bioreactor varied between 3 and 5 days, respectively.

6. Example 6: Analysis of Lipids Derived from ONC-T18

301. The total lipid fraction of ONC-T18 was extracted using a modified Bligh & Dyer method. Specifically, 2.0 g of dried cell biomass was rehydrated overnight at 4°C in 8 ml of distilled H₂O. 30 ml of methanol:chloroform (2:1 vol/vol) was added to mixture and gently shaken at 120 rpm for 20 min, with resultant supernatant decanted. Pellet was then resuspended in methanol:chloroform:H₂O (2:1:0.8 vol/vol/vol) and the process repeated with supernatants being pooled and moved to a separation funnel. 5 ml of chloroform and 5 ml of H₂O were then added to funnel resulting in the formation of a two-phase liquid system. After vigorous mixing within separation funnel, the chloroform layer was removed, concentrated under N₂ gas, resuspended in chloroform and stored at -20°C under analyzed. Approximately 1 µl of the total lipid fraction was spotted on multiple chromarods, separated and analyzed using an Iatroscan MK6 TLC/FID instrument.

302. Analysis of results shows that the fatty acid component which ONC-T18 produces under heterotrophic fermentation is almost entirely triglyceride (at least 95%) in nature. In addition to the neutral fatty acid fraction mentioned above. ONC-T18 also produces a discernable carotenoid and phospholipid fraction. On subsequent isolation of the phospholipid fraction, first via a 50% and then a 75% burn followed by solvent-based separation, it was determined that a large and complex phospholipid fraction was present. Results showed the present of phosphotidylcholine, phosphotidylserine and phosphotidic acid components within the sample.

7. Example 7: Production of antioxidants using the strain, ONC-T18

303. The eukaryote, ONC-T18 was cultured using conditions and medium as mentioned previously. The resultant cellular biomass after heterotrophic fermentation is collected via centrifugation, filtration or settling. Cells were harvested by centrifugation at 3800 x g and washed with phosphate buffered saline. The cellular biomass (fresh or freeze-dried) was

suspended in 10 x volume of acetone, agitated for 5 minutes at 200 rpm, centrifuged at 3800 x g for 5 minutes and concentrated to dryness by N₂ evaporation. The pigments were then immediately resuspended in a minimal amount of 10% acetone in hexane and stored at -20°C until HPLC analysis. Identification of carotenoid extracts was then carried out on an Agilent 1100 HPLC (Agilent, Palo Alto, CA, USA) equipped with a variable wavelength detector set at 470nm. Samples were injected through a Symmetry C18 guard column (Waters, Milford, MA, USA) to a Bondclone C18 reverse-phase column (Phenomenex, Torrance, CA, USA; 10 µm particles; 3.9 x 300 mm i.d.). The injection volume was 10 µl and a flow of 1.00 ml/min 10% acetone in hexane over a 25 minute period was used. Quantitative data of carotenoids was based on comparison of the peak area with known standards (in this case astaxanthin, canthaxanthin, β-cryptoxanthin, zeaxanthin, echinenone and β-carotene; ChromaDex, Santa Ana, CA, USA). In the absence of a known standard such as in the case of the carotenoid, phoenicoxanthin, the astaxanthin peak area was used to calculate its concentrations. Carotenoid identity was further confirmed via HPLC-MS using a Waters HPLC equipped with a photo-diode array (Waters model 996) leading into a Micromass ESI-Q-ToF Mass spectrometer (Waters, Milford, MA, USA). HPLC analysis of ONC-T18 subsequently revealed the presence of several antioxidant compounds (between 50 to 1250 mg kg⁻¹) within the cellular biomass. These compounds included the antioxidant carotenoids astaxanthin, zeaxanthin, canthaxanthin, echineone and beta-carotene in the range of 1 to 20 mg kg⁻¹, 0.25 to 10 mg kg⁻¹, 1 to 20 mg kg⁻¹ 1 to 20 mg kg⁻¹ and 1 to 200 mg kg⁻¹, respectively, as well as several unidentified flavenoid polyphenolic compounds.

8. Example 8: Comparison with Known Microorganisms

304. The ability of ONC-T18 to produce DHA, EPA and DPA was compared with that of known microorganisms. The amount of cellular biomass per liter of medium, the percent content of fats or fatty acids per dried cell biomass, the percent content of DHA, EPA and DPA in total fatty acids, and the amount of DHA, EPA and DPA obtained when DHA, EPA and DPA are produced by cultivation of *Thraustochytrium aureum* ATCC 34304, *Thraustochytrium* sp. ATCC 20891, *Thraustochytrium* sp. ATCC 20892, *Thraustochytrium roseum* ATCC 28210, *Thraustochytrium* sp. ATCC 26185, *Schizochytrium* sp. ATCC 20888, *Schizochytrium aggregatum* ATCC 28209 and *Schizochytrium limacinum* MYA-1381, as well as when DHA, EPA and DPA are produced by cultivation of ONC-T18 according to the present invention.

Table 5. Comparison of the lipid production and biomass characteristics of several representative Thraustochytrid strains.

Microorganism	Cellular biomass amount (g l ⁻¹)	Percent lipid content (% g ⁻¹)	Percent content of DHA (% g ⁻¹)	Percent content of EPA (% g ⁻¹)	Percent content of DPA (% g ⁻¹)	Total DHA (g l ⁻¹)	Total EPA (mg l ⁻¹)	Total DPA (mg l ⁻¹)
<i>Thraustochytrium</i> sp ATCC 20891	1.8	no data	12	no data	no data	no data	no data	no data
<i>Thraustochytrium</i> sp ATCC 20892	3	7	35	no data	no data	0.07	no data	no data
<i>Thraustochytrium</i> sp ATCC 26185	2.3	no data	41.9	3.1	10	no data	no data	no data
<i>T. aureum</i> ATCC 34304	4-5	8-20	24-51	3.6-9.3	no data	0.1-0.5	0.0001	no data
<i>T. roseum</i> ATCC 28210	8-17	18-25	50	no data	no data	0.6-2.1	no data	no data
<i>Schizochytrium</i> sp. ATCC 20888	10.5	50	25-37	no data	no data	1.95	no data	no data
<i>S. aggregatum</i> ATCC 28209	1.4	1.7	6.0	6.1	no data	1	1	no data
<i>S. limacinum</i> SR21 MYA-1381	23-40	40-53.5	29.7-34	0.2-0.4	no data	3.0-7.2	0.08	no data
ONC-T18	25-55	45-80	24-34.2	0.1-2	6-10	4.6-13	0.2-0.8	0.9-3.8

305. As shown in Table 5, it is apparent that, when cultivation is carried out using ONC-T18 according to the present invention, the cellular biomass values per liter medium were extremely high as compared with the other strains tested. Moreover, according to the present invention, ONC-T18 has a very high percent content of lipids compared with the other strains mentioned above. Furthermore, according to the present invention, the percent content of DHA and DPA within ONC-T18 is extremely high, with EPA levels shown to be comparable to all strains screened. Thus, it appears that ONC-T18 has the ability to produce large quantities of DHA, EPA and DPA under fermentation conditions as mentioned within example 1.

9. Example 9: Alternative Carbon Source information

306. ONC-T18 has been shown to grow preferentially on media where the main nitrogen sources are yeast extract, sodium glutamate and/or peptone and the main carbon source is D-glucose. As a result of detailed metabolic profiling of ONC-T18 it was noted that glycerol (carbon source) was also a viable alternative. Furthermore, fish oil processing waste streams containing glycerol were also tested for applicability as low-cost nutrient alternatives. Experiments using 200 ml media in 500 ml flasks, grown at 25°C for 3 days, 120 rpm in the case of the glycerol were undertaken. The glycerol content of two fish oil processing waste products, GWW (glycerol water wash) and GAW (glycerol acid wash), constituted 40% vol:vol of the 200 ml medium (adjusted to pH 6.5), while 6% glycerol was added to 200 ml medium (wt:vol) as control.

Table 6: Fatty acid, biomass and glycerol content for alternative carbon source study.

	Percentage (%) fatty acid to total lipid content by weight					TFA (mg g ⁻¹)	Glycerol (g L ⁻¹)	Biomass (g L ⁻¹)
	AA	EPA	DHA	DPA n-3	DPA n-6			
6% Glycerol (wt:vol)	0.29	0.52	26.31	0.24	9.49	426.12	76.00	9.13
40% GAW (vol:vol)	0.37	1.32	19.69	0.42	6.36	294.55	68.59	5.94
40% GWW (vol:vol)	0.46	5.55	12.46	1.01	3.82	274.33	2.70	3.08

307. Analysis of these results has determined that the use of fish oil waste stream components, such as glycerol by-products, as carbon sources in large-scale fermentation of ONC-T18 while resulting in a reduced total fatty acid amount, represent a maintained DHA content within the microbial cells (figure 10).

10. Example 10: Multiplier of dry cell weight

308. *Thraustochytrium* sp. ONC-T18 can be grown for the production of omega-3 oils in a variety of reactor configurations up to 100,000L. All fermentations begin with the preparation of a 10-20% final volume inoculum, which is used to establish the fermentation culture. Initial medium configurations comprise up to 6 g/L sea salt, 10 g/L nitrogen source and 60 g/L carbon source, with fed-batch addition of another 75 g/L carbon source after 24 to 36 hours of initial fermentation for an additional 72 to 96 hours and occurs within the temperature range 18-25°C. For example, using the medium 6 g/L sea salt, 2 g/L yeast extract, 8 g/L L-glutamate and 60 g/L D-glucose (with an addition 75 g/L added after 36 hours), grown at 25°C for 96 hours, ONC-T18 was able to produce 40 g/L dry cell weight (dcw), 80% (dcw) total fatty acid (TFA)/lipid fraction (between C14:0 and C24:0) and 30% (TFA) DHA. Similarly, it is possible to increase dry cell weight by multiplying both nitrogen and carbon media components to exact a similar multiplication effect on biomass without affecting either TFA or DHA contents. For example, using the medium 24 g/L sea salt, 8 g/L yeast extract, 32 g/L L-glutamate and 300 g/L D-glucose, grown at 25°C for 312 hours, ONC-T18 was able to produce 80 g/L dry cell weight (dcw), 60% (dcw) total fatty acid (TFA)/lipid fraction (between C14:0 and C24:0) and 38% (TFA) DHA.

11. Example 11: Growth of *Thraustochytrium* sp. ONC-T18 on various alternative, carbon (C) and nitrogen (N) sources and the effect on dry cell weight and lipids

309. Growth of *Thraustochytrium* sp. ONC-T18 on a variety of low-cost nitrogen and carbon sources was investigated. Specifically, 50 ml of ONC-T18 was cultured in 250 ml flasks containing 6 g/L artificial sea salts, for 72 hours at 25°C. Carbon and nitrogen source concentrations are shown below with 2 g/L of each nitrogen source listed, used in conjunction

with 8 g/L of L-glutamate (with the exception of fish meal where 4 g was used). Carbon sources were switched as indicated. All experiments were performed in triplicate; all extractions for fatty acid methyl ester analysis were performed in triplicate along with triplicate GC injections.

310. Results indicate that *Thraustochytrium* sp. ONC-T18 produces optimal dry cell biomass (i.e. greater than the two control media) when grown on the nitrogen sources EMD yeast extract and fish meal. Conversely, lipid was found to be less than control, while DHA was optimal using corn steep liquor and EMD peptone. Finally, the carbon source dextrose was found to increase lipid content, while fructose and dextrose producing high DHA content than the controls.

10 Table 7: Growth of *Thraustochytrium* sp. ONC-T18.

Medium (salt 6 g/l, growth 72 hrs, 50 ml cultures)		C (g/l)	N (g/l)	dcw/l medium (g)	Lipid (mg/g)	Lipid (g/l)	DHA (mg/g)	DHA (g/l)	DHA (% lipid)
Nitrogen Sources	Corn Steep Liquor-MSG	60	10	11.36	371.97	4.33	111.64	1.244	29.72
	Cotton Seed-MSG	60	10	9.99	297.08	2.70	45.20	0.500	16.94
	EMD™ YE-MSG	60	10	15.49	343.90	5.02	70.68	0.786	20.70
	EMD™ YE	60	10	35.79	189.01	6.76	37.14	0.448	19.65
	EMD™ Peptone-MSG	60	10	11.70	379.48	4.19	83.50	0.926	23.33
	Sigma™ YE-MSG	60	10	9.77	257.86	3.28	54.60	0.618	19.69
	Sigma™ YE	60	10	10.39	341.98	3.53	58.30	0.629	17.01
	Fermtch™ YE-MSG	60	10	13.99	269.53	3.82	56.97	0.664	21.10
	Fermtch™ YE	60	10	17.07	243.23	4.15	48.01	0.530	19.74
	Fish meal (62% protein)	60	12	19.53	290.72	5.68	73.59	0.828	25.31
Carbon Sources	Fructose	60	10	14.57	498.54	8.09	96.97	1.070	21.55
	Dextrose	60	10	14.98	623.91	9.87	113.69	1.232	18.94
	Corn Dextrin	60	10	4.65	89.69	0.39	25.69	0.278	26.75
	Gelatin	60	10	7.09	31.87	0.13	11.86	0.127	27.70
	Starch (corn)	5	10	4.85	94.04	0.46	19.49	0.206	20.72
		30	10	3.13	90.07	0.28	23.78	0.256	26.40
	Starch (wheat)	5	10	8.03	86.96	0.47	17.62	0.185	17.76
		30	10	18.16	18.59	0.34	3.83	0.042	20.58
Control medium (1)		60	10	16.92	487.59	8.25	70.87	0.768	13.25
Control medium (2)		60	10	10.88	483.06	6.06	74.64	0.818	16.19

Abbreviations:

MSG = L-glutamate (sodium) YE = Yeast extract

12. Example 12: Extraction Techniques for isolation of total lipids and fractions

15 311. A variety of methods for the isolation of selected omega-3 oils were tested in order to determine optimal isolation efficiency. These methods included: the standard Bligh & Dyer method (Bligh & Dyer, *Can J. Biochem. Physiol.*, 37:912-917, 1959); the combined extraction and transesterification method used specifically with *Thraustochytrid* species allowing
20 for processing of samples for rapid GC FAME analysis (Lewis et al., *J. Microbiol. Methods*, 43:107-116, 2000); extraction by simultaneous saponification (Cartens et al., *J. Am. Oil Chem. Soc.* 73:1025-1031, 1996); and solid phase extraction using silica gel columns which can

selectively isolate triglycerides, diglycerides and monoglycerides (Pinkart et al., *J. Microbiol. Methods*, 34:9-15, 1998; Bateman & Jenkins, *J. Agric. Food Chem.*, 45:132-135, 1997).

312. Specifically, 40 grams of dry cell weight *Thraustochytrium* sp. ONC-T18 biomass produced in a single fermentation run (see example 1) was divided into 0.44 g lots and used for each technique. All techniques were performed in triplicate with efficiencies analyzed using fatty acid methyl ester determination via FID-GC, again in triplicate with triplicate runs per sample. Results demonstrate that total fatty acid content might vary between individual methods with fluctuations most probably due to solvent:compound saturation, biomass disruption considerations and other physical condition considerations (e.g. temperature and time).

Table 8: Extraction Techniques for isolation of total lipids and fractions.

Bligh and Dyer

	DHA	EPA	C14:0	C14:1	C15:0	C16:0	C16:1	C18:1	C20:0	C20:4	C22:5	TFA
	mg omega-3 per gram of biomass (mg/g)											
1	104.39	4.25	36.28	5.82	113.94	77.27	4.92	44.01	1.13	1.67	28.86	430.99
2	136.75	5.45	46.51	7.40	142.96	98.38	6.07	56.49	1.40	2.19	37.92	552.98
3	134.59	4.78	42.51	6.91	128.54	87.01	5.20	51.10	1.30	2.10	35.98	532.91
Av.	125.24	4.83	41.77	6.71	128.48	87.55	5.40	50.53	1.28	1.99	34.25	505.63

Direct Transesterification

	DHA	EPA	C14:0	C15:0	C16:0	C16:1	C18:0	C18:1	C20:0	C20:4	C22:5	TFA
	mg omega-3 per gram of biomass (mg/g)											
1	104.39	4.24	36.39	5.42	112.94	75.27	5.42	44.01	1.13	1.67	28.86	420.99
2	89.83	4.54	34.81	5.60	103.04	73.43	5.56	42.85	0.98	1.87	25.35	392.88
3	101.64	4.25	37.16	5.98	106.94	75.98	5.35	43.95	1.11	1.78	26.46	410.65
Av.	98.65	4.34	36.12	5.67	107.64	74.89	5.44	43.60	1.07	1.77	26.89	408.17

Simultaneous saponification

	DHA	EPA	C14:0	C15:0	C16:0	C16:1	C18:0	C18:1	C20:0	C20:4	C22:5	TFA
	mg omega-3 per gram of biomass (mg/g)											
1	204.85	6.75	46.55	8.56	182.26	134.81	8.73	105.04	2.16	3.20	66.68	785.25
2	188.51	6.17	47.64	9.32	208.29	121.25	10.35	95.80	2.53	2.89	61.41	770.14
3	198.25	6.12	47.21	9.65	207.71	136.51	9.58	98.50	2.41	3.10	63.58	782.54
Av.	197.20	6.35	47.13	9.18	199.42	130.86	9.55	99.78	2.37	3.06	63.89	779.31

Solid phase extraction

	DHA	EPA	C14:0	C15:0	C16:0	C16:1	C18:0	C18:1	C20:0	C20:4	C22:5	TFA
	mg omega-3 per gram of biomass (mg/g)											
1	169.17	0.42	68.41	10.83	204.43	140.14	8.09	76.97	1.75	3.00	47.05	748.33
2	172.26	0.44	69.59	11.01	207.01	143.74	8.11	78.72	1.74	3.27	47.86	819.04
3	173.65	0.43	69.21	11.31	208.97	146.64	8.16	77.64	1.73	3.64	46.98	785.64
Av.	171.69	0.43	69.07	11.05	206.80	143.51	8.12	77.78	1.74	3.30	47.30	784.34

N.B: Each value listed above is the average of triplicate runs using FID-GC for FAME analysis

a) Materials and Methods**(1) Isolation and Maintenance of Thraustochytrids**

313. Seventy marine samples including: *Spartina alterniflora*, *Zostera marina* and
5 sediment were collected in eastern Canadian coastal sites from Nova Scotia, Prince Edward
Island, New Brunswick, Newfoundland and Labrador between July and August 2002. Samples
were placed in 20 mL vials containing 10 mL of sterile 0.2 μm filtered natural seawater and 300
mg L^{-1} penicillin and 500 mg L^{-1} streptomycin. Suspensions were baited with sterile pollen (*Acer*
10 sp.) and incubated for 48 hours at 18°C, according to (Bremer, *Marine Mycology - A Practical*
Approach, Fungal Diversity Press, Hong Kong, pp 49-61 (2000)). Pollen grains were then
transferred by loop and streaked onto B1 agar plates (1 g L^{-1} yeast extract, 1 g L^{-1} peptone, 10 g
 L^{-1} agar to 1 L natural seawater) containing antibiotics and incubated. Single, irregular, hyaline
colonies made up of spherical or limaciform cells and atypical of either yeast or bacterial
colonies were picked and sub-cultured at least three times on B1 plates for purity.

(2) Biomass production for fatty acid screening

314. To screen isolates for growth and fatty acid production, liquid medium was
prepared using 0.2 μm filtered natural seawater containing 2 g L^{-1} peptone (BD, Franklin Lakes,
NJ, USA) and 2 g L^{-1} yeast extract (BD, Franklin Lanes, NJ, USA), which was sterilized by
autoclaving, followed by the addition of 5 g L^{-1} , 0.2 μm filter sterilized glucose (Sigma-Aldrich,
20 St. Louis, MO, USA) (Bowles et al., *J Biotechnol* 70:193-202 (1999)). A 30 mL volume culture
was inoculated by loop from an agar plate and grown for 4 days at 18°C on a shaker at 100
RPM. 5 mL of this culture was then used to inoculate a 95 ml culture incubated for a further 4
days (stationary phase). Cells were harvested by centrifugation at 4,500 RPM, rinsed with 5 mL
of distilled water and re-centrifuged. The cell pellets were freeze dried, weighed and stored at -
25 80°C prior to derivatisation for fatty acid analysis.

(3) Preparation of fatty acid methyl esters (FAME)

315. Fatty acid methyl ester (FAME) extraction was via the direct transesterification
method, modified from Lewis et al. (*J Microbiol Meth.* 43:107-116 (2000)). Specifically, 20 mg
of freeze dried material and 3 ml of transesterification reaction mix (methanol:hydrochloric
30 acid:chloroform (10:1:1 vol/vol)) were added. Cells were vortexed for 10 seconds to ensure even
dispersal of biomass and placed at 90°C for 120 minutes. Once transesterification was complete,
samples were removed and allowed to cool to room temperature. Water (1 ml) was then added
and vortexed for 10 seconds. FAMES were then extracted via the addition of 3 x 2 ml aliquots of

hexane:chloroform (4:1), vortexed for 10 seconds and allowed to sit until clear liquid separations were achieved.

(4) Gas chromatographic (GC) analysis of FAMES

316. GC analysis of FAMES was carried out using two internal standards (200 μ l each). One hexacosanoic acid (C23:0) is added prior to transesterification and the other, nonadecanoic acid (C19:0) added directly before analysis. Analyses was performed using an Agilent 6890 GC (Agilent Technologies, Palo Alto, CA, USA) equipped with a 30 m x 0.32 m internal diameter (0.25 μ m film thickness) OMEGAWAX 320 fused-silica capillary column (Sigma-Aldrich, St. Louis, MO, USA) and flame ionization detector (injection volume 1 μ l, carrier gas H₂ with a constant flow of 5.0 ml min⁻¹ and set at 250°C, split ratio 50:1 to FID detector at 275°C). Confirmation of FAME identity was performed using a Trace GC-DSQ mass spectrometer (Thermo Electron, Boston, MA, USA) and comparison of retention times for laboratory standards.

(5) Genetic identification

317. The genomic DNA was extracted using the MoBio UltraClean Microbial DNA Isolation Kit (MoBio Laboratories, Carlsbad, CA, USA) according to manufacturer instructions. The oligonucleotide primers used in amplifying the 18S rRNA gene, were modified from Honda et al. (*J Eukaryot Microbiol.* 46:637-647 (1999)) namely T18S1F 5'-CAACCTGGTTGATCCTGCCAGTA-3' and T18S5R 5'-TCACTACGGAAACCTTGTTACGAC-3'. A 20- μ l PCR reaction mixture contained 2U Biolase™ DNA polymerase (Bioline, Boston, MA, USA), 1 x NH₄ reaction buffer, 3 mM MgCl₂, 1M Betaine (Sigma-Aldrich, St Louis, MO, USA), 200 μ M of mix PCR nucleotides (Promega, Madison, WI, USA), 1 μ M of each forward and reverse primer (MWG Biotech., High Point, NC, USA) and 100 ng of genomic DNA template. After an initial denaturation step for 3 minutes at 94°C, PCR amplification was performed using a Eppendorf Master Cycle Gradient thermal cycler (Eppendorf, Westbury, NY, USA), using a program of 45 seconds at 94°C, 30 seconds at 64°C and 2 minutes at 72°C for 30 cycles, followed by a 10 minute final extension at 72°C. The PCR product was purified using MoBio UltraClean PCR Clean-up Kit (MoBio Laboratories Inc, Carlsbad, CA, USA) for direct sequencing (MWG Biotech., High Point, NC, USA) using primers FA2, FA3, RA1, R (Mo et al., *Mar Biol* 140:883-889 2002), T18S1F and T18S5R. The resulting sequences were aligned and compared to nucleotide sequences of similar microorganisms stored in GenBank (Benson et al., *Nucleic Acids Res* 33:D34-38 (2005)) using DS Gene (Accelrys, San Diego, CA, USA). A phylogenetic tree was subsequently generated using the Neighbor-Joining method (Saito and Nei, *Mol Biol Evol* 4:406-425 (1987)), with the

statistical significance assessed using 1,000 bootstrap resamplings (Felsenstein, *Evolution* 39:783-791 (1985)).

(6) Identification of carotenoids

318. Cells were harvested by centrifugation at 3800 x g and washed with phosphate
5 buffered saline. Then resuspended in 10 x volume of acetone (Sigma-Aldrich, St Louis, MO, USA), agitated for 5 minutes at 200 RPM, centrifuged at 3,800 x g for 5 mins and concentrated to dryness by N₂ evaporation. Followed by resuspension in a minimal amount of 10% acetone in hexane prior to HPLC analysis. Identifications were carried out on an Agilent 1100 HPLC (Agilent, Palo Alto, CA, USA) equipped with a variable wavelength detector set at 470nm.
10 Samples were injected through a Symmetry C₁₈ guard column (Waters, Milford, MA, USA) to a Bondclone C₁₈ reverse-phase column (Phenomenex, Torrance, CA, USA; 10 µm particles; 3.9 x 300 mm i.d.). The injection volume was 10 µl and a flow of 1 ml min⁻¹ 10% acetone in hexane over a 25 minute period was used. Carotenoid identity was further confirmed with mass spectrometry analysis (Micromass ESI-QToF MS, Waters, Milford, MA, USA). Quantitative data
15 for each carotenoid was based on the development of a calibration curve using standards (astaxanthin, zeaxanthin, canthaxanthin, echinenone and β-carotene) and comparing peak area with defined concentrations.

(7) Fermentation optimization

319. The effect of carbon, nitrogen and sea salt on fatty acid and DHA production
20 were examined using batch cultures in 250 ml Erlenmeyer flasks shaken at 130 RPM for 3 days at 25°C. Further cultivation studies were carried out using a Biostat[®] Bplus Twin 5L Bioreactor (Sartorius BBI Systems Inc., Bethlehem, PA, USA). A 100 ml inoculum was used to inoculate 4.9L of medium in the bioreactor. Glucose concentration was measured using the Glucose (HK) Assay Kit (Sigma-Aldrich, St Louis, MO, USA) according to the manufacturers instructions.
25 The media constituents and the conditions employed in the bioreactor are detailed with the relevant results.

b) Results

320. A collection and screening process was developed whereby members of the protist family Labyrinthulida, especially the genus, Schizochytrium and Thraustochytrium, were
30 isolated using pollen-baiting and selective bacteriological media. This study, covering 20 unique collection sites dispersed throughout Atlantic Canada, produced 68 pure strains, identified microscopically. Selection of oleaginous strains, having more than 20% of their cell dry weight being fatty acids, was based upon results of GC PUFA profiling, biomass productivity, maximal TFA, DHA and to a lesser extent EPA concentrations (Fig. 11), according to the method of

(Lewis et al., *J Microbiol Meth* 43:107-116 (2000)). Values for biomass, TFA and subsequent DHA and EPA productivities ranged from 100 to 2300 mg L⁻¹, 27.1 to 321.14, 5.18 to 83.63 and 2.97 to 21.25 mg g⁻¹, respectively (Fig. 11).

321. All isolates which grew in liquid medium (54 out of 68), produced major amounts of omega-3 polyunsaturated fatty acid, particularly DHA which comprised between 22 and 80% of the total C20 to C22 content of these cells (Fig. 11). This confirms previous findings, whereby thraustochytrids isolated from cold temperate environments have fatty acid profiles with DHA being up to 53% of the total fatty acid present (Bowles et al., *J Biotechnol* 70:193-202 (1999) and Huang et al., *Mar Biotechnol* 5:450-457 (2003)). Of particular interest is ONC-T18 which produces up to 90% of its C20 to C22 content as DHA which is approximately 35% of the total intracellular fatty acids. This DHA content was shown to be equivalent to those of several commercial production strains, such as *Schizochytrium* sp. ATCC 20888 (32%) and *S. limacinum* MYA-1381/SR21 (34%) (Barclay et al., *J Appl Phycol* 6:123-129 (1994) and Yokochi et al., *Appl Microbiol Biotechnol* 49:72-76, (2003)). Furthermore, all isolates synthesized eicosapentaenoic acid (EPA), varying between 2 and 20% w/w of total PUFAs identified (Fig. 11). In addition to the omega-3 oils produced, approximately 80% of all isolates synthesized the omega-6 PUFAs, arachidonic acid (AA) or docosapentaenoic acids (DPA), at concentrations varying between 1 and 18% and 3 and 7% w/w, respectively (Fig. 11).

322. Huang et al. (*Mar Biotechnol* 5:450-457 (2003)) suggested that for thraustochytrids isolated from the tropical coastal waters of Japan and Fiji, five polyunsaturated fatty acid profiles could be described, namely DHA/DPA (n-6), DHA/DPA/EPA, DHA/EPA, DHA/DPA/EPA/AA and DHA/DPA/EPA/AA/docosatetraenoic acid (Huang et al., *Mar Biotechnol* 5:450-457 (2003)). In the case of this collection of thraustochytrids, isolated from the temperate waters of Atlantic Canada, four PUFA profiles could be determined, three of which are identical to those mentioned above, namely DHA/DPA/EPA at 7.4% of collection, DHA/EPA at 13% of collection and DHA/DPA/EPA/AA, 74%, with a fourth comprising a mixture of DHA/EPA/AA at 5.6%.

323. Through direct sequencing of the 18S rDNA gene, ONC-T18 was positively identified as a member of the Thraustochytrid family (GenBank Accession Number: DQ374149). Phylogenetic analysis indicated that ONC-T18 formed a unique group (97.5% identity) with *Thraustochytrium striatum* T91-6 (Fig. 12) (Leander and Porter, *Mycologia* 93:459-464 (2001)). While *Thraustochytridae* sp. MBIC 11093, N1-27 and *Thraustochytrium* sp. CHN-1, collected from the coastal tropical waters of Japan, and found to be significant producers of DHA (Carmona et al., *Biosci Biotechnol Biochem* 67:884-888 (2003) and Huang et

al., *Mar Biotechnol* 5:450-457 (2003)), were shown to be 96, 95.5 and 94.5% similar, respectively. Genetic diversity is quite low between all members of the Thraustochytriidae shown in figure 12, ranging from 97.5-91.0% similarity throughout. Yet, these species are globally distributed, with two-thirds isolated from the tropical coastal waters of Japan, China and Israel and the remaining from temperate waters off America, Europe and Canada.

5 324. The fatty acid profile of ONC-T18 included high contents of C22 PUFA, very low levels of C18 and C20 FA, and the occurrence of odd-chain saturated fatty acids (15:0 and 17:0), similar to that of Schizochytrium sp. KH105 or S. limacinum SR21. Furthermore, analysis of carbon and nitrogen utilization profiles for strains ONC-T18, SR21 and KH105 showed a similar pattern of assimilation. The content of n-6 DPA in strain ONC-T18 ranged from 6-10%, which seems to be extremely high when considering the limited occurrence of n-6 DPA in the biosphere. Similar levels of n-6 DPA were reported however, by Nakahara et al. (*J Am Oil Chem Soc* 73:1421-1426 (1996)) in Schizochytrium sp. SR21 (6-10%) and Ellenbogen et al. (*Comp Biochem Physiol* 29:805-81 (1969)) in T. aureum (9.5%) and T. roseum (6.6%).

15 325. Analysis of the fatty acid profile of ONC-T18 under three different culture configurations: (1) agar plate; (2) conical flask and (3) bioreactor and grown on the same medium (Fig. 13), shows a decrease in the diversity of PUFAs present and an overall increase in TFA from agar plate to bioreactor. Specifically, agar plates exhibited an array of PUFAs, while the flask and bioreactor grown cultures were dominated by one or two intermediates (Fig. 13). Compared to Thraustochytrium aureum, which grew better in flask culture than in a stirred tank fermenter (Ilda et al., *J Ferment Bioeng* 81:76-78 (1996)), ONC-T18 grew better in a bioreactor. This result is in agreement with that of (Nakahara et al., *J Am Oil Chem Soc* 73:1421-1426 (1996)), who found that Schizochytrium sp. SR21 showed high resistance to mechanical stirring, and therefore thrived under bioreactor conditions.

25 326. Furthermore, carotenoid pigments were found to be produced in plate, flask and bioreactor fermentations of Thraustochytrium sp. ONC-T18, resulting in a pale orange discoloration. Production of these antioxidants is maximal within bioreactor fermentations concurrently with fatty acid production. Moreover, through the use of HPLC mass spectrometry, it was determined that these antioxidant compounds were identified as astaxanthin, zeaxanthin, canthaxanthin, echineone and β -carotene (Fig. 14), being conjugated to various PUFAs. Similar results were reported amongst members of the thraustochytid group of protists. Specifically, Schizochytrium aggregatum was shown to produce echinenone and canthaxanthin (Valadon, *Trans Br Mycol Soc* 67:1-15 (1976)), while Carmona et al. (*Biosci Biotechnol Biochem* 67:884-888 (2003) and Huang et al. (*Mar Biotechnol* 5:450-457 (2003))) demonstrated the production of

astaxanthin, echinenone, canthaxanthin, phoenicoxanthin (not zeaxanthin as in ONC-T18) and β -carotene by *Thraustochytrium* sp. CHN-1, a close relative of ONC-T18 (Fig. 12). In this study, concentrations of these carotenoids were found to be an order of magnitude less than those of CHN-1 with the major compound being β -carotene, rather than astaxanthin. Thus, within

5 *Thraustochytrium* spp., PUFA and carotenoid production can be linked so that the storage fats being produced may be protected from oxidation.

327. Previously, it has been determined that the relative amounts of the principal fatty acid components (myristic, palmitic and oleic acids) may be altered somewhat by changing the growth conditions of the culture (Ilda et al., *J Ferment Bioeng* 81:76-78 (1996)). In this way, one

10 can manipulate the final fatty acid composition and hence, physical properties of the desired PUFA in a controlled fashion during fermentation (Sijtsma et al., *Recent Res Devel Microbiol* 2:219-232 (1998)). In an attempt to limit the factors inhibiting both biomass and omega-3 PUFA production in ONC-T18, carbon, nitrogen and sea salt components in nutrient media were manipulated (Table 9), along with duration of culture (Fig. 15).

15 Table 9: Mean biomass production (SD \leq 15%), total fatty acid (TFA) and DHA content of *Thraustochytrium* sp. ONC-T18.

Glucose (g L ⁻¹)	Biomass (g L ⁻¹)	TFA (% biomass)	DHA (% TFA)	DHA (g L ⁻¹)
5	12.13	5.21	29.18	0.18
20	13.73	29.59	24.01	0.98
40	16.69	59.39	23.88	2.37
60	21.08	51.01	26.17	2.81
100	18.40	69.49	31.55	4.03
160	10.68	9.40	30.01	0.30

YE (g L ⁻¹)	MSG (g L ⁻¹)	Biomass (g L ⁻¹)	TFA (% biomass)	DHA (% TFA)	DHA (g L ⁻¹)
10	0	22.33	34.53	20.20	1.56
8	2	22.81	44.00	17.52	1.72
6	4	22.64	50.69	16.23	1.86
4	6	24.46	69.07	24.19	4.09
2	8	26.09	81.73	20.99	4.47
0	10	7.50	1.97	28.81	0.04

Sea salt (g L ⁻¹)	Biomass (g L ⁻¹)	TFA (% biomass)	DHA (% TFA)	DHA (g L ⁻¹)
2	24.70	59.23	31.44	4.60
6	21.08	51.01	26.17	2.81
15	22.90	69.32	25.32	4.02
30	17.76	61.02	25.25	2.74
40	17.27	68.21	24.02	2.83
50	18.77	59.63	22.56	2.53

328. Within this study, as the concentration of nitrogen decreased, total fatty acid content increased, with the highest total fatty acid content (approximately 80%) obtained at 1% concentration of yeast extract and or monosodium glutamate (w/v). Cultures with a low nitrogen concentration, however, also limited cell growth and hence total fatty acid production. Optimal production in this experiment was obtained using 8 g L⁻¹ monosodium glutamate and 2 g L⁻¹ yeast extract, producing 26.1 g L⁻¹ biomass and 4.5 g L⁻¹ DHA (Table 9). Furthermore, increases in carbon up to 100 g L⁻¹ effectively increased DHA yield, this is in agreement with results obtained for *Schizochytrium* sp. SR21 (Yokochi et al., *Appl Microbiol Biotechnol* 49:72-76, (2003)) and contrary to those shown in *T. aureum* where glucose concentrations above 10 g L⁻¹ were inhibitory (Ilda et al., *J Ferment Bioeng* 81:76-78 (1996)). Maximum DHA yields of more than 4.0 g L⁻¹ were obtained in glucose medium, with yields more than 5 times that of *T. aureum* (Bajpai et al., *J Am Oil Chem Soc* 68:509-514 (1991)) and *T. roseum* (Li and Ward, *J Ind Microbiol* 13:238-241 (1994)) and comparable to that of *Schizochytrium* sp. SR21 and KH105 (Aki et al., *J Am Oil Chem Soc* 80:789-794 (2003)). Finally, ONC-T18 exhibited classical euryhaline abilities, being able to withstand salinities ranging from 2.0 to 50.0 g L⁻¹, resulting in biomass productivity of 25-30% variability (Table 9). In the same experiment DHA g L⁻¹ values were found to vary up to 45% between optimal at 4.6 g L⁻¹ and minimal at 2.5 g L⁻¹ (Table 9).

329. The biomass, TFA and DHA produced by ONC-T18 over a 168 h period in a 5 L bioreactor are presented in Figure 15. The growth curve depicted is typical of several achieved under identical conditions. Maximum biomass production was reached after 120 h, close to the point of carbon source (i.e. glucose) depletion. This was also the point at which total fatty acid content of the biomass reached a maximum at around 70% biomass. Interestingly, after only 24 h of cultivation, DHA content spiked to 30% total fatty acid, thereafter remaining constant at 20-25%. These results are consistent with those of other fatty acid producing *Thraustochytrid* strains, yet there is disparity with regards to the rate at which these reactions occur.

c) Discussion

330. Previously most studies of *Labyrinthomycoota* identified strains which are unable to store total fatty acid in amounts greater than 20% of biomass. For example, prior to the isolation of *Schizochytrium* sp. SR 21 which is able to accumulate up to 50% of biomass as fat, *T. aureum* was the best accumulator at 20% (Bajpai et al., *J Am Oil Chem Soc* 68:509-514 (1991)). ONC-T18, on the other hand, is able to accumulate up to 80% of its biomass as lipid.

331. For oleaginous micro-organisms such as ONC-T18 to accumulate oil, it typically should be grown in a culture medium with a limited amount of nitrogen (usually exhausted after 24 to 36 h) and abundant amounts of a carbon source. Once the nitrogen is depleted, the

oleaginous microbes continue to assimilate the carbon source but are no longer able to undergo cell division due to a lack of nitrogen (thus preventing protein and nucleic acid synthesis). The result being the conversion of these carbon sources (i.e. sugars such as glucose) into storage oils. In this regard, ONC-T18 is considered to grow more slowly than other Thraustochytrid strains, such as G13 (Bowles et al., *J Biotechnol* 70:193-202 (1999) and Huang et al., *Mar Biotechnol* 5:450-457 (2003), yet it produces DHA at faster rates and demonstrates a unique ability to incorporate elevated amounts of total fatty acids. Finally, the ability of ONC-T18 to grow at very low salt concentrations with both high biomass and total fatty acid productivity is remarkable. Lending itself well to scale up by negating the corrosive nature of salt water on industrial fermentation equipment.

VII. CLAIMS

What is claimed is:

1. A eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has
5 at least 94% identity to the sequence set forth in SEQ ID NO:1.
2. The microorganism of claim 1, wherein the microorganism produces unsaturated
fatty acids having a profile shown in figure 2.
3. The microorganism of claim 1, wherein the microorganism is from the phylum
Labyrinthulomycota.
- 10 4. The microorganism of claim 1, wherein the microorganism is from the class
Labyrinthulomycetes.
5. The microorganism of claim 1, wherein the microorganism is from the subclass
Thraustochytridae.
6. The microorganism of claim 1, wherein the microorganism is from the order
15 Thraustochytriales.
7. The microorganism of claim 1, wherein the microorganism is from the family
Thraustochytriaceae.
8. The microorganism of claim 1, wherein the microorganism is from the genus
Thraustochytrium.
- 20 9. The microorganism of claim 1, wherein the microorganism is *Thraustochytrium* sp.
10. The microorganism of claim 1, wherein the microorganism is *Thraustochytrium*
aureum.
11. The microorganism of claim 1, wherein the microorganism is *Thraustochytrium*
roseum.
- 25 12. The microorganism of claim 1, wherein the microorganism is *Thraustochytrium*
striatum.
13. The microorganism of claim 1, wherein the microorganism is from the genus
Schizochytrium.
14. The microorganism of claim 1, wherein the microorganism is *Schizochytrium* sp.
- 30 15. The microorganism of claim 1, wherein the microorganism comprises an omega 3 or
omega 6 fatty acid.

16. The microorganism of claim 1, wherein the microorganism comprises DHA or DPA.
17. The microorganism of claim 1, wherein the microorganism produces a lipid or fatty acid fraction of at least about 4 wt.% to 6 wt.%.
18. The microorganism of claim 17, wherein the lipid comprises DHA.
- 5 19. The microorganism of claim 17, wherein the lipid composition comprises from about 25 wt.% fatty acid fraction to about 40 wt.% fatty acid fraction of n-3 DHA, from about 6 wt.% fatty acid fraction to about 10 wt.% fatty acid fraction of n-6 DPA, and from about 0 wt.% fatty acid fraction to about 3 wt.% fatty acid fraction of n-3 EPA.
- 10 20. The microorganism of claim 1, wherein the microorganism is from the family Thraustochytriaceae and has ATCC accession number 20888, 20889, 20890, 20891, or 20892.
21. A composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 94% identity to the sequence set forth in SEQ ID NO:1.
- 15 22. The composition of claim 21, wherein the composition further comprises a medium.
23. The composition of claim 21, wherein the composition further comprises nutrients.
24. The composition of claim 21, wherein the composition is a biomass.
25. The composition of claim 21, wherein the microorganism is from the phylum Labyrinthulomycota.
- 20 26. The composition of claim 21, wherein the eukaryotic microorganism is from the class Labyrinthulomycetes.
27. The composition of claim 21, wherein the eukaryotic microorganism is from the subclass Thraustochytridae.
28. The composition of claim 21, wherein the eukaryotic microorganism is from the order Thraustochytriales.
- 25 29. The composition of claim 21, wherein the eukaryotic microorganism is from the family Thraustochytriaceae.
30. The composition of claim 21, wherein the eukaryotic microorganism is from the genus *Thraustochytrium*.
- 30 31. The composition of claim 21, wherein the eukaryotic microorganism is

~~PCT/IB2006/003977~~
Thraustochytrium sp.

32. The composition of claim 21, wherein the eukaryotic microorganism is *Thraustochytrium aureum*.
33. The composition of claim 21, wherein the eukaryotic microorganism is *Thraustochytrium roseum*.
34. The composition of claim 21, wherein the eukaryotic microorganism is *Thraustochytrium striatum*.
35. The composition of claim 21, wherein the eukaryotic microorganism is from the genus *Schizochytrium*.
36. The composition of claim 21, wherein the eukaryotic microorganism is *Schizochytrium* sp.
37. The composition of claim 21, wherein the eukaryotic microorganism produces unsaturated fatty acids having a profile shown in figure 2.
38. The composition of claim 37, wherein the unsaturated fatty acid comprises an omega 3 or omega 6 fatty acid.
39. The composition of claim 37, wherein the unsaturated fatty acid comprises DHA or DPA..
40. The composition of claim 21, wherein the eukaryotic microorganism can produce a lipid or fatty acid fraction of at least about 4 wt.% to 6 wt.%.
41. The composition of claim 40, wherein the lipid comprises DHA.
42. The composition of claim 40, wherein the lipid composition comprises from about 25 wt.% fatty acid fraction to about 40 wt.% fatty acid fraction of n-3 DHA, from about 6 wt.% fatty acid fraction to about 10 wt.% fatty acid fraction of n-6 DPA, and from about 0 wt.% fatty acid fraction to about 3 wt.% fatty acid fraction of n-3 EPA.
43. The composition of claim 21, wherein the eukaryotic microorganism is from the family Thraustochytriaceae and has ATCC accession number 20888, 20889, 20890, 20891, or 20892.
44. A composition comprising a eukaryotic microorganism having an 18S sequence, wherein the 18S sequence has at least 80% identity to the sequence set forth in SEQ ID NO:1

45. A composition comprising from about 25 wt.% fatty acid fraction to about 40 wt.% fatty acid fraction of n-3 DHA, from about 6 wt.% fatty acid fraction to about 10 wt.% fatty acid fraction of n-6 DPA, and from about 0 wt.% fatty acid fraction to about 3 wt.% fatty acid fraction of n-3 EPA.
- 5 46. A method of preparing a lipid composition, the method comprising: culturing the eukaryotic microorganism of any of claims 1-20, in a heterotrophic medium, and isolating the lipid composition.
47. The lipid composition prepared according to the method of claim.46.
48. A delivery device comprising a composition of any of claims 21-45 or 47..
- 10 49. The delivery device of claim 48, wherein the delivery device comprises a microcapsule, a microsphere, a nanosphere or nanoparticle, a liposome, a noisome, a nanoerythroosome, a solid-liquid nanoparticle, a leuprolide, a gel, a gel capsule, a tablet, a lotion, a cream, a spray, an emulsion, or a powder.
- 15 50. A microcapsule, comprising an agglomeration of primary microcapsules and a loading substance, each individual primary microcapsule having a primary shell, wherein the loading substance comprises the composition of any of claims 21-45 or 47, and is encapsulated by the primary shell, and wherein the agglomeration is encapsulated by an outer shell.
- 20 51. The microcapsule of claim 50, wherein the primary shell and/or outer shell comprises a surfactant, gelatin, polyphosphate, polysaccharide, or a mixture thereof.
52. The microcapsule of claim 50, wherein the primary shell and/or outer shell comprises gelatin type B, polyphosphate, gum arabic, alginate, chitosan, carrageenan, pectin, starch, modified starch, alfa-lactalbumin, beta-lactoglobulin, ovalbumin, polysorbition, maltodextrin, cyclodextrin, cellulose, methyl cellulose, ethyl cellulose, hydropropylmethylcellulose, carboxymethylcellulose, milk protein, whey protein, soy protein, canola protein, albumin, kosher gelatin, non-kosher gelatin, Halal gelatin, non-Halal gelatin, or a mixture thereof.
- 25 53. The microcapsule of claim 50, wherein the primary shell and/or outer shell comprise a complex coacervate.
- 30 54. The microcapsule of claim 50, wherein the primary shell and/or outer shell comprise gelatin type A.

55. The microcapsule of claim 50, wherein the primary shell and/or outer shell comprise fish gelatin.
56. The microcapsule of claim 50, wherein the primary shell and/or outer shell comprise a gelatin with a Bloom number of from about 0 to about 300.
57. The microcapsule of claim 50, wherein the primary shell and/or outer shell comprises a gelatin with a Bloom number of from about 0 to about 50.
58. The microcapsule of claim 50, wherein the primary shell and/or outer shell comprise a gelatin with a Bloom number of from about 51 to about 300.
59. The microcapsule of claim 50, wherein the primary shell and/or outer shell comprise a gelatin with a Bloom number of about 0, about 210, about 220, or about 240.
60. The microcapsule of claim 50, wherein the primary shell and/or outer shell comprise a coacervate of gelatin and polyphosphate.
61. The microcapsule of claim 50, wherein the loading substance comprises oil from *Thraustochytrium*, *Schizochytrium*, or a mixture thereof.
62. The microcapsule of claim 50, wherein the outer shell has an average diameter of from about 1 μm to about 2,000 μm .
63. The microcapsule of claim 50, wherein the outer shell has an average diameter of from about 20 μm to about 1,000 μm .
64. The microcapsule of claim 50, wherein the outer shell has an average diameter of from about 30 μm to about 80 μm .
65. The microcapsule of claim 50, wherein the primary shell has an average diameter of from about 40 nm to about 10 μm .
66. The microcapsule of claim 50, wherein the primary shell has an average diameter of from about 0.1 μm to about 5 μm .
67. The microcapsule of claim 50, wherein the loading substance is from about 20% to about 90% by weight of the microcapsule.
68. The microcapsule of claim 50, wherein the loading substance is from about 50% to about 70% by weight of the microcapsule.
69. A nutritional supplement comprising the composition of any of claims 21-45 or 47, the delivery device of any of claims 48-49, or the microcapsule of any of claims 50-

68.

70. The nutritional supplement of claim 69, wherein the supplement is in the form of a tablet, gel-cap, capsule, liquid, or syrup.

71. A foodstuff comprising the composition of any of claims 21-45 or 47, the delivery device of any of claims 48-49, the microcapsule of any of claims 50-68, or the nutritional supplement of any of claims 69-70.

72. The foodstuff of claim 71, wherein the foodstuff is a baked good, a pasta, a meat product, a frozen dairy product, a milk product, a cheese product, an egg product, a condiment, a soup mix, a snack food, a nut product, a plant protein product, a hard candy, a soft candy, a poultry product, a processed fruit juice, a granulated sugar, a sauce, a gravy, a syrup, a nutritional bar, a beverage, a dry beverage powder, a jam or jelly, an infant formula, or a baby food.

73. The foodstuff of claim 71, wherein the foodstuff is a fish product, a companion pet food, a livestock or an aquaculture feed.

74. The foodstuff of claim 71, wherein the foodstuff is bread, tortillas, cereal, sausage, chicken, ice cream, yogurt, milk, salad dressing, rice bran, fruit juice, a dry beverage powder, rolls, cookies, crackers, fruit pies, or cakes.

75. A method of delivering a composition to a subject, comprising administering to the subject the delivery device of any of claims 48-49, the microcapsule of any of claims 50-68, the nutritional supplement of any of claims 69-70, or the foodstuff of any of claims 71-74.

76. The method of claim 75, wherein the subject is a mammal.

77. The method of claim 75, wherein the subject is a human.

78. A use of a microcapsule of any of claims 50-68 and to prepare a medicament for delivering a loading substance to a subject.

79. A method of lowering cholesterol levels, triglyceride levels, or a combination thereof in a subject, comprising the step of administering to the subject an effective amount of the composition of any of claims 21-45 or 47, the delivery device of any of claims 48-49, the microcapsule of any of claims 50-68, the nutritional supplement of any of claims 69-70, or the foodstuff of any of claims 71-74.

80. A method of supplementing essential trace elements in a subject, the method

PCT/US2006/022150

comprising the step of administering to the subject an effective amount of a the
composition of any of claims 21-45 or 47, the delivery device of any of claims 48-49,
the microcapsule of any of claims 50-68, the nutritional supplement of any of claims
69-70, or the foodstuff of any of claims 71-74, wherein the composition, delivery
5 device, microcapsule, supplement, and foodstuff comprises an essential trace
element.

81. A method improving insulin sensitivity in a subject, comprising the step of
administering to the subject an effective amount of the composition of any of claims
21-45 or 47, the delivery device of any of claims 48-49, the microcapsule of any of
10 claims 50-68, the nutritional supplement of any of claims 69-70, or the foodstuff of
any of claims 71-74.

82. A method of reducing hyperglycemia in a subject, comprising the step of
administering to the subject an effective amount of the composition of any of claims
21-45 or 47, the delivery device of any of claims 48-49, the microcapsule of any of
15 claims 50-68, the nutritional supplement of any of claims 69-70, or the foodstuff of
any of claims 71-74.

83. A method of reducing hypercholesterolemia in a subject, comprising the step of
administering to the subject an effective amount of the composition of any of claims
21-45 or 47, the delivery device of any of claims 48-49, the microcapsule of any of
20 claims 50-68, the nutritional supplement of any of claims 69-70, or the foodstuff of
any of claims 71-74

84. A method of reducing body fat in a subject, comprising the step of administering to
the subject an effective amount of the composition of any of claims 21-45 or 47, the
delivery device of any of claims 48-49, the microcapsule of any of claims 50-68, the
25 nutritional supplement of any of claims 69-70, or the foodstuff of any of claims 71-
74.

85. A method of promoting weight loss in a subject, comprising the step of administering
to the subject an effective amount of the composition of any of claims 21-45 or 47,
the delivery device of any of claims 48-49, the microcapsule of any of claims 50-68,
30 the nutritional supplement of any of claims 69-70, or the foodstuff of any of claims
71-74.

86. A method of treating or preventing diabetes in a subject, comprising the step of

~~PCT/US2006/003977~~

administering to the subject an effective amount of the composition of any of claims 21-45 or 47, the delivery device of any of claims 48-49, the microcapsule of any of claims 50-68, the nutritional supplement of any of claims 69-70, or the foodstuff of any of claims 71-74.

- 5 87. A pharmaceutical formulation comprising a the composition of any of claims 21-45 or 47, the delivery device of any of claims 48-49, the microcapsule of any of claims 50-68, and a pharmaceutical carrier.
88. A foodstuff comprising the composition of claim 21.
89. The foodstuff of claim 88, wherein the foodstuff is a baked good, a pasta, a meat
10 product, a frozen dairy product, a milk product, a cheese product, an egg product, a condiment, a soup mix, a snack food, a nut product, a plant protein product, a hard candy, a soft candy, a poultry product, a processed fruit juice, a granulated sugar, a sauce, a gravy, a syrup, a nutritional bar, a beverage, a dry beverage powder, a jam or jelly, an infant formula, or a baby food.
- 15 90. The foodstuff of claim 88, wherein the foodstuff is a fish product, or pet companion food, a livestock or an aquaculture feed.
91. The foodstuff of claim 89, wherein the foodstuff is bread, tortillas, cereal, sausage, chicken, ice cream, yogurt, milk, salad dressing, rice bran, fruit juice, a dry beverage powder, rolls, cookies, crackers, fruit pies, or cakes.
- 20 92. A method of lowering cholesterol levels, triglyceride levels, or a combination thereof in a subject, comprising the step of administering an effective amount of the composition of claim 21, a nutritional supplement comprising the composition of claim 21, a delivery device comprising the composition of claim 21, or a foodstuff comprising the composition of claim 21.
- 25 93. A method of supplementing essential trace elements in a subject, the method comprising the step of administering an effective amount of the composition of claim 21, a nutritional supplement comprising the composition of claim 21, a delivery device comprising the composition of claim 21, or a foodstuff comprising the composition of claim 21.
- 30 94. A method improving insulin sensitivity in a subject, comprising the step of administering an effective amount of the composition of claim 21, a nutritional supplement comprising the composition of claim 21, a delivery device comprising the

PCT/US2006/022150
composition of claim 21, or a foodstuff comprising the composition of claim 21.

- 5 95. A method of reducing hyperglycemia in a subject, comprising the step of administering an effective amount of the composition of claim 21, a nutritional supplement comprising the composition of claim 21, a delivery device comprising the composition of claim 21, or a foodstuff comprising the composition of claim 21.
- 10 96. A method of reducing hypercholesterolemia in a subject, comprising the step of administering an effective amount of the composition of claim 21, a nutritional supplement comprising the composition of claim 21, a delivery device comprising the composition of claim 21, or a foodstuff comprising the composition of claim 21.
- 15 97. A method of reducing body fat in a subject, comprising the step of administering an effective amount of the composition of claim 21, a nutritional supplement comprising the composition of claim 21, a delivery device comprising the composition of claim 21, or a foodstuff comprising the composition of claim 21.
- 20 98. A method of promoting weight loss in a subject, comprising the step of administering an effective amount of the composition of claim 21, a nutritional supplement comprising the composition of claim 21, a delivery device comprising the composition of claim 21, or a foodstuff comprising the composition of claim 21.
- 25 99. A method of treating or preventing diabetes in a subject, comprising the step of administering an effective amount of the composition of claim 21, a nutritional supplement comprising the composition of claim 21, a delivery device comprising the composition of claim 21, or a foodstuff comprising the composition of claim 21.
100. A pharmaceutical formulation comprising the composition of claim 21.




FIGURE 1

FIGURE 2




FIGURE 3




FIGURE 4





FIGURE 5

Microbial Sources of PUFAs

Micro-organism


Micro-organism	PUFA cell content (mg g ⁻¹)	PUFA Productivity (mg L ⁻¹ d ⁻¹)
<i>Phaeodactylum tricornutum</i> (diatom)	18.7 (EPA)	47.8
<i>Monodus</i> sp. (microalga)	34.4 (EPA)	25.7
<i>Mortierella alpina</i> 15-4 (fungi)	67.0 (ARA)	118.0
<i>Shewanella</i> sp. SCRC-2738 (bacterium)	10.4 (EPA)	64.5
Thraustochytrids (protists)	100 ⁺ (DHA)	1000

FIGURE 6



0.1

FIGURE 7







FIGURE 8

Modified from Ratledge, C. (2004). *Lipid Technol.* 16:34-39.

FIGURE 9 PUFA metabolic pathways







FIGURE 10

FIGURE 11



Grouping of isolates collected based on their C20 and C22 PUFA profiles. Key:
 ⊠ Arachidonic acid; ⊡ Eicosapentaenoic acid; □ Docosapentaenoic acid, n-6; and
 ▨ Docosahexaenoic acid. Results were compared to two reference strains: ATCC 20891 and MYA-1381.

FIGURE 12






FIGURE 13



14/16

FIGURE 14

Name	Retention Time (min)	Amount ($\mu\text{g/ml}$)	Carotenoid ($\mu\text{g/g}$)
Astaxanthin	8.2	0.38	1.53
Zeaxanthin	11.2	0.11	0.42
Canthaxanthin	15.2	1.03	4.11
Echinenone	24.6	0.37	1.46
β -Carotene	30.3	5.07	20.23


FIGURE 15

FIGURE 16

